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This thesis discusses the development of biodegradable polymers, nanoparticles, 
and microparticles for gene delivery and immune activation. The bulk of this thesis 
focuses on trying to understand basic principles important to the development of 
polymer-based gene delivery nanoparticles and acellular artificial antigen presenting cells 
(aAPC) for CD8+ T cell activation, In addition to the basic work, these technologies can 
be applied to many areas of human health and I have focused on applications in cancer 
and ophthalmology. 
 The root cause of many diseases has a genetic component, from single gene 
disorders like hemophilia to multifactorial disorders like cancer. As a result, gene therapy 
has enormous therapeutic potential if it can be done safely and efficiently. The vast 
majority of the effort into gene therapy has been directed at co-opting viruses as vectors 
for gene delivery, as viruses have evolved to be supremely efficient at getting their 
genetic information into foreign cells, but viral gene therapy has been hampered by high 
profile setbacks in clinical trials, owing to the potential for insertional mutagenesis and 
overly aggressive host immune responses to the vector. Theoretically, non-viral gene 
therapy should overcome these limitations by reducing the host response, enabling 
unlimited cargo capacity, and should be easier to produce and standardize. However, 
non-viral gene therapy has thus far been unable to achieve the required high transfection 
efficacies seen with viruses. A class of synthetic cationic polymers, poly(ß-amino)esters 
(PBAEs), have shown promise, but in order to develop next-generation synthetic polymer 
vectors for gene delivery, a deeper understanding of the relationship between polymer 
design and functional outcomes is required. In this thesis, I investigated structure-
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function relationships within a library of PBAEs that we developed, with an eye towards 
investigating the impact of polymer properties on critical barriers to intracellular delivery. 
To extend this work, we looked to develop PBAEs for non-viral gene delivery to the eye, 
by investigating how different particle formulations might enable differential delivery to 
ocular cell types, and by performing a pilot study looking at in vivo gene delivery to the 
mouse retina via subretinal injection. We found that polymer hydrophobicity was a 
critical dimension that significantly effected polymer vector performance. We also found 
that the amine termini of PBAEs were critical to vector function at the level of 
nanoparticle uptake even though they did not substantially alter any putative key 
nanoparticle properties. We found that polymer formulations that worked well for one 
cell class worked well for another cell type within that class but may not work well for a 
different cell class, and demonstrated that PBAEs could engender high levels of gene 
expression in the mouse retina.  
Tumor immunotherapy requires the activation of cytotoxic T lymphocytes (CTLs) 
against tumor-specific targets. This activation process occurs in vivo through the 
interaction of activated antigen presenting cells (APCs) with CD8+ T-cells in the lymph 
nodes. As an alternative to inducing biological APCs to create the targeted response of 
interest in the CD8+ T cell population, acellular artificial antigen presenting cells (aAPC) 
have been designed that mimic biological APC by presenting proteins for signal 1 
(antigen specificity) and signal 2 (costimulation) on the surface of spherical particles. 
When activated, biological APCs undergo significant changes to surface composition 
AND surface morphology; however, in the quest to mimic this process and engender 
immune responses with aAPCs, the focus has been squarely on the changes to surface 
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protein composition. We hypothesized that artificial antigen presenting cell (aAPC) shape 
(or morphology) is a critical parameter that modulates T-cell activation and proliferation. 
We hypothesized that high aspect ratio ellipsoidal aAPCs, rather than spherical aAPCs, 
might enable increased contact between aAPCs and T-cells, result in enhanced T-cell 
activation in vitro, and mediate enhanced aAPC-based tumor killing in vivo in melanoma 
mouse models. To this end, we fabricated ellipsoidal aAPCs using PLGA microparticles, 
and tested the effects of shape on T-cell activation and tumor prevention by aAPCs in 
vitro and in vivo. We found that ellipsoidal aAPCs were substantially more efficient than 
their spherical counterparts at CTL activation, that increased aspect ratio resulted in 
increased activation, and that ellipsoidal aAPCs reduced / delayed tumor growth and 
increased mouse survival as compared to spherical and non-cognate controls in a 
melanoma tumor prevention study in vivo.  
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1 Chapter 1: Introduction to the thesis 
1.1 Objectives 
Gene therapy has the potential to treat a wide variety of diseases, but the 
development of gene delivery in the clinic has been hampered by high profile setbacks 
with viral gene delivery. Non-viral gene therapy, however, has thus far been unable to 
achieve the required high transfection efficacies seen with viruses. A class of synthetic 
cationic polymers, poly(ß-amino)esters (PBAEs), have shown promise, but in order to 
develop next-generation synthetic polymer vectors for gene delivery, a deeper 
understanding of the relationship between polymer design and functional outcomes is 
required. We hypothesized that understanding how polymer chemical structure relates to 
the barriers inherent to intracellular gene delivery will help to optimize our gene delivery 
formulations and will enhance our understanding of the pivotal barriers to successful non-
viral, polymer based gene delivery. To that end, I synthesized a library of degradable 
end-modified poly(β-amino ester)s and investigated structure-function relationships and 
how polymer properties such as hydrophobicity and buffering capacity relates to non-
viral gene delivery efficacy (Aim 1). We hypothesize that polymer structure can be tuned 
so that polymeric gene delivery nanoparticles have specific efficacy in one type of cell 
over another type of cell. To investigate this, we used the gene delivery library to deliver 
DNA to three different, interrelated cell types – human umbilical vein endothelial cells 
(HUVECs), human retinal endothelial cells (HRECs), and retinal pigment epithelial cells 
(RPEs). This allowed us to examine the ability of diverse, but structurally related library 
of PBAEs, to deliver genes to two endothelial cell types (HUVEC and HREC) and one 
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epithelial cell type (RPE) which is also found in the retina (Aim 2a). We were also 
interested in extending this study to investigate whether we could use this technology for 
in vivo delivery to the RPE (Aim 2b). 
The critical component of cancer immunotherapy revolves around the activation of 
anti-tumor cytotoxic T cells (CTL) by antigen presenting cells (APCs). Artificial antigen 
presenting cells (aAPC) have been designed to mimic true APC by presenting proteins 
for signal 1 (antigen specificity) and signal 2 (costimulation) on the surface of spherical 
particles. We hypothesized that artificial antigen presenting cell (aAPC) shape is a critical 
parameter that modulates T-cell activation and proliferation. We hypothesized that high 
aspect ratio ellipsoidal aAPCs, rather than spherical aAPCs, might enable increased 
contact between aAPCs and T-cells, result in enhanced T-cell activation in vitro, and 
mediate enhanced aAPC-based tumor killing in vivo in melanoma mouse models. To this 
end, we fabricated ellipsoidal aAPCs using PLGA microparticles, and tested the effects 
of shape on T-cell activation and tumor prevention by aAPCs in vitro and in vivo (Aim 3). 
The specific aims defined for this thesis were as follows: 
 
Aim 1. Synthesize a library of degradable end-modified poly(β-amino ester)s and 
investigate structure function relationships and the impact of polymer properties on non-
viral gene delivery. 
a. Synthesize a library of degradable end-modified poly(β-amino ester)s 
b. Investigation of structure-function relationships such as the effect of base polymer 
hydrophobicity and end-group modification 
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c. Characterize key members of the library with respect to the barriers to 
intracellular gene delivery 
 
Aim 2. Optimize gene delivery for ocular applications in vitro and in vivo 
a. Deliver DNA to HUVECs, HRECs, and RPEs in vitro to optimize gene delivery 
for ocular applications and examine the performance of the library across multiple 
cell types with an eye towards identifying if the polymers display cell type 
specificity 
b. As a proof of concept, deliver DNA to the RPE in vivo using a subretinal injection 
model 
 
Aim 3. Fabricate novel biodegradable microparticles with varying shapes as aAPCs and 
measure their efficacy at stimulating T-cells in vitro and in vivo. 
a. Construction and characterization of biodegradable ellipsoidal aAPCs  
b. Evaluate in vitro interactions and efficacy of ellipsoidal aAPCs 
1) Determine how shape and formulation affects T-cell activation, proliferation, 
and function 
2) Mechanistic analysis of aAPC shape in interaction with T-cells 
c. Evaluate in vivo interactions and efficacy of ellipsoidal aAPCs 
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1.2 Summary of contributions 
The major contributions and accomplishments of this thesis work are: 
Chapter 2. State of the Art 
• Sunshine JC, Bishop CJ, Green JJ. "Advances in polymeric and inorganic 
vectors for nonviral nucleic acid delivery." Therapeutic Delivery. 2011; 2(4):493-
521 
• Sunshine, J.C., Green, J.J. Nanoengineering Approaches to the Design of 
Artificial Antigen Presenting Cells. Nanomedicine (2013). 
Chapter 3.  
• Sunshine JC, Bhise NB, Green JJ. “Degradable polymers for gene delivery.” 
Conference Proceedings IEEE Engineering in Medicine and Biology Society. 
2009; 1:2412-5. 
• Green! JJ,! Sunshine( JC,! Bhise! N,! Shmueli! RB,! Tzeng! SY.( ! "Multicomponent!
Degradable!Cationic!Polymers.”!!U.S.!Patent!PX10753X02.!!Filed:!May!17,!2010.!
• Poster( Presentation( H( Sunshine( JC,! Bhise! N,! Shmueli! R,! Divi! S,! Rauck! B,!
Green! JJ.! “HighXThroughput!Development! of!Degradable! Polymers! for! Gene!
Delivery”! presented! at! the! Johns! Hopkins! NanoBio! Symposium.! Baltimore,!
MD.!May!18,!2009.!
• Poster Presentation - Sunshine JC, Bhise N, Akanda M, Shmueli R, Li D, 
Green JJ. “Biphasic degrading polymers for intracellular delivery” presented at 
the 10th US-Japan Symposium on Drug Delivery Systems. Maui, HI. Dec. 16-20, 
2009  
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• Poster Presentation - Sunshine JC, Bhise N, Shmueli R, Li D, Akanda M, 
Green JJ. “Bioreducible Cationic Polymers for Gene Delivery: Backbone, End-
Capping Still Matters” presented at the Johns Hopkins NanoBio Symposium. 
Baltimore, MD. April 29, 2010. 
Chapter 4.  
• Sunshine JC, Akanda MI, Li D, Kozielski KL, and Green JJ. “Effects of Base 
Polymer Hydrophobicity and End-Group Modification on Polymeric Gene 
Delivery.” Biomacromolecules. 2011; 12(10),3592–3600 
Chapter 5. 
• Sunshine JC, Peng DY, Green JJ. “Uptake and transfection with polymeric 
nanoparticles are dependent on polymer end-group structure, but largely 
independent of nanoparticle physical and chemical properties.” Molecular 
Pharmaceutics. 2012; 9(11),3375-3383 
• Poster Presentation - Peng DY, Sunshine JC, Green JJ. "Characterization of 
Degradable Poly(ester amines) and Poly(amidoamines)for Non-viral Gene 
Delivery" presented at the Annual Meeting of the Biomedical Engineering 
Society. Austin, TX. October 6-9, 2010, and at the 2011 INBT Annual 
Symposium, Baltimore, MD. May 13, 2011. 
Chapter 6. 
• Shmueli RB*, Sunshine JC*, Xu Z, Duh EJ, Green JJ. “Gene delivery 
nanoparticles specific for human microvasculature and microvasculature.” 
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Nanomedicine: NBM. 2012; 8(7):1200-7. * These authors contributed equally to 
this manuscript 
• Poster Presentation - Shmueli R, Sunshine JC, Duh E, Green JJ. "Non-viral 
Gene Delivery for Microvasculature and Macrovasculature," presented at the 
Wilmer Eye Institute Research Day, Baltimore, MD. April 15, 2011.  
Chapter 7. 
• Sunshine JC*, Sunshine SB*, Handa JT, Green JJ. “Poly(β-amino ester)-
Nanoparticle Mediated Transfection Of Retinal Pigment Epithelial Cells in vitro 
and in vivo.” PLoS ONE. 2012; 7(5), e37543. * These authors contributed equally 
to this manuscript 
• Poster Presentation - Sunshine JC, Sunshine SB, Handa JT, Green JJ. 
"Transfection of Retinal Pigment Epithelial Cells with a Combinatorial Library of 
Poly(beta-amino)esters" presented at the Wilmer Eye Institute Research 
Day, Baltimore, MD. April 15, 2011, and at ARVO (Association for Research in 
Vision and Opthalmology), Ft. Lauderdale, FL. May 1-5, 2011. 
Chapter 8. 
• Sunshine JC*, Perica KP*, Schneck JP, Green JJ. “Particle shape dependence of 
CD8+ T cell activation by artificial antigen presenting cells.” Biomaterials. 2013. 
* These authors contributed equally to this manuscript 
• Green JJ, Perica K, Schneck J, Sunshine JC. “Artificial Cells of Defined and 
Dynamic Size and Shape.”  U.S. Prov. Patent.  Filed: December 15, 2011 
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• Poster Presentation - Sunshine JC, Perica K, Schneck JP, Green JJ. “Particle 
shape matters for T-cell activation by artificial Antigen Presenting Cells (aAPC)” 
presented at the 2012 INBT Annual Symposium, Baltimore, MD. May 4, 2012. 
• Talk - Sunshine JC, Perica K, Schneck JP, Green JJ. “T-cell activation by  
artificial antigen presenting cells (aAPC): Effects of particle shape” presented at 
the 86th ACS Colloid and Surface Science Symposium, Baltimore, MD. Jun. 10-
13, 2012.!
• Talk( H(Sunshine( JC,!Perica!K,!Schneck!JP,!Green!JJ.!“ShapeXdependence!of!TX
cell!induction!by!artificial!Antigen!Presenting!Cells!(aAPC)”!presented!at!the!
10th! USXJapan! Symposium! on! Drug! Delivery! Systems.!Maui,! HI.! Dec.! 16X20,!
2011.!
• Talk( H( Sunshine( JC,!Perica!K,!Schneck!JP,!Green!JJ.! “NonXSpherical!Artificial!
Antigen! Presenting! Cells! for! Tumor! Immunotherapy”! presented! at! the!
Society!for!Biomaterials.!Boston,!MA.!Apr.!10X13,!2013.!
Chapter 9. 
• Sunshine JC, Green JJ. “Nanoengineering approaches to the design of artificial 
antigen presenting cells.” Nanomedicine. 2013; 8(7), 1173-1189 
!
Other Peer-Reviewed Publications 
• Bhise N, Gray R, Sunshine JC, Htet S, Ewald A, Green JJ. "The relationship 
between terminal functionalization and molecular weight of a gene delivery 
polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D 
organotypic cultures." Biomaterials. 2010; 31(31):8088-96 
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• Bhise N, Shmueli RB, Sunshine JC, Tzeng SY, Green JJ. "Drug delivery 
strategies for therapeutic angiogenesis and antiangiogenesis." Expert Opinion on 
Drug Delivery. 2011; 8(4):485-504 
• Tzeng SY, Guerrero-Cázares H, Martinez EE, Sunshine JC, Quiñones-Hinojosa 
A, Green JJ. "Non-Viral Gene Delivery Nanoparticles based on Poly(beta-amino) 
esters for Treatment of Glioblastoma." Biomaterials. 2011; 32(23):5402-10 
• Bishop, CJ, Ketola, TM, Tzeng, SY, Sunshine, JC, Urtti, A, Lemmetyinen, H, 
Vuorimaa-Laukkanen, E., Yliperttula, M., Green, J.J. The Effect and Role of 
Carbon Atoms in Poly(beta-amino ester)s for DNA Binding and Gene Delivery. 
Journal of the American Chemical Society (2013). 
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1.3 Outline of the Thesis 
This thesis describes the development and characterization of a PBAE library with 
respect to structure function relationships within the library and polymer properties 
related to intracellular barriers to entry. It also describes optimization of the PBAE library 
for use in ocular applications both in vitro and in vivo. Finally, the development, 
characterization, and optimization of a biodegradable, non-spherical, acellular artificial 
Antigen Presenting Cell (aAPC) system for tumor immunotherapy is discussed.   
Chapter 2 presents an overview of the current state of the art techniques and 
nanotechnology platforms developed for cationic polymer-based non-viral gene delivery 
vectors and for artificial antigen presentation on acellular substrates. Chapter 3 reports 
the development of initial PBAE vectors and their performance in trasfection of cancer 
cells and non-cancerous fibroblasts. The effect of small changes in molecular structure on 
transfection efficiency is discussed. Chapter 4 describes the synthesis of the PBAE 
library in full, and details structure-function relationships within the library, particularly 
focusing on the relationship of base polymer hydrophobicity to transfection and 
cytotoxicity. Chapter 5 details an investigation into PBAE polymer and nanoparticle 
properties relevant to the barriers to intracellular delivery; in particular, the particle size, 
charge, binding affinity, polymer buffering capacity, polymer degradation rate were 
studied as they related to particle uptake, cell transfection and cytotoxicity. 
Chapter 6 reports the performance of the polymer library across three related cell 
types – two endothelial cell types (human umbilical vein endothelial cells or HUVECs, 
and human retinal endothelial cells or HRECs) and 2 ocular cell types (the HRECs and 
retinal pigment epithelial cells or RPEs). Of particular interest, the performance of the 
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library was highly correlated between the 2 endothelial cell types (HUVEC and HREC), 
but not very highly correlated between the epithelial cell type (RPE) and either 
endothelial cell type. Chapter 7 describes an initial, pilot, in vitro and in vivo study to 
determine the feasibility of using PBAEs for gene delivery to the retinal pigment 
epithelium. 
Chapter 8 describes the development of a biodegradable, non-spherical, acellular 
aAPC system for tumor immunotherapy. Spherical and ellipsoidal aAPCs were 
synthesized and characterized by SEM, fluorimetry, and confocal imaging, and were 
tested in vitro for their comparative ability to induce cognate-peptide specific T cell 
proliferation at a variety of particle doses, protein densities, and particle aspect ratios. 
The aAPCs were then compared in a tumor-prevention model in vivo.   
Chapter 9 presents concluding remarks and suggests future directions to be pursued 
for building on the work described herein. This includes preliminary work on using 
PBAEs for transfection of dendritic cells for genetic vaccine delivery, the development of 
nanoscale biodegradable aAPCs, and suggestions to improve the current generation of 
artificial antigen presenting cells using nanoengineering approaches.(
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2 Chapter 2: State of the Art 
2.1 Cationic Polymers for Non-viral Nucleic Acid 
Delivery1 
Nucleic acid therapies have enormous potential in the clinic, from treatment of 
specific genetic diseases such as cystic fibrosis [1], Leber hereditary optic neuropathy [2], 
hemoglobinopathies [3, 4] and hemophilia [5], to the treatment of cancer [6, 7] and 
cardiovascular disease [8] and the use of genetic vaccines [9]. !Additionally, nucleic acid 
delivery plays a crucial role in cellular engineering and basic biomedical research, 
through the ability to knock in and knock down genes and proteins in the lab, as well as 
in the creation of induced-pluripotent stem-cells (iPSCs) by viral [10, 11] and non-viral 
[12] methods.  
The central challenge for effective therapy using nucleic acids is finding a safe 
and effective delivery system [13]. With regards to gene therapy, since viral gene therapy 
can have serious safety concerns [14],  recent efforts have focused on non-viral methods. 
There are several barriers to cellular entry and delivery of the nucleic acid cargo 
that challenge the development of an effective delivery vehicle (Fig. 2.1). The vehicle 
needs to form a stable complex with its nucleic acid cargo, protect it from degradation 
extracellularly, arrive at the cell of interest, get internalized (typically via either receptor-
mediated endocytosis and or non-specific endocytic pathways), escape endo-lysosomal 
degradation, release its cargo, and harmlessly degrade or otherwise be removed.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This chapter contains excerpts from an article that was published as Sunshine JC, Bishop CJ, Green JJ. 
“Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery.” Therapeutic 
Delivery. 2011; 2(4):493-521. 
! 12!
After escaping the endosomal compartment and making it into the cytoplasm, 
DNA and agRNA need to make it to the nucleus. This is among the largest challenges 
remaining to non-viral gene delivery. Recently, several groups have shown that it takes 
between 30 and 100 times more DNA delivered to the cytoplasm than it does to the 
nucleus to give the same level of gene expression, even in dividing cells [15]. Dividing 
cells are more easily transfected because mitosis-associated nuclear envelope breakdown 
greatly enhances nuclear localization of plasmids and transfection efficiency; however 
this is not a requirement - plasmids can enter the nuclei through nuclear pore complexes 
(NPCs) in the absence of cell division, although significantly less efficiently [16].  
Yet simply getting to the nucleus is not the end of the line. Cohen et al showed 
that cells transfected with lipofectamine or polyethylenimine contained between 75 and 
50,000 plasmids/nucleus [17]. They also noted that a subpopulation of cells that 
contained only 3x the average number of cells had 100x the expression of the rest of the 
population, indicating that downstream processes aside from nuclear importation are also 
crucial [17].  
Various cationic polymer systems have been utilized for nucleic acid delivery. A 
wide range of structures have been explored, including linear and branched non-
degradable polycations as well as biodegradable and bioreducible polycations and 
oligosacharides. Some of the most commonly use polymer structures are shown in Fig. 
2.2. All of these polymers have secondary or tertiary amino groups, a portion of which 
are protonated at neutral pH, which enables electrostatic interaction with the anionic 
nucleic acid.  
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Poly-l-lysine (PLL) was the first polymeric gene transfection agent developed, 
and was shown to condense DNA into small complexes with rod (25-50 nm) or toroidal 
(40 to 80 nm) structure [18]. PLL can be synthesized by several-step polymerization of 
ε,N-benzyloxycarbonyl-α,N-carboxy-L-lysine anhydride[19]. PLL is limited by its high 
cytotoxicity and lack of bio-degradability, so various groups since then have conjugated 
PLL to a variety of other molecules such as poly-ethylene glycol (PEG)[20], targeting 
ligands such as asialoorosomucoid [21], transferring [22], galactose [23, 24], lactose [25], 
folate [26], and endosomolytic groups like histidine [27]. 
Poly(ethylenimine) (PEI) was the second polymeric transfection agent developed 
[28]. Branched PEI (b-PEI) can be synthesized from aziridine monomers under acidic 
conditions, and linear PEI (l-PEI) can be synthesized by the hydrolysis of poly(2-proplyl-
2-oxazoline)[29], or by polymerization of aziridine monomers at lower temperatures [30]. 
Compared to later generation nucleic acid delivery agents, PEI is extremely cytotoxic, 
leading to necrosis and apoptosis [31]. The high proportion of nitrogen atoms provides 
for a strong buffering effect (“the proton sponge effect”) that is advantageous for 
endosomal escape, as described below. 25 kDa b-PEI has been shown to be an efficient 
transfection reagent with reduced toxicity as compared to higher molecular weight b-PEI 
[32]. For delivery of shorter nucleic acids (e.g. mRNA) only low molecular weight PEI (2 
kDa or less) leads to efficient biological effect, as complexes with higher molecular 
weight PEI are too stable and do not release the nucleic acid into the cytoplasm [33]. 
Poly(lactide-co-glycolide) (PLGA) microspheres have been used extensively in 
nucleic acid delivery for their utility in and their relative biocompatibility and 
biodegradability. PLGA is synthesized by co-polymerization of glycolic acid and lactic 
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acid with various catalysts, and hydrolytically degradable. Microparticles can be formed 
from pre-made polymer by emulsion evaporation, emulsion diffusion, solvent 
displacement and salting out techniques, and particle size depends on the formulation 
conditions and molecular weight of the starting material [34]. Both the polymer and its 
degradation products are well tolerated in animal studies [35, 36]. 
As opposed to mostly linear, cross-linked, or other branched systems, dendrimers 
such as poly(amido amine) (PAMAM) dendrimers are synthesized iteratively to produce 
nanoscale structures characterized by dendritic connectivity and radial symmetry. 
Advantages of dendrimeric systems include precise, nanoscale, structural control, densely 
modifiable surface chemistry (for addition of targeting ligands, modification of surface 
charge etc), and high charge density for complexation and buffering. PAMAM 
dendrimers were first synthesized in the mid 1980s [37]. Typically, ethyenediamine or 
ammonia are used as cores and allowed to undergo repeating two-step reactions whereby 
methyl acrylate is added by Michael addition to all the primary amines, and then the ester 
groups are amidated by a large excess of ethylenediamine to produce primary amine 
termini. They have been extensively studied for gene delivery [38, 39] as well as 
oligonucleotide delivery [40-43]. Interestingly, thermal degradation of the dendrimers 
was shown to increase transfection efficacy [44].  
Poly(β-amino ester)s (PBAE) are synthesized by Michael addition of either 
primary or bis(secondary) aliphatic amines to diacrylate compounds [45], and their 
simple chemistry leads them naturally to a combinatorial approach to synthesis and 
screening of polymer libraries[46-50]. They are hydrolytically degradable at the 
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backbone ester linkages, and their tertiary amines along the backbone allow for buffering 
of the endosome.  
 
2.1.1 Physical Requirements 
When designing gene therapy vectors it is important to note that physical 
properties such as size, aspect ratio, molecular weight, surface area, shape, polydispersity, 
zeta potential, and others, can have an impact on cytotoxicity and delivery [51]. To meet 
certain barrier requirements for gene delivery, surface modifications can be used to 
modify the physical properties of the delivery system to improve circulation time and 
solubility (i.e., PEGylation) [52] [cb1], localization (i.e., folic acid, RGD) [53], 
biostability (i.e., zeta potential: amine or carboxylic groups) [52],  cytotoxicity (addition 
of carboxyl or hydroxyl groups) [54, 55], internalization, and inhibition of 
reticuloendothelial system clearance [56, 57]. 
 
2.1.1.1 Shape)
Recently, manipulation of particle shape has come into focus as a new method for 
modulating drug delivery [58]. Local shape of the particle where it made contact with the 
cell and not the overall shape dictated whether or not it was internalized by a macrophage 
[59]. Elongated particles have been shown to circulate longer and avoid phagocytosis 
more effectively than spherical particles [60], however, spherical particles are much more 
efficiently internalized into target tissues as compared to elongated particles [61]. 
Seeking to take advantage of this property, a group has recently constructed PLGA-based 
shape shifting particles (one way, from ellipsoid to spherical) in response to temperature, 
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pH, or a chemical signal and demonstrated efficient uptake of the spheres as compared to 
the ellipsoids (Fig. 2.3) [62].  
Other nanoparticle morphologies may prove worthwhile investigating to assess 
cytotoxicity and nucleic acid delivery as potential vectors. DeSimone used soft 
lithography using polydimethylsiloxane and perfluoropolyether to make a mold enabling 
nanoparticle replication in a non-wetting template. Using this, nanoparticles with diverse 
shapes synthesizable (i.e., 200 nm trapezoidal particles, 200 x 800 nm bar particles, 3 µm 
arrow particles, and 2.5 x 1 µm2 hexnut particles with 1 µm holes) [63].  
 
2.1.1.2 Size)
Polymer nanoparticles have been developed with a wide variety of sizes for 
different purposes. Nanoparticles of approximately 100 nm show prolonged blood 
circulation and a relatively low rate of mononuclear-phagocyte system uptake [64]. 
Particles with a 1-5 µm diameter are likely to be trapped in the liver and phagocytosed by 
Kupffer cells [62]. Particles larger than 5 µm are likely to be trapped in the capillary beds 
[62]. When NPs are greater than 200 nm they are likely to be filtered in the spleen, 
whereas the NPs less than 100 nm are likely to leave the blood vessels through 
fenestrations in the endothelial lining [62]. NPs that are ~50-200 nm have been known to 
accumulate in tumors by the enhanced permeability and retention (EPR) effect (as a 
result of leaky vasculature and the absence of a draining lymphatic system) [65, 66]. It 
has been suggested that the particles must not exceed 300 nm to take advantage of the 
EPR effect [67]. Sizes smaller than 50 nm are likely to enter most cells and sizes smaller 
than 20 nm can extravasate [66, 68]. The glomerular apparatus’ capillary wall has 
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fenestrations of approximately 4–5 nm and it has been reported that nanoparticles >8 nm 
cannot be filtered through the glomerular filtration system, which would increase 
circulation half-life [69]. 
 
2.1.1.3 Charge)
When particles have neutral or slightly negative zeta potentials, they have a 
greater propensity to escape the reticuloendothelial system (RES) of the body and avoid 
nonspecific interaction with other biological milieu [70, 71]. However, when zeta 
potentials are positive, nanoparticles are more easily able to bind negatively charged cell 
membranes of target cells [72]. For example, the maximum zeta potentials of lysine-, 
arginine-, and histidine modified nanoemulsions were reported at 50 (highest transfection 
efficiency), 43, and 7 mV (lowest transfection efficiency), respectively [73]. On the other 
hand, NPs with positive zeta potentials can have greater affinity for anionic 
proteoglycans on the surface of cell membranes which can enhance cell contact and 
promote cellular uptake and internalization [74]. 
Some nanoparticles may be more or less cytotoxic depending on their charge (i.e., 
AuNPs are less cytotoxic when anionic [75]. It is important to consider zeta potentials 
when complexing nucleic acids via ionic interactions. The interaction must be strong 
enough to condense the nucleic acid to protect against restriction enzymes. It is important 
to note that zeta potentials of nanoparticles can switch signs when in the presence of 




Biocompatibility is crucial for maintaining an appropriate host response during 
gene therapy. In depth assessments and characterizations are required to elucidate the 
physicochemical differences responsible for low cytotoxicity and acceptable viability. 
PEI lacks degradable linkages and is too toxic for therapeutic applications, 
inducing both apopotosis and necrosis in an endothelial cell model [78].  PEI’s efficacy 
and cytotoxicity are both often positively correlated with the molecular weight used, so 
low molecular weight PEI, while possessing reduced cytotoxicity, also is typically less 
efficacious (cite). As a result, a number of investigators have synthesized an array of 
degradable PEIs consisting of LMW PEIs and degradable cross-linkers, in the hopes of 
achieving higher efficacy with the reduced cytotoxicity of low molecular weight PEIs [79, 
80]. 
Other groups have focused on developing new, biodegradable polymers for non-
viral gene delivery, which we will review here by method of degradation. Biodegradable 
polymers should be able to both reduce the cytotoxicity associated with the transfection 
reagent as well and potentially improve dissocation of the vector from its cargo to allow 
the cargo to be utilized intracellularly. 
Multiple strategies have been formulated using ester bonds to allow hydrolytic 
cleavage of the polymer. Amine containing hydrolyzable polymers have been utilized 
which are effective gene delivery agents with significantly decreased cytotoxicity as 
compared to non-degradable polymers such as poly(ethylenimine) (PEI) [28] and 
poly(lysine) (PLL) [18]. These structures include poly(lactide-co-glycolide) (PLGA) [81], 
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hyperbranched poly(amino ester)s [82], poly(lactic acid) (PLA) [36], and linear poly(β-
amino ester)s (PBAE) [45], among others.   
PBAEs are synthesized by simple Michael addition of primary or bis-secondary 
amines with diacrylate esters [45, 83]. Libraries of PBAEs have been developed for gene-
vector screening [46-50]. Studies have shown that amine-terminated PBAEs are more 
effective at pDNA transfection than acrylate-terminated versions. Modification of the 
polymer ends with different amines can lead to virus-like efficacy in human primary cells 
in vitro (Fig. 2.4) [84]. Tuning of polymer end group leads to significant differences in 
transfection efficacy, and the optimal endgroup for each cell type appears to be cell-type 
specific [85, 86].  PBAEs also have been shown to be non-toxic to human primary cells 
in vitro [87] and in mice in vivo [88, 89]. 
 
2.1.1.5 “Stealth”)properties)
After intravenous administration, a variety of serum proteins bind to the surface 
of the nanoparticles, which are recognized by the scavenger receptor on the macrophage 
cell surface and internalized, leading to a significant loss of nanoparticles from the 
circulation [90]. Addition of hydrophilic moieties, like poly(ethylene glycol) (PEG), 
poly(N-(2-hydroxypropyl-methacrylamide) (pHPMA), and various oligosaccharides, 
have been shown to increase solubility, prolong circulation time, neutralize zeta potential, 
and reduce interactions with the environment within the bloodstream due to a higher 
tolerance against incubation with serum proteins [91, 92]. One disadvantage of this 
approach is that while it may stabilize the polyplex in serum and reduce cytotoxicity, it 
may also interfere with complexation and reduce transfection efficiencies depending on 
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the extent of addition [93]. Modification of the surface of preformed particles with 
PEG/pHPMA that can bind to exposed surface amino groups has been shown to alleviate 
this problem [91, 94]. Recently, Name et al. showed that adding PEG to PAMAM 
dendrimers via bis-aryl hydrazone bond linkages into the vector significantly enhanced 
the buffering capacity of the vector even with a high degree of PEGylation [95]. PEG can 
be added to a variety of nanoparticles and can be further modified to provide targeting 
[96-99], or can be attached by degradable bonds (such as matrix metaloproteinases 
(MMP)) that can be cleaved to expose underlying functionalities [100-104]. 
 
2.1.2 Nucleic Acid Complexation 
Polymers for nucleic acid delivery typically rely on electrostatic interaction 
between the cationic polymer and the anionic phosphate backbone of nucleic acid 
substrate. For polymer:DNA complexes, requirements include condensation of the 
plasmid to an appropriate scale for internalization, neutralization of the negatively 
charged phosphate backbone of the DNA, and protection of DNA from degradation both 
intra- and extracellularly [105, 106]. Sufficient cationic charge is crucial to condense 
DNA, but it is also correlated with increased cytotoxicity, and higher DNA binding 
affinity may lead to decreased DNA release and reduced transport through the cytoplasm 
[107]. Alternatively, hydrolytically degradable nanoparticles can be formed through 
encapsulation of DNA by non-cationic polymers such as PLGA.  These particles degrade 
to release their nucleic acid cargo and the size of the particlecan be controlled in the 
nanometer to micrometer range, depending on the method of particle formation used. 
Methods have been developed to protect the cargo from destruction during these 
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processes [81] but are still limited by low encapsulation efficiency and potential DNA 
degradation in the hydrolyzing polymer core [108]. 
Chitosan can form nanoparticles through a process called ionotropic gelation. 
Upon exposure to multivalent polyanions such as sodium tripolyphosphate (TPP), 
nanoparticles spontaneously form via linkages between the phosphate groups of TPP and 
the amino groups of chitosan [109]. Chitosan has been optimized to allow for the 
encapsulation of both hydrophilic and hydrophobic drugs and has been utilized in nucleic 
acid delivery [110, 111], most successfully as hybrid co-polymers with various 
polycations [112-114]. Chitosan is a versatile nucleic acid delivery agent, with recent 
work demonstrating the successful delivery of anti-sense oligodeoxynucleotides (asODN) 
using a folic acid (FA) conjugated hydroxypropyl-chitosan carrier, resulting in 35% 
inhibition of tumor growth [53],  hepatocyte targeted gene delivery using a galactosylated 
chitosan-graft-polyethylenimine (GC-g-PEI)/DNA complexes-loaded 
poly(organophosphazene) thermosensitive biodegradable hydrogel [115], and siRNA 
[116].  
 
2.1.3 Cellular Targeting  
By utilizing a targeting moiety, smaller dosages can elicit comparable therapeutic 
responses while minimizing side effects and reducing the cost of therapy [117]. There are 
two types of targeting; passive and active. Passive targeting utilizes natural processes 
such as the enhanced permeability and retention effect, which utilizes the leaky tumor 
vasculature and lack of efficient lymphatic drainage in a solid tumor to lead to passive 
accumulation of drug at the tumor site, given sufficient circulation time [118]. Active 
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targeting consists of an additional ligand to assist in localization or internalization such as 
antibodies or their fragments (i.e., J591 against prostate-specific membrane antigens 
[119], anti-HER2 (Trastuzumab) [120], etc) [121], folic acid([122]),  sugars (i.e., 
galactose, mannose, and lactose) [123], peptides (RGD) [124, 125], transferrin [126],  
and nucleic acid aptamers [127],  Large target moieties, however, may hamper the 
internalization and or gene unpacking and may be disadvantageous and thus removing the 
target moiety at the cell surface may be worthwhile [117]. Targeting moieties are 
typically attached chemically but can be physically adsorped to the delivery system as 
well [128]. Interestingly, it has been shown that biodistribution of cargo at the 
accumulation site is independent of the presence of targeting ligands [66]. If there is 
preference for a tumor site and the targeting ligand is not a factor then the EPR effect is 
likely responsible for the biodistribution. The reason for improved functionality when 
targeting ligands are used appears to be due to an increase in cell internalization and 
specificity of the nanoparticles rather than tissue localization. Non-targeted nanoparticles 
have a propensity to end up in the extracellular space and tumor-associated macrophages 
[66]. 
Cationic polymers have been modified with targeting ligands for various 
applications. For example, the addition of lung surfactant to ternary nanoparticles for 
aerosol-based gene therapy enhances gene delivery to the lung, resulting in 12-fold 
higher transfection compared to pure nanoparticles and 30-fold higher compared to 
polyethylenimine [129]. Insulin adsorption significantly increased gene expression of 
PEI-pDNA nanoparticles up to 16-fold on alveolar epithelial cells but not on bronchial 
epithelial cells [130]. 
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2.1.4 Endosomal Escape 
In the early experiments with non-viral gene delivery, non-degradable polycations, 
including poly(l-lysine) (PLL), polyethylenimine (PEI) were used. A major advantage of 
PEI is the “proton sponge” effect due to PEI’s extensive buffering capacity. When  
PEI:DNA complexes gain entry to the endosome, the secondary and tertiary amines in 
PEI function tobuffer acidification of the endosome.  This causes an influx of negatively 
charged chloride ions into the endosome to maintain electroneutrality as protons are 
continually pumped into the endosome.  Eventually, this leads to osmotic swelling and 
rupture of the endosomes and release of the vector and cargo into the cytoplasm. This 
mechanism has been widely explored for gene and siRNA delivery [28, 131]. This 
concept has also been extended and heavily used in the design of next-generation 
biodegradable vectors which also contain this buffering capacity. 
Another widely used buffering moiety is the imidazole ring of histidine. It is a 
weak base with a (pKa ~ 6) capable of buffering the endosome. For example, a 
poly(phosphazene) based polymer has been histidylated, and the resulting polymer 
showed improved transfection and reduced cytotoxicity when compared to the histidine-
free polymer and branched PEI [132]. 
Newer methods for endosomal escape involve functionalizing a polymer with 
peptides that enhance endosomal release. Melittin enables release of nonviral gene 
transfer particles into the cytoplasm and also enhances their transport into the nucleus, 
possibly via the cationic cluster KRKR near the C terminus of the peptide [133]. 
Modifying melittin either by reversible acetylation of a lysine residue in melittin [134] or 
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replacement of two glutamines with glutamic acids which get neutralized at acidic pH 
[135] takes advantage of the acidification of the endosome to induce membrane lysis only 
in the endosomal compartment and reduces the cytotoxicity associated with use. 
Functionalizing polylysine with polyethylene glycol and a pH-responsive melittin peptide 
was shown to be an efficient siRNA delivery agent [136]. !
Anionic fusogenic peptides, such as INF1-4, INF7, E5, and E5WYG, contain 
glutamate residues that protonate under acidic conditions (pH 5-5.5) in the endosome, 
triggering a conformational change from a random coil to alpha-helix, leading to 
membrane disruption [137-139]. Adding these peptides to polymeric vehicles was shown 
to enhance the endosomal escape rate constant by two orders of magnitude [140].  
 
2.1.5 Release of Cargo / Degradation 
Nucleic acids must be released from the vector to have an effect. This can be done 
by taking advantage of the redox potential gradient [141], acidic environment of the 
endosome [142], MMPs [143, 144], photocatalysis [145], and hydrolytic degradation of 
the carrier [45, 146, 147].  It has been shown that plasmid unpacking can be a limiting 
step with regards to gene expression for sufficiently large polymer constructs [148].  
 
2.1.5.1 Bioreducible)polymers)
Using bioreducible polymers via incoporation of disulfide linkages takes 
advantage of the relative reducing environment of the intracellular space. Intracellular 
reduction of the disulfide bond occurs via the glutathione (GSH) pathway. GSH is 
regenerated from its oxidized form by glutathione reductase, and is an important 
! 25!
component in a multitude of pathways as well as playing a major function as part of 
cellular defense against oxidative stress. Disulfide bonds are stable extracellularly, 
preventing particle breakdown before the nano-complex reaches the cell surface, whereas 
the reducing environment of the intracellular space allows for enhanced polymer 
breakdown and nucleic acid release [149-153].  
Disulfide bonds have been shown to degrade intracellularly within 3 hours [154]. 
When cell lines with different intrinsic glutathione levels were compared, increased 
cellular GSH levels were associated with improved transfection of mRNA polyplexes. No 
clear trend was observed for plasmid DNA or siRNA containing complexes; rather, the 
cell line which demonstrated the best DNA transfection was the fastest dividing cell line 
[155]. 
Enhancing release of the pDNA cargo can lead to dramatic gains in transfection 
efficiency. Carlisle et al condensed pDNA with thiolated polyethylenimine (PEI-SH) and 
surface-coated the resulting nanoparticles using thiol-reactive poly[N-(2-
hydroxypropyl)methacrylamide] (PHPMA) with 2-pyridyldisulfanyl or maleimide groups, 
forming reducible disulphide-linked or stable thioether-linked coatings, respectively. 
Interestingly, disulfide-linked complexes showed 40-100-fold higher transfection activity 
than thioether-linked ones, demonstrating the utility of the bioreducible approach in 
enhancing pDNA release [103]. Chen et al synthesized a series of reducible 
hyperbranched poly(amido amine)s and found that reducible polymers were able to 
achieve nearly 200-fold higher transfection as compared to control polymers [156].   
  Combination of hydrolyzable and bioreducible functional groups as a single 
polymer might also help further tune the release profile[157]. 
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 Reducible polymers have also been used to deliver siRNA. Histidine containing 
reducible polycations based on CH(6)K(3)H(6)C monomers (His6 RPCs) were examined 
for their utility in delivering siRNA. Co-delivery of EGFP siRNA with pEGFP plasmid 
DNA reduced reporter gene expression by 85%. Interestingly, while as with most 
polymer systems, larger polymer size correlated with increased DNA transfection 
efficiency, effective delivery of siRNA was only possible with smaller polymers (36-80k) 
[158]. 
Low molecular weight PEI has also been crosslinked via disulfide linkages to 
show reduced cytotoxicity and equivalent DNA transfection efficacy to higher MW PEI 
[159].  In another study, reducible poly(amido ethylenimine) (SS-PAEI) was synthesized 
by addition copolymerization of triethylenetetramine and cystamine bis-acrylamide 
(poly(TETA/CBA)) and used as a carrier for siRNA. Under normal conditions they 
demonstrated significantly higher suppression of VEGF with poly(TETA/CBA) than 
linear-polyethylenimine. The addition of dl-buthionine sulfoxamine, which reduces 
intracellular level of reduced glutathione reduced the RNAi activity level of 
poly(TETA/CBA) formulation to that of L-PEI, showing that reduction of the polymer 
was crucial to gene knockdown [160].!
Jere et al used a reducible polyspermine (RPS) carrier composed of multiple 
spermine units with disulfide linkages and showed improved efficacy in gene delivery 
and in gene knockdown compared to 25K PEI. RPS delivered anti-Akt1 sh/si/ssiRNA 
and altered the cancer cell survival, proliferation and metastasis to different extents 




signals (NLS) are recognized by importin-α, which then binds to importin-β, and this 
complex is allowed through the NPC. Once inside the nucleus, the importin-β binding 
domain is released by binding to RanGTP and the cargo is released [164]. By electron 
microscopy and gold nanoparticles complexed to NLSs, Panté and Kann were able to 
show that the largest rigid particle to achieve nuclear entry through NPCs was ~39 nm in 
diameter including NLSs [165].  
Strategies for obtaining access to the nucleus have relied primarily on diffusion 
through the cytoplasm and presentation of NLS to allow pDNA access to the nucleus 
[166]. Numerous groups have tried to complex synthetic or naturally occurring NLS 
peptides with the delivered DNA, with variable efficacy [167], and the ones which have 
been successful may be due to the peptides inducing improved nanoparticle complexation 
and not increased nuclear import [166].  A single NLS has been shown to be sufficient to 
carry the DNA through the NLS [168], but the addition of hundreds of NLS sequences to 
a plasmid lead to no nuclear localization of the plasmids [169], since multiple NLS sites 
might lead to the machinery attempting to pull a single plasmid through through multiple 
NPC at the same time, as well as potentially inhibit translation. 
Two of the best characterized NLSs are the classical NLS from SV40 Large T-
antigen (PKKKRKV) and the bipartite NLS in which the classical NLS is split into two 
halves (typically KKKX5−20RK). Proteins containing these NLS are bound by importins 
which allow access to the nucleus via the nuclear pore complex (NPC) [170]. Plasmids 
containing as little as 72 bp of the SV40 enhancer target to the nucleus of most cells 
within several hours, due to the enhancer containing binding sites for a number of 
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ubiquitously expressed mammalian transcription factors, each of which functions in the 
nucleus and contains an NLS [171].  
 
2.1.7 Conclusions and Future Directions 
Polymeric and inorganic based-vectors for nucleic acid delivery need to overcome 
many crucial barriers to entry in the delivery process, and a variety of novel approaches 
have been investigated to overcome those challenges. A wide array of materials have 
been investigated for their potential in this area, including degradable and non-degradable 
cationic polymers, oligo- and polysaccharides, among many others, each with unique 
properties and potential advantages. 
Firstly, the vector must be stably complexed to the nucleic acid cargo and needs 
to stay compacted until cellular entry. The size, shape, surface charge, and surface 
functionality of the nanoparticles are crucial to efficient delivery, increased circulation 
time, and specific cellular entry of the nanoparticles. Size is a crucial parameter in 
determining the passive biodistribution of the nanoparticle delivery system, and charge 
shielding / PEGylation has been shown to improve circulation time and increase 
accumulation at tumor sites as a result of the EPR effect. Various groups have 
synthesized particles of different shapes and even developed shape-shifting particles 
whose shape-change can be triggered by pH, heat, and light.  
The vast majority of delivery systems achieve cellular entry via endocytosis. For 
delivery of isRNA, interaction with TLR7 in the endosome is the end-goal, so 
nanoparticles should be designed to remain in the endosome and present the isRNA to 
TLR7 there. For siRNA and all DNA based systems, there needs to be a mechanism for 
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endosomal escape. The classical mechanism employed by non-viral vectors involves the 
proton-sponge effect, but novel endosomolytic peptides and acid triggered exposure of 
hydrophobic residues have also been utilized to engineer endosomal escape. Hydrolysis, 
bioreduction, and photolysis have been utilized extensively to reduce toxicity and 
promote unpacking of the cargo intracellularly. Trafficking DNA-based cargo to the 
nucleus remains an area of need, mostly relying on diffusion to bring the DNA to the 
nucleus and NLS sequences to allow nuclear import via the NPC.  
 There is a major need for fundamental understanding of how cationic polymer 
structure plays a role in overcoming the barriers to gene and nucleic acid delivery 
outlined above. The cationic-polymer based gene delivery component of my thesis 
focuses extensively on attempting to further describe structure-function relationships that 
we were able to extract from our combinatorial library approach to developing PBAE 
vectors for gene delivery (Aim 1). In addition, understanding how and why polymers 
work well in one cell type and not in another may help point the way to the 
generalizability of in vitro results, and may enable more efficient design of gene delivery 
vectors for particular applications (Aim 2).  
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2.2 Next Generation Artificial Antigen Presenting Cells 
for Tumor Immunotherapy 
Synthetic biomaterials and particles can be engineered to be ‘biomimetic’, where 
they act similarly in an organism to natural biological molecules and cells.  This 
biological mimicry can be beneficial for wound healing and regenerative medicine, new 
types of advanced therapeutics, coatings on medical devices, and other applications. One 
particular area where biomimetic particles have significant potential to advance medicine 
is in the field of tumor immunotherapy.  
The main goal of tumor immunotherapy is to encourage the body’s own immune 
responses to aberrant cells. The recognition that there are tumor-infiltrating immune cells, 
T lymphocytes or T cells, and the identification of the genes that are targeted by T cells in 
melanoma, led to the identification of tumor antigens for immunotherapy [172, 
173] .Tumor antigens are specific biological molecules that are present at the nanoscale 
on the surfaces of cancer cells, but are not present on the surfaces of healthy cells. 
Numerous human tumor antigens recognized by T cells have now been identified and 
these antigens are promising targets for tumor immunotherapy[174].  
A variety of approaches for tumor immunotherapy have been investigated, with the 
most common approach involving natural biological antigen presenting cells interacting 
with T cells. However, there are challenges with these approaches including efficacy, 
safety, cost, and general flexibility.  If there was an off-the-shelf synthetic product that 
was relatively easy to manufacture, biocompatible and safe, and could engender strong 
and specific T-cell responses against an antigen, it would be a boon for the treatment of 
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many types of cancer as well as being beneficial for the treatment of other diseases such 
as infectious diseases[175]. To construct such an off-the-shelf synthetic product, 
biomimetic acellular artificial antigen presenting cells, there are many important design 
parameters to consider.  
Much of the focus to date has in the development of aAPCs has centered on the 
identity of the surface-presented proteins used to target the T cell population and induce a 
response. Spherical, cell-sized (2-10 µm), isotropic (homogeneous surface presentation) 
aAPCs that present some of the same protein signals on their surface as biological antigen 
presenting cells (APCs) have been developed and well characterized, and are already 
attractive options for ex vivo T cell proliferation and have shown in vivo efficacy in 
mouse models[175-183]. 
 
2.2.1 How Biological Antigen Presenting Cells Work 
Antigens on a tumor cell are recognized by a T cell by its T cell receptor (TCR).  
To accomplish this, naïve T cells must be directed to productively respond to TCR 
binding by antigen presenting cells that present specific antigen to T cells via major 
histocompatability complex (MHC) molecules.  There are two classes of MHCs with 
different functions and that present different peptides. MHC class II molecules present 
peptides obtained via the endosomal-lysosomal route and serve to present peptides which 
come from outside the cell; thus presentation of non-self peptides in class II MHC is 
crucial to mediating the immune response to extracellular pathogens. MHC class I 
molecules, on the other hand, bind to peptides generated by the proteasome, and are used 
generally used to present peptides whose source is internal to the cell; thus presentation 
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of peptides in class II MHC is crucial to mediating the immune response to intracellular 
pathogens and cancer. Class I MHC function to activate CD8+ T-cells or cytotoxic T-
lymphocytes (CTL), whose primary function within the adaptive immune system is the 
recognition and killing of infected or cancerous cells within the body. There is a strong 
argument that class I MHC restricted tumor antigens that can be recognized by CTLs 
make the best “tumor rejection antigens”, as class I MHC are present in all cells, CTLs 
are the primary effector arm of the immune response against cancer, and the fact that loss 
of HLA class I expression in cancer patients is strongly associated with disease 
progression[184]. Thus, control over CD8+ T cell fate is critical to the success of tumor 
immunotherapy.  
T cell fate is be dictated not only by the antigen recognized, but the context in 
which the antigen is recognized (Fig. 2.5). Naïve T cells that recognize pMHC (pMHC), 
without co-stimulation by secondary signals, are directed to become unresponsive to 
further stimuli (anergy) or die, which allows for T cell tolerance to form outside the 
immune organs. Professional APCs, like DCs, in addition to presenting peptide antigen-
in-MHC on the surface (which is termed signal 1), provide secondary signals to the T cell 
in two main ways. Principally, recognition dependent activation is modulated by 
expression of surface molecules such as B7.1 that interact with other surface molecules 
on the T cell surface such as CD28 (termed signal 2) [185]. Secretable 
immunostimulatory factors like cytokines also serve to help direct T cell fate; these are 
often termed signal 3[186]. In addition to the identities of the molecules involved in the 
process, the interaction between a biological APC and a T cell requires close apposition 
of membranes over a large area of surface contact, and results in large-scale protein 
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rearrangements and the subsequent formation of the immune synapse (Fig. 2.6a, IS)[187, 
188]. 
 
2.2.2 Artificial aAPCs  
Artificial antigen presenting cells (aAPCs) are a promising, but relatively early-
stage concept that relies on cell-sized constructs mostly for ex vivo expansion. Currently, 
the more commonly used approach for T cell immunotherapy involves the use of ex vivo-
expanded autologous tumor-specific T cells [189, 190]. Other currently used approaches 
involve pulsing autologous, in vitro expanded and activated dendritic cells (DCs) with 
synthetic peptide epitopes from tumor associated antigens (TAA) or the TAA themselves 
for induction of tumor-specific CTLs [191]. However, these approaches are often 
unsuccessful and lead to induction of a T cell response that is unable to recognize the 
tumor cells. Isolation of specific T-cell subsets has been greatly aided by the development 
of peptide specific tetramers / multimers that consist of pMHC (or HLA) arranged into a 
multimeric particle by linking 4 (or more) HLA molecules to an avidin-derivative core 
[192, 193]. One major advantage of the “streptamers” is that function of the T cell is 
preserved following selection, whereas with tetramers, the selected T cell population 
shows impaired function [193]. Alternative approaches involve transfecting or 
transducing DCs with DNA or RNA to produce the TAA[194], or inserting conventional 
or chimeric T cell receptors into T cells to impart the desired specificity[195, 196]. !
As an alternative to the conventional approach of accessing native antigen 
presenting cells and using them to direct the immune response, there has been increasing 
interest in developing particle systems that can substitute for the function of the 
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biological APC. These particles as a class are termed artificial antigen presenting cells 
(aAPC). Recent advances in the development of cell-based aAPCs was recently reviewed 
by Turtle et al[183] and is outside our scope here.  
An ideal aAPC system would provide the same signals (antigen recognition, 
surface constimulation, and secretable factors) to the T cell target as the biological APCs 
(Fig. 2.5). aAPC have been generated by coupling proteins that deliver Signal 1 and 2 to 
the surface of particles made from a range of materials, including liposomes [180, 197], 
magnetic [198-201], polystyrene [181], and degradable polymeric particles [178, 202, 
203]. Each material has its own advantages and disadvantages for their use as aAPCs. 
Liposomes have fluid membranes that closely mimic biological membranes and can be 
used for delivery of drugs, but are substantially less stable than hard particles. Magnetic 
particles are of particular interest for ex vivo T cell expansion, because they can be 
readily removed from the expanded T cell population before re-infusion. Biodegradable 
particles can be useful for their release properties, and are be very biocompatible so may 
be very suitable for in vivo applications, but present challenges to extended surface 
presentation. Artificial aAPCs have been mostly investigated for their 
immunostimulatory properties towards CD4+ or CD8+ T-cells. However, it is important 
to note that the same bioengineering approaches can be used to potentially synthesize 
killer aAPCs which kill targeted T cell subsets to eliminate auto-reactive clones that are 
responsible for auto-immune disease [204, 205] or to generate aAPCs which stimulate 
and expand natural killer T (NKT) cells [206, 207]. 
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2.2.3 Signal 1 and 2 – Antigen presentation and costimulation 
One of the advantages with a synthetic approach is the ability to pattern the 
surface with defined surface molecules and specified ratios. This allows the precise study 
of the effects of those particular protein sets in isolation or in combination. The biological 
recognition signal consists strictly of pMHC and TCR, so TCR-subset-specific aAPC 
systems have utilized surface pMHC or pMHC multimers (dimers[208] or 
tetramers[209]) for the purpose of targeting. The vast majority of aAPC systems tested, 
however, instead use anti-CD3 mAb as their targeting ligand. CD3 itself is a co-receptor 
that is part of the TCR complex regardless of TCR antigen specificity, and when used in 
aAPC systems, is used to stimulate the TCR of any T cell in an antigen-independent 
fashion.  
The first study detailing the use of HLA molecules in a completely artificial 
system to activate T cells was published in 1978 by Engelhard et al, who showed that 
CTL induction was possible using 100-nm phospholipid vesicles presenting on their 
surface purified HLA antigens [180]. The critical finding of this study revealed that CTL 
activation was very sensitive to the density of antigen presented. The highest level of 
CTL function was elicited by liposomes containing 20 molecules per vesicle (2000 
molecules/µm2), which was the lowest density tested in this initial study. Higher density 
vesicles (100 and 400 molecules per vesicle or 10000 and 40000 molecules/µm2) showed 
lower maximal levels of function.  For optimal function, however, this system required a 
high ratio of liposomes to target cells (100 liposomes / target cell).  
Multiple biological molecules can function as “signal 2” and can induce positive 
costimulation or negactive costimulation (repression) depending on their identity. These 
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surface molecules interact dynamically to modulate the response to TCR triggering. 
Studies with polystyrene microparticles have helped to identify the importance of co-
stimulation to effective aAPC function. Polystyrene (PS) microparticles functionalized 
with anti-TCR antibody and B7-1 showed that co-stimulation by B7-1 is sufficient for the 
induction of effector function in CD4+ and CD8+ T cells [210], but that CD8+ responses 
were transient in nature and required higher density of costimulatory molecules on the 
surface than that required by CD4+ cells. In addition, ICAM-1 (critical for cell-cell 
adhesion and the major component of the pSMAC) was shown to also be able to provide 
co-stimulation for CD8+ T cell activation and synergize with B7-1 for induction of IL-2 
production, but failed to do so for CD4+ T cells [211]. 
 
2.2.4 Signal 3 – Cytokine release 
  One of the advantages of a biodegradable aAPC system compared to a non-
degradable aAPC system is that the biodegradable system can be engineered to release 
soluble factors from within the aAPC in addition to presenting factors that are attached to 
the aAPC surface. In addition, for in vivo administration, biodegradable aAPC would 
offer the promise of avoiding in vivo accumulation and increasing biocompatability, as 
the eventual dissolution of the particle would allow for complete elimination of the 
system from the body. 
  One major difficulty with constructing biodegradable aAPC is that degradation of 
the particle tends to lead to loss of surface function. Initial work by Shalabi et al showed 
that polyglycolic acid (PGA) microparticle could be used to release immunomodulatory 
compounds, and could also be made into and aAPC by irreversible absorption of anti-
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CD3 and anti-CD28 onto the surface [212]. Subsequently, using a novel method which 
relies on the incorporation of avidin-palmitic acid conjugates into the surface of the 
poly(lactic-co-glycolic) acid (PLGA) particles [213], Steenblock et al. were able to 
develop a PLGA-based biodegradable aAPC which could stably present ligand on its 
surface in solution for over 20 days [177]. This method relies on the hydrophobic chain 
of the palmitic acid partitioning into the hydrophobic PLGA core, while the avidin 
partitions to the surface of the particles and is available to bind biotinylated anti-CD3 and 
anti-CD28 antibody. 
  In addition, because PLGA is biodegradable, IL-2 could be released from the 
particle core, allowing the aAPC to incorporate cytokine signaling (signal 3) in addition 
to antigen recognition and surface co-stimulation (Fig. 2.5). Importantly, paracrine 
release of IL-2 from the particles resulted in superior T cell expansion compared to 
exogenous administration of equivalent amounts of cytokine [177]. Paracrine delivery of 
IL-2 upon T cell contact resulted in increased IL-2 in the contact region and increased 
proliferation of CD8+ T cells in vitro 10-fold compared to bulk IL-2 administration. 
Additionally, these responses appear to require sustained release of low levels of IL-2 and 
depend on close contact between the aAPC and T cell [178].  
 
2.2.5 Particle size as a critical parameter 
Polysytrene particles have been extensively studies as platforms for the 
development of aAPCs, and studies in this system have enhanced our understanding of 
critical parameters in designing acellular aAPCs. Perhaps most critically, the effect of 
particle size on aAPC function was first studied using polystyrene (PS) particles [181]. 
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Testing various sized spherical PS particles with class I MHC immobilized on the surface, 
Mesher found that 4-5 µm particles provided optimal stimulus. Smaller particles showed 
decreased stimulation, and this decreased stimulation could not be overcome by 
increasing the dose of the smaller particles. These results indicated that receptor 
occupancy over a large surface area of contact is a critical determinant for activation. 
While efficient and effective nanoscale aAPC might have better properties for in vivo 
applications, such as improved draining to lymph nodes, and reduced likelihood of safety 
concerns (such as aAPC becoming trapped in a capillary bed), these data point to the 
potential advantages of microscale aAPCs. 
 
2.2.6 Particle shape 
The use of non-spherical particles has generated increasing interest in recent years 
for biomedical applications. From a biomimetic perspective, the various morphologies of 
bacterial and viruses are suspected to play a role in their ability to efficiently invade and 







A wide variety of shapes have been generated by top-down and bottom up 
approaches [215, 216]. Particles have been made that mimic the mechanobiology of red-
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blood cells, resulting in increased circulation times and dramatically improved their 
biodistribution profiles [217]. Recent advances in the ability to generate particles with 
diverse shapes has enabled the study of the effect of shape on cellular internalization, 
phagocytosis, particle attachment, and circulation half-life [218]. Local particle curvature 
appears to dictate whether or not the particle will be phagocytosed [219, 220]. In 
particular, high aspect ratio (AR) ellipsoidal microparticles (in particular, those with AR 
> 20) have reduced phagocytosis compared to spherical particles, because when the low 
curvature sides of the particle encounter a phagocytic cell, the low curvature prevents the 
cell from engulfing the particle. In addition, the shape of the particle also modulates the 
degree of particle attachment to macrophages independent of the rate it internalizes the 
particle. In particular, prolate ellipsoids (a>b=c) showed the lowest internalization rates 
but most efficient particle attachment, when compared to oblate ellipsoids (a=b>c) or 
spherical particles [221]. Particle shape has also been implicated in increasing circulation 
time for particles injected into the bloodstream of mice, by aligning with blood flow in a 
superior fashion to spherical particles and reducing phagocytosis [222, 223]. 
To date, nearly acellular artificial antigen presenting cell systems have utilized 
spherical particles in their constructs. However, both the dramatic morphological changes 
that come with activation of dendritic cells, and the potential improvements in terms of 
decreased particle internalization and increased particle attachment indicates that particle 
shape may play a key role in future aAPC systems, and helps to motivate the 
development of non-spherical artificial antigen presenting cells described herein. 
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2.2.7 Methods to engineer polymeric aAPC shape 
Perhaps the simplest and most accessable method developed for generating non-
spherical particles uses a film stretching technique originally developed by Ho et al[224] 
and more recently adapted to generate polymeric micro- and nanoparticles of varied 
shape (Figure 6) [225]. Polymeric particles are suspended in a solution containing high 
quantities of poly(vinyl)alcohol (PVA) and some glycerol as a plasticizer, and then the 
particle solution is cast into a film by pouring onto a leveling table and allowing the water 
to evaporate over time. This film can then be cut into pieces, and stretched under heating 
on a stretching device, cooled, and then the particles are removed by dissolving the film. 
The advantages of this approach are that it does not require complex technology and 
generation of particles with complex shape is possible. This process lends itself less 
efficiently to large-scale batch synthesis, and batch-to-batch variability due to 
inhomogeneous stretching can be a moderate issue; however, the ease of application and 
the control over equivalent volume in comparison samples made this method an easy 
choice for our purposes here.  
One of the most versatile approaches to generating a vast array of potential shapes 
is Particle Replication in Nonwetting Templates (PRINT) technology [226]. By using 
photocurable perfluoropolyether (PFPE) molds and fluorinated surfaces, PRINT is able to 
produce isolated, harvestable individual particles. It can be used to generate 
monodisperse micro- and nanoparticles (sub-100 nm) of various polymers such as PLG, 
poly(pyrrole) and polyethyelene glycol, and can be used to incorporate proteins, DNA, 
and small molecules into the shaped particles.  In addition, particles can be printed that 
are 100% protein [227]. 
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High AR particles, as noted above, are of considerable interest due to favorable 
reduction in phagocytosis and increase in cellular binding properties.!High AR particles 
can be generated using PRINT by using a mechanical elongation strategy. This involves 
fabricating an initial PDMS mold, deforming that mold, and using the deformed mold to 
generate a new mold [228]. Due to limitations in deformation extent, this process can be 
repeated in cycles to generate very high aspect ratio particles. !
Continuous flow lithography also been developed for synthesis of particles with 
diverse shapes [229]. In this process, an acrylate oligomer stream containing a 
photoinitiator is flowed through a PDMS microfluidic device, and the flowing oligomer 
is exposed to controlled pulses of UV light shined through a transparency mask that is 
patterned by lithography. The limitation here is that continuous flow lithography cannot 
readily fabricate sub-3 µm shapes, as the process is limited by polymerization times and 
the feature sizes that are printable on a transparency mask (polymerization time is 
inversely related to the size of the transparency mask). A modified stop-polymerize-flow 
method was suggested to enable synthesis of 1-µm particles. 
 
2.2.8 Conclusion  
Acellular aAPC have particularly shown great initial promise for ex vivo 
activation of CTL and have been investigated for in vivo applications as well. The 
development of aAPCs has focused mainly on the choice of proteins to use for surface 
presentation to T cells when conjugated to various spherical, micro-scale particles. Key 
recent advances have allowed for the development of acellular aAPCs that incorporate 
more biological cues than antigen recognition (signal 1) and costimulation (signal 2). 
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aAPCs have been developed that incorporate secretable cues (cytokines, “signal 3”) and 
surface geometric cues that operate from the nanoscale to the microscale, such as 
interfacial geometry, surface protein organization and segregation, and dynamic protein 
rearrangement. Early work has demonstrated a critical role for particle size, showing that 
the surface area available for contact is crucial in these systems.  
Biodegradable particles offer strong biocompatablility and are useful for release 
of secretable cues or other immunomodulatory factors. Recent advances in the 
development of methods for the generation of non-spherical biodegradable particles may 
enable next-generation aAPC with interfacial geometry that more closely mimics the 








Figure 2.3. Time-lapse video microscopy stills of shape-dependent phagocytosis by 
macrophage. (A) Shape-switching poly(lactide-co-glycolide)– ester elliptical disk allows 
macrophage internalization. (B) Poly(lactide-co- glycolide)–ester elliptical disk that does 






Figure 2.5: Biological vs. acellular artificial Antigen Presenting Cell schematic: A 
schematic depicting a biological APC interacting with a T cell (left) and an aAPC 
interacting with a T cell (right). In the biological setting, the recognition signal (“signal 
1”) is provided by the interaction of pMHC with the T cell receptor complex, composed 
of a TCR heterodimer and signaling CD3 chains. Costimulation (“signal 1”) occurs 
through a variety of cell-surface protein mediators; the B7.1:CD28 interaction is often 
used in aAPC constructs. T cell fate is also determined classically by the cytokine mileau 




Figure 2.6: Immune synapse disruption by patterned substrates. Immune synapse 
formation is dependant on the shape of the substrate. T cells with fluorescently stained 
TCRs (green) were added to supported lipid bilayers containing pMHC (unlabeled) and 
ICAM (red) on the surfaces without patterning (A), with 2-µm parallel lines (B), with 5-
µm boxes (C), and with hexagonal lines (D, 1-µm spacing). Reprinted with permission 







Figure 2.7: Diverse non-spherical particle shapes. Diverse shapes can be made using a 
film stretching method using microparticles (a-h). Adapted with permission from [225], 











































































































































































































































































































































































































































































































































































































































3 Chapter 3: Degradable Polymers for Gene Delivery2 
Gene delivery has great potential, both as a therapeutic to treat disease on the 
genetic level and as a technology to enable regenerative medicine.  The central challenge 
is finding a safe and effective delivery system.  As viral gene therapy can have serious 
safety concerns, many recent efforts have focused on non-viral methods that utilize 
biomaterials.  Many materials have been shown effective for delivering genes in vitro 
including cationic lipids, sugars, peptides, and polymers [1-3].   
One of the lead delivery polymers is polyethylenimine (PEI), which due its 
cationic structure, can be very effective for binding DNA and forming gene delivery 
particles [4].  PEI is also particularly effective at promoting endosomal escape of 
PEI/DNA particles through the proton sponge mechanism [5, 6].  This is critical to 
prevent lysosomal degradation of the DNA and to enable efficient delivery of the DNA to 
the cytoplasm.  This endosomal escape mechanism has been used in the design of other 
synthetic gene delivery polymers, including polylysine-based polymers that contain an 
imidazole group in the side chain [7]. Although PEI shows promise compared to other 
biomaterials, it also leads to significant cytotoxicity [8] and has lower effectiveness than 
viral methods.      
One newer group of polymers used for gene delivery are poly(β-amino ester)s [9].  
They are useful due to their ability to bind DNA, promote cellular uptake, facilitate 
escape from the endosome, and allow for DNA release in the cytoplasm [10-12].  Unlike 
PEI, they are readily biodegradable due to their ester linkages, which reduces cytotoxicity 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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[10, 13].  It has been shown that within this class, acrylate-terminated polymers have low 
gene delivery, whereas amine monomer-terminated polymers have higher delivery [14].  
Recently, end-modification with diamine monomers has shown that some of these 
polymers can rival adenovirus for gene delivery in vitro and are also effective in vivo [15, 
16]. 
 Another interesting approach to increase gene delivery effectiveness while 
reducing cytotoxicity is adding bioreducible linkages to polymers.  Disulfide linkages 
have been added to PEI to produce bioreducible versions with lower cytotoxicity than 
high molecular weight versions of the parent polymer [17, 18].  Other researchers have 
shown that bioreducible poly(amido amines) can have higher efficacy than PEI while also 
having reduced cytotoxicity [19, 20]. 
 It was recently demonstrated that IMR-90 human primary fibroblasts can be 
reprogrammed to induced pluripotent stem cells with integrating viruses [21].  
Reprogramming human differentiated cells into undifferentiated, pluripotent cells could 
potentially enable a patient to receive a customized cell therapy that is a perfect genetic 
match.    
In this initial study, we investigated how small modifications to the monomer 
ratio used during polymerization in combination with modifications to end-capping group 
chemical structure used post-polymerization affects gene delivery.  We compared how 
chemical structure tunes gene delivery efficacy between a cancerous fibroblast line and 
human primary fibroblasts.  In particular, we highlight that small changes to the 
molecular weight or changes to just the ends of the polymer, while leaving the main chain 
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of the polymer the same, significantly enhances or decreases the overall delivery of the 
polymer.   
 
3.1 Materials and Methods 
3.1.1 Polymer Synthesis 
1,4-butanediol diacrylate (Alfa Aesar), 5-amino-1-pentanol (Alfa Aesar), 1-(3-
aminopropyl)-4-methylpiperazine (Lancaster), 1-(3-aminopropyl)pyrrolidine  (Acros 
Organics), 4-aminophenyl disulfide ( Sigma-Aldrich), dimethyl sulfoxide (Sigma-
Aldrich), 25 kDa polyethylenimine (Sigma-Aldrich), and Lipofectamine 2000 
(Invitrogen) were used as received.  Polymers were synthesized using a two-step 
procedure that is described in Fig. 3.1.  Acrylate-terminated poly(1,4-butanediol 
diacrylate-co-5-amino-1-pentanol) was first synthesized at two different acrylate 
monomer to amine monomer molar ratios, 1.05:1 and 1.2:1.  For the 1.05:1 ratio, 3532 
mg of 1,4-butanediol diacrylate (17.8 mmol) was added to 1754 mg of 5-amino-1-
pentanol (17.0  mmol) and for the 1.2:1 ratio, 3532 mg of 1,4-butanediol diacrylate (17.8 
mmol) with 1533 mg of 5-amino-1-pentanol (14.8 mmol).  
Reactions took place in DMSO (500 mg/mL) in glass vials in the dark under 
magnetic stirring for 48 hrs at 40°C.  As a second step, three amine-containing small 
molecules were individually conjugated to the ends of each polymer post-polymerization.  
Reactions were performed by mixing 321 mg of poly(1,4-butanediol diacrylate-co-5-
amino-1-pentanol) in DMSO (500 mg/mL) with 800 µL of 0.25 M amine solution. 
Excess amine is used to fully end-modify the base polymer. Reactions were performed in 
1.5 mL tubes in a multi-tube vortexer with constant agitation for 24 hours at room 
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temperature.  Polymers were stored at -20°C with desiccant until use.  Polymers were 
analyzed by gel permeation chromatography using a Waters Breeze System and 3 
Styragel Columns (7.8 x 300mm) in series:  HR1, HR 3, and HR 4.  The eluent was 95% 
THF/5% DMSO/0.1M piperidine and ran at 1 mL/min. 
3.1.2 Cell Culture 
COS-7 and IMR-90 cells (ATCC, Manassas, VA) were grown following ATCC 
recommended protocols and reagents.  COS-7s were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM, ATCC) supplemented with 10% fetal bovine serum (ATCC) 
and 100 units/mL of penicillin and streptomycin (Invitrogen).  IMR-90s were grown in 
Eagle’s Minimum Essential Medium (EMEM, ATCC) supplemented with 10% fetal 
bovine serum (ATCC) and 100 units/mL of penicillin and streptomycin.  Cells were 
subcultured upon confluence and IMR-90s were used prior to passage eight. 
3.1.3 Gene Delivery Assays 
Cells were plated in white 96-well plates at 15,000 cells in 100 µL per well and allowed 
to adhere overnight. CMV-Luc  
DNA (Elim Biopharmaceuticals, Hayward, CA) was diluted in 25 mM sodium acetate 
(pH=5) to 0.06 mg/mL. Polymers at 100 mg/ml in DMSO were diluted in 25 mM sodium 
acetate buffer to concentrations that generate the varying polymer to DNA weight ratios 
(20, 40, 60, 100). One hundred microliters of diluted polymer solution was mixed 
vigorously with 100 µL of DNA solution in a 96-well plate using a multichannel pipette.   
After 10 minutes wait time, 20 µL of each formulation was added to the cells that 
contained 100 µL of complete media per well.  Particles were incubated with the cells for 
four hours and then removed with a 12-channel aspirator wand.  Warm, complete media 
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was added to the cells (100 µL/well) and they were allowed to grow for two days at 37°C 
and 5% CO2.  Polyethylenimine/DNA particles were formed in a similar manner to the 
other polymers, except that they were formed at a w/w ratio of 1 (N/P~8) in 150 mM 
NaCl solution as has been previously described [4, 22].  Lipofectamine 2000 was used 
following the manufacturer instructions.  Forty-eight hours post transfection, gene 
expression was measured using Bright-Glo luminescence assay kits (Promega), a 
Synergy 2 multilabel plate reader (Biotek), and a one second read time per well.  Protein 
content per well was measured using the BCA protein assay kit (Pierce) and the Synergy 
2 plate reader to measure absorbance at 562 nm.       
 
3.2 Results and discussion 
  Base acrylate-terminated polymers were synthesized via the conjugate addition of 
5-amino-1-pentanol to an excess of 1,4-butanediol diacrylate in a manner similar to that 
previously described, but at a lower temperature and for a longer reaction time while 
being dissolved in DMSO [15, 16]. Polymerizations were performed at molar ratios of 
1.05:1 and 1.2:1 at 40 °C for 48 hrs.  Subsequently, the polymers were end-modified by 
conjugate addition of 1-(3-aminopropyl)-4-methylpiperazine (Poly 1), 1-(3-
aminopropyl)pyrrolidine  (Poly 2), or 4-aminophenyl disulfide (Poly 3) to the base 
polymers at room temperature for 24 hrs (Fig. 3.1).  Polymers were analyzed by gel 
permeation chromatography as shown in Table 1.  For the 1.2:1 molar ratio, polymers 
had Mw ~ 6 kDa.  At a 1.05:1 molar ratio, the molecular weight was higher, Mw ~ 6.5-
8.5 kDa.  Gene delivery particles were formed in buffer through self-assembly between 
the cationic polymers and anionic DNA.   
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At lower weight ratios (20 and 40 w/w), polymeric particles formed with 
polymers synthesized at 1.05:1 were generally more efficient for gene delivery than the 
same polymers formed at 1.2:1.  This is likely due to the higher MW of these polymers.  
In some cases, these changes were dramatic.  For example, for Poly 1 at 20 w/w, the 
1.05:1 ratio is more than 10-fold as effective as the 1.2:1 ratio with COS-7 cells and 400-
fold more effective for IMR-90s.  Interestingly, the difference in MW between these two 
polymers is only ~ 1.5 kDa.  However, at higher weight ratios (60 and 100 w/w), this 
trend is not seen and the effectiveness of both polymer synthesis conditions is 
comparable.  The one exception to this trend is Poly 2, which has comparable delivery 
between the two synthesis ratios at 60 and 100 w/w in COS-7 cells, but in IMR-90 cells, 
only the 1.05:1 ratio polymer is effective at any weight ratio tested.  Thus small changes 
to MW may be able to tune delivery properties to alter cell-type specificity.      
Certain end-modifying groups also appeared to show cell-type specificity.  For example, 
Poly 3 at 60 w/w or 100 w/w has very high gene delivery to the COS-7 cancerous 
fibroblasts, but very poor delivery to the IMR-90 human primary fibroblasts.  In 
comparison to Lipofectamine 2000, Poly 3 (1.2:1 ratio and 60 w/w) enables twice the 
gene expression in COS-7 cells, but over 200-fold less expression in IMR-90s.  For 
transfection of IMR-90s, Poly 1 or Poly 2 at a polymerization ratio of 1.05:1 and polymer 
to DNA weight ratio of 100 were the most effective.  These conditions enabled 
transfection of human primary fibroblasts in serum-containing media at 8-10 fold the 
levels of Lipofectamine 2000.  Lipofectamine 2000 is a leading-commercially available 
lipid-based transfection reagent and the polymers presented here can achieve comparable 
or higher delivery to both cancerous and primary cell types.  Compared to 25 kDa 
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branched polyethylenimine, a leading of-the-shelf gene delivery polymer, the polymers 
presented here are up to 2-3 orders of magnitude more effective.  In all cases, cells 
remained viable and comparable to untreated controls as determined by visual inspection 
and relative levels of protein content per well through the BCA assay.      
Small molecule amine containing end-groups were chosen to increase DNA 
binding affinity compared to acrylate terminated polymers and to potentially improve 
endosomal release of the particles (Poly 1 and Poly 2) or bioreducible release of the DNA  
(Poly 3).  As these small structural modifications also lead to a significant change in cell-
type specificity, the end-group may also play an important role in directing particle 
uptake.  We are currently quantifying these mechanisms to better understand 
structure/function relationships of these materials.  Further exploration of polymer 
structures may lead not only to safe and effective transfection reagents, but also to 




Fig. 3.2.  Gene delivery efficacy of Poly 1, Poly 2, Poly 3, and commercial reagents PEI 
and Lipofectamine 2000 to COS-7 cells (above) and IMR-90 cells (below).  Luciferase-
encoding DNA is delivered and expression is measured as relative light units per gram 
protein.  Ratio 1.05:1 and 1.2:1 refer to polymerization conditions and wt/wt is the weight 




Table 3.1: Polymer Molecular Weight 
 Ratio Mn Mw PDI 
Poly 1 
1.05:1 5415 7696 1.42 
1.2:1 4580 6124 1.34 
Poly 2 
1.05:1 4249 6459 1.52 
1.2:1 3943 5714 1.45 
Poly 3 
1.05:1 5680 8521 1.50 


































































4 Chapter 4: Effects of Base Polymer Hydrophobicity 
and End Group Modification on Polymeric Gene 
Delivery3 
4.1 Introduction 
Gene therapy holds out the promise of specific therapy designed to target the root 
causes of a plethora of diseases, ranging from single gene diseases such as sickle cell 
anemia and hemophilia, to diseases with a genetic basis such as cancer, diabetes, and 
heart disease. Since viruses have long evolved to be exceptionally efficient at getting 
their genetic information into cells, scientists and clinicians initially took advantage of 
this to develop viral vector-based gene therapeutics. Unfortunately, the field had 
significant setbacks when tragedies occurred in clinical trials, including deaths due to 
excessive immune responses to the viruses, as well as subsequent cancer generation due 
to insertional mutagenesis [1-3]. The major effort in this field remains in the viral arena – 
75% of clinical trials for gene therapy use viral vectors [4]. Due to the potential 
drawbacks of viral vectors, including their immunogenicity, potential for insertional 
mutagenesis, small cargo capacity, and difficulty involved in large-scale production, a 
wide variety of non-viral vectors have been investigated for their nucleic acid delivery 
efficacy [5, 6]. Among the polymers investigated, poly(beta-amino) esters have 
particularly shown promise as gene delivery vectors [7-11], with some formulations 
rivaling adenoviral transfection efficacy in hard to transfect human cell lines [12]. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This chapter contains excerpts from an article that was published as Sunshine JC, Akanda MI, Li D, 
Kozielski KL, and Green JJ. “Effects of Base Polymer Hydrophobicity and End-Group Modification on 
Polymeric Gene Delivery.” Biomacromolecules. 2011; 12(10),3592-3600. 
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Promising recent applications of these polymers include their use in cancer therapy [13-
15], as electrostatic coatings on gold nanoparticles for efficient delivery of siRNA [16], 
as biodegradable hydrogels [17, 18], and as pH-responsive components of polymeric 
micelles for drug release [19]. 
 Poly(beta-amino) esters (PBAE) are synthesized by simple Michael addition of 
diacrylates to primary (or bis-secondary) amines. Previous studies have noted that amine-
terminated versions of the polymers were far superior to corresponding diacrylate-
terminated versions [8], and thus have investigated whether modification of the ends of 
the polymers would have a dramatic effect on transfection efficacy [20]. Modification of 
the ends of the polymer has been shown to be important not only with regard to 
improving the efficacy of a particular polymer backbone, but the particular end group 
which is optimal appears to be a function of the cell type investigated [21]. There is a 
relationship between which polymers transfect well in 2D as compared to 3D culture 
methods, but the relationship is not perfect and some formulations can be better at 
transfecting cells in 2D monolayer or 3D culture [22]. Some convergence of optimal 
structure has been previously reported, including that small particle sizes have been 
associated with improved transfection, and that optimal polymers tend to contain amino-
alcohol side chains [23]. 
 One additional advantage of this library approach to vector design is that it can 
provide the means to productively analyze structure function relationships across a wide 
or narrow window of potential structures. However, previous studies have not looked at 
the systematic modification of all three structural and chemical elements that compose 
the polymer: backbone, side chain, and end-group. Here, we do this and synthesize a new 
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library of 320 end-modified PBAEs that differ by single carbon changes to the monomers 
that compose the backbone and side chains and small functional changes to the end-group. 
In this way we can analyze the contributions of spacer length, side chain length, and 
overall hydrophobicity / hydrophilicity of the end-modified polymer to the resulting 
transfection efficacy. 
We characterize the transfection efficacy and toxicity of the nanoparticles that 
these polymers form with DNA through self-assembly. The best performing polymer 
formulations show superior transfection efficacy to commercially available alternatives 
with better toxicity profiles, and the data reveal insight into structure function 
relationships within this polymer library. 
 
4.2  Materials and Methods 
4.2.1 Materials 
All reagents and solvents were obtained from commercial suppliers and used as 
received.  Monomers were purchased from Acros Organics [1-(3-aminopropyl)-4-
methylpiperazine (E8)], Alfa Aesar [3-amino-1-propanol (S3), 4-amino-1-butanol (S4), 
5-amino-1-pentanol (S5), 1,4-butanediol diacrylate (B4), 1,6-hexanediol diacrylate (B6), 
1-(3-aminopropyl)-4-methylpiperazine (E7)], Fluka [2-(3-aminopropylamino)ethanol 
(E6)], Monomer-Polymer and Dajac Labs [1,3-propanediol diacrylate (B3), 1,5-
pentanediol diacrylate (B5)], Sigma Aldrich [3-aminopropane-1,2-diol (S3o), 1,3-
butanediol diacrylate (B3m), 2-(benzoyloxymethyl)-2-ethylpropane-1,3-diyl diacrylate 
(BL1), ethoxylated bisphenol A diacrylate (BL2), glycerol 1,3-diglycerolate diacrylate 
(BH1), 1,3-diaminopropane (E1), 4-aminophenyl disulfide (E9), 
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cystaminedihydrochloride (E10), 2-(1H-imidazol-4-yl)ethanamine (E12)], and TCI 
America [1,3-diaminopentane (E3), 2-methyl-1,5-diaminopentane (E4), (PEO)4-bis-
amine (E5)]. Plasmids (CMV-Luc and CMV-eGFP) were amplified by Aldevron (Fargo, 
ND) and used as recieved. FuGENE® HD, LipofectamineTM 2000, and Opti-MEM I were 
purchased from Invitrogen and used according to manufacturer instructions. CellTiter 
96® AQueous One MTS assay and the BrightGloTM assay system were purchased from 
Promega, and were used according to manufacturer’s instructions. Dulbecco’s Modified 
Eagle Medium (DMEM) was purchased from Invitrogen and supplemented with 10% 
FBS and 1% penicillin/streptomycin.  
 
4.2.2 Polymer Library Synthesis 
The library of PBAEs was synthesized by adding primary amines (S) to diacrylate 
(B) compounds (1.2:1 molar ratio of diacrylate:amine, 5 g total reaction mass) without 
solvent, stirring at 1000 rpm at 90 °C for 24 hours. In a second step, the base polymers 
were dissolved in anhydrous DMSO (Sigma Aldrich) at 167 mg/ml. 480 microliters of 
base polymer at 167 mg/ml (80 mg) was then mixed with 320 microliters of a 0.5M 
solution of one end-capping amine (E), and allowed to react, while vortexing at 1000 rpm 
(VWR shaker) at room temperature for 24 hours. Eight diacrylate bases, 4 amino alcohol 




4.2.3 Gel Permeation Chromatography 
 Organic phase GPC was performed using 94% THF/5% DMSO/1% piperidine 
(v/v) as the eluent at a flow rate of 1.0 ml/minute in a Waters GPC system equipped with 
a Waters 717plus autosampler (Waters Corporation, Milford, MA). Three Waters 
Styragel columns (HR1, HR3, and HR4) were used in series, and the detector (Waters 
2414 refractive index detector) and columns were maintained at 40 °C throughout the 
runs. The molecular weights of the polymers are reported relative to monodisperse 
polystyrene standards (Shodex, Japan). 100 µl of each sample prepared at 5 mg/ml was 
injected, and each sample was given 40 minutes to elute off of the column. 
 
4.2.4 1H-Nuclear Magnetic Resonance (NMR) 
 All 32 base polymers and at least one representative end-modified polymer for 
each of the 10 end-modification reactions were characterized on a Bruker spectrometer 
by 1H-NMR spectroscopy (400 MHz, d6-DMSO); for the complete spectra of all the 
polymers, see supplementary information. As an example, for base polymer B3-S5: 1.15-
1.25 (2H, quint, NCH2CH2CH2CH2CH2OH), 1.25-1.35 (2H, quint, 
NCH2CH2CH2CH2CH2OH), 1.35-1.45 (2H, quint, NCH2CH2CH2CH2CH2OH), 1.85-1.95 
(2H, quint, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)), 2.3-2.4 (6H, t, 
CH2CH2NCH2CH2(COO)CH2CH2CH2(COO) and t, NCH2CH2CH2CH2CH2OH), 2.6-2.7 
(4H, t, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)), 3.3-3.4 (2H, obsc, 
NCH2CH2CH2CH2CH2OH), 4.0-4.1 (4H, t, 
CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)), 4.1-4.2 (t, CH2(COO)CH=CH2), 
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4.25-4.35 (br, NCH2CH2CH2CH2CH2OH), 5.9-6 (d, COOCH=CH2), 6.1-6.2 (dd, 
COOCH=CH2), 6.3-6.4 (d, COOCH=CH2). For the end-modified polymers, end-
modification was verified by the disappearance of the peaks at 5.9-6, 6.1–6.2, and 6.3-6.4 
ppm which correspond to the acrylate protons. However, the E9 reactions with base 
polymers left residual acrylate protons after reaction, indicating incomplete reaction and 
presence of the acrylate-terminated base polymers. All the other end-modifying amines 
resulted in complete elimination of acrylate peaks, corresponding to a complete reaction.  
Amide formation (peaks at 7.9 ppm corresponding to CO-NH and 3.0-3.2 
corresponding to CONHCH2) was noted in a subset of the end-modified polymers, but 
not in any of the base polymers. Amide formation (quantified by the ratio of peaks 
corresponding to CONHCH2 and COOCH2) was highest with polymers modified with E1, 
E3, E4 (two primary amines), was moderate with polymers modified with E6 (one 
primary, one secondary amine), and was minimal in end modified polymers containing 
E5, E7, E8, E10, and E12 (Table 4.1). Increasing amide formation also resulted in 
decreased molecular weight of the end-modified polymers (Fig. 4.1) with the same 
pattern (Fig. 4.2, linear regression R2 = 0.5637, p < 0.0001), indicating that amide 
formation was the direct cause of the decrease in molecular weight seen with the end-
capping step. These trends, however, do not appear to have any impact on the 
transfection efficacy of the resulting end-modified polymer (Fig. 4.3, linear regression R2 
= 0.0605, p > 0.05; not significant), indicating that small extent of amide bond formation 
and resulting decrease in molecular weight do not significantly impact the transfection 
efficacy of the end-modified polymers. 
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4.2.5 Polymer Solubility 
 Solubility was measured for a subset of polymers in the buffer used to dissolve 
the polymers and form the nanoparticles (25 mM sodium acetate (NaAc) in water) 
through a plate-reader absorbance assay. Ten microliters of 100 mg/ml polymer solution 
in DMSO was added to 40 microliters of 25 mM NaAc, forming a milky mixture. 
Absorbance of each well at 620 nm was measured with a plate reader (BioTek Synergy 2). 
Sequentially, each well was diluted by addition of another 10 microliters of 25 mM NaAc 
buffer, was mixed by pipetting up and down 5 times, and the resulting well was re-
measured with the plate reader.  Complete solubility was determined by comparing the 
absorbance at 620 nm for each well with a reference well containing the same amount of 
DMSO and 25 mM NaAc, and the result was also confirmed by eye. 
 
4.2.6 Luciferase Transfection and Viability Screening 
COS-7 cells were seeded at 15,000 cells/well (50,000 cells/cm2) into 96-well 
plates in complete DMEM and allowed to adhere overnight. Polymers were then 
aliquoted into 96-well U-bottom plates and dissolved in 25 mM sodium acetate buffer 
(pH 5.2). Separately, CMV-Luc DNA (Elim Biopharm) was diluted and aliquoted out. 
Diluted polymer was added to CMV-Luc DNA using a multichannel pipette and mixed 
vigourously by pipetting up and down. Nanoparticles were given 10 minutes to complex, 
and then were added to cells (20 microliters of nanoparticles added to 100 microliters of 
fresh complete DMEM). Final particle composition for all polymers was 600 nanograms 
of CMV-Luc DNA and 36 micrograms of polymer (60 wt/wt polymer:DNA ratio). As 
positive controls, LipofectamineTM 2000 (Invitrogen) and FuGENE® HD were prepared 
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in Optimem I (Invitrogen) according to manufacturer’s instructions and added to cells in 
the concentrations described in the text. After four hours of incubation, the media (and 
remaining particles) were removed by pipetting, and the media was replaced with fresh 
warmed DMEM. Twenty four hours after transfection, metabolic activity was assessed by 
the CellTiter 96® AQueous One MTS assay (Promega) and was normalized to untreated 
control wells. Briefly, 20 microliters of assay reagent was added to cells. Cells were 
placed back in the incubator for 1 hour, and then absorbance of each well at 590 nm was 
measured with a plate reader (BioTek Synergy 2). Plates were washed with 1x PBS and 
fresh media was added to each plate. 48 hours after transfection, luminescence was 
measured on a plate reader using the BrightGloTM luciferase assay system. Briefly, 100 
microliters of room-temperature assay reagent was added to 100 microliters of media on 
cells. The plate was swirled for precisely 2 minutes, and then the luminescence was 
measured. 
 
4.2.7 GFP Transfection and Flow Cytometry 
Cell plating, particle formulation, and transfection protocol for the GFP 
transfection was the same as above, except using EGFP-N1 DNA (Clontech) and 
particles were formulated at 30, 60, and 90 polymer:DNA wt:wt ratios instead of only 60 
wt. 48 hours post transfection, the cells were washed and trypsinized with 30 microliters 
of 0.25% trypsin-EDTA. 170 microliters of FACS buffer (1x PBS, 2% FBS, 0.5% 
propidium iodide) was added to cells and the 200 microliters was transferred to Starstedt 
96-well round-bottom plates. The plates were centrifuged for 5 minute at 1000 rpm, 
removed from the centrifuge, and 170 microliters was removed from on top of the cell 
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pellet. The cell pellet was resuspended in the residual 30 microliters and placed on an 
Intellicyt high-throughput loader and reader attached to an Accuri C6 flow cytometer. 
Each well was run dry, and in between each well we included a 1-second PBS wash to 
minimize well to well contamination. The Hypercyt software was used to discriminate 
between wells and FlowJo was used for FACS analysis.   
 
4.3  Results and Discussion 
4.3.1 Characterization of the Polymer Library 
The library of PBAEs was synthesized by adding primary amines to diacrylate 
compounds (1.2:1 molar ratio of diacrylate:amine) at 90 °C for 24h (Scheme 4.1a). 
These specific monomers were chosen so that single carbon changes to the backbone 
monomers and to the side chain monomers could be evaluated in the synthetic polymers. 
In a second step, the base polymers were end-capped by end-capping amines (at 10-fold 
molar excess of amine to diacrylate termini) at room temperature for 24 hours (Scheme 
4.1b). These end groups were chosen so that the presence of small molecule functional 
groups could be evaluated and compared across base polymers with differential structure. 
Eight diacrylate bases, 4 amino alcohol side chains, and 10 primary-amine containing 
end-groups were used to synthesize 320 total polymers (Scheme 4.1c). In order to more 
closely match the underlying structure to the naming convention used, we have chosen a 
separate naming convention from previous studies. Here, the number after “B” (for 
“base”) corresponds to the number of carbons between acrylate groups in the diacrylate, 
so B3 means than there are 3 CH2 units between acrylate groups in the diacrylate base. 
The number after “S” (for “side chain”) corresponds to the number of carbons between 
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the amine group and the hydroxyl group in the side-chain. Previous top-performing base 
polymers termed “C32”, “C28”([24](correspond to B4-S5 and B4-S4 respectively. The 
“E” (for “end group”) refers to which end-modifying amine was chosen; they are 
organized into structurally similar groups but the numbers are simply sequential.  The 
modifier “m” refers to an added methyl group (so B3m has an added methyl group 
compared to B3) and the modifier “o” to an added hydroxyl group (so S3o has an added 
hydroxyl group compared to S3). Every base polymer was characterized with respect to 
its base polymer molecular weight. Weight-averaged molecular weights of the polymers 
in the library ranged from 2,000 to 48,000, and number-averaged molecular weights 
ranged from 1,500 to 12,000 (Fig. 4.4, Table 4.2).  While many of the base polymers 
(8/32) had a weight-averaged molecular weight (Mw) of approximately 10,000 Da (+/- 
2,000 Da), some polymers had an especially high Mw (40-50,000 Da, such as B4-S4, B6-
S4, and BL2-S3o), and others had an especially low MW (under 3,000, such as BL1-S3 
and BH1-S4).  The viscosity of the starting monomers appears to have a significant effect 
on the molecular weight obtained using this synthesis protocol. S3o is relatively more 
viscous than S3, S4 or S5; polymers synthesized with S3o all had Mw of less than 9,000 
Da, except for BL2-S3o. S4 containing polymers with simple hydrocarbon backbones 
(B3, B3m, B4, B5, B6) all had Mw of greater than 10,000. BL1, BL2, and BH1 all 
needed to be solvated in order to be effectively mixed with the amino alcohol side chains, 
and the resulting polymers in general were all smaller than the Mw obtained from the 
neat synthesis protocol.   
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4.3.2 Effect of Polymer:DNA ratio 
To form nanoparticles, PBAEs were dissolved in 25mM NaAc (pH 5.2) to 
generate positive charge on the amines and complexed with CMV-Luc DNA at varying 
polymer:DNA weight ratio (wt/wt). Before screening the entire library at a particular 
polymer:DNA ratio, we looked at the effect of formulation ratio on polymer transfection 
efficacy. To do this, we tested a subset of 21 representative polymers for gene delivery at 
a wide range of wt/wts: 30, 60, 80, 100, 125, and 150 (Fig. 4.5, Table 4.3). Maximal 
luminescence was achieved at 60 wt/wt for most polymers tested. However, interestingly 
for B3-S5 end-modified polymers, maximal luminescence intensity was not achieved 
until a high 125-150 wt/wt ratio. Since maximal luminescence in general was achieved at 
60 wt/wt ratio, we used this wt/wt ratio when subsequently screening the entire library of 
320 structures. By testing all polymers at the same weight ratio, the influence of structure 
can directly be evaluated without the formulation ratio producing possible confounding 
effects. 
 
4.3.3 Effect of Base Polymer Composition 
To evaluate the effect of base-composition of the polymers on transfection 
efficacy, polymers were allowed to spontaneously form nanoparticles at a fixed weight 
ratio (60 wt/wt) and then added to COS-7 cells as and examined for transfection efficacy 
by total well luminescence from BrightGlo (Fig. 4.6, Table 4.4). To quantify 
cytotoxicity/cell viability, separate experiments were also conducted in parallel with the 
same nanoparticles and following the same transfection procedure. Twenty-four hours 
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after incubation, metabolic activity was assessed by the CellTiter 96® AQueous One MTS 
assay and was normalized to untreated control wells (Fig. 4.7, Table 4.5). 
Previous studies have shown that polymer molecular weight may play a role in 
transfection efficacy, with increasing molecular weight corresponding to increasing 
transfection efficacy.23 At least within this library of polymers, this effect appears to be 
muted (Fig. 4.8), as there was no correlation between increasing molecular weight of the 
base polymer and increasing average transfection efficacy for all end-modified polymers 
from the same base polymer (linear regression, R2 = 0.003, p = 0.7833),. 
Polymers containing simple hydrocarbon backbones were more effective than 
polymers containing bulkier hydrophobic or hydrophilic backbones. In particular, 
polymers containing the bulkier hydrophobic backbones (BL1 and BL2) were toxic to the 
cells at the tested wt/wt and DNA dose, while polymers containing the hydrophilic 
backbone (BH1) were relatively non-toxic but did not promote transfection.  
Single carbon changes to the base polymers in the polymer library produced 
dramatic results for transfection efficacy. Interplay was found between the relative 
hydrophobicity and hydrophilicity of the diacrylate and amino alcohols used to 
synthesize the base polymers. To evaluate the differences seen by this library approach 
statistically, we converted the luciferase luminescence data for the end-modified 
polymers containing B3, B3m, B4, B5, and B6 diacrylates and S3o, S3, S4, and S5 side 
chains to log-scale and performed analysis of variance (GraphPad Prism).  
Other studies have looked at modifying cationic polymers with hydrophobic 
moieties to increase transfection efficacy. Hydrophobic modification of polycations has 
been shown to be beneficial for gene delivery for a variety of reasons. Increased 
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hydrophobicity may enhance polymer-DNA binding by providing for physical 
encapsulation, in addition to charge-charge interactions [25].(Additionally, a general 
mechanism for uptake of non-viral gene delivery particles results from adsorptive 
endocytosis; enhancing the hydrophobicity of the polymer could result in increased 
interaction with the cell membrane and promote this process [25].(Hydrophobic 
modifications have been also used to improve gene dissociation from the polycation, by 
decreasing the electrostatic interactions between the cationic polymer and DNA [26, 27], 
and have been shown to improve the performance of the gene-carrier in the presence of 
serum [28]. 
A few excellent recent examples of studies looking at hydrophobic modification 
of a polycation base polymer show that with hydrophobic modifications, usually some 
modification improves the product, but too much hydrophobicity can decrease efficacy. 
N-alkylation of linear polyethyleneimine (PEI) with varying alkyl chain lengths (1, 2, 3, 4, 
and 8-carbon chains) at 11% of the backbone amines produced dramatic results. Gene 
delivery to the lung in a mouse model increased 8-, 26-, and 7-fold when modified by 1, 2, 
or 3 carbons, decreased moderately when modified by 4 carbons, and decreased 
substantially (200-fold) when modified by 8-carbon chains, as compared to 22 kDa linear 
PEI [25]. In addition, 11% alkylation produced the most transfection boost with N-ethyl-
PEI, as compared to derivatization of 5%, 14%, or 20% of the backbone amines [25]. In 
other work, poly(amidoamine) (PAMAM) dendrimers were functionalized with 4-8 alkyl 
chains (12-16 carbons in length) [29]. Cellular uptake was improved by both increasing 
the amount of functionalization and increasing length of alkyl-chain modification (as 
! 90!
these chains act as a lipid coating for the PAMAM dendrimer), whereas transfection 
efficacy was optimal with the shortest chain length (12-carbons) [29].  
Modification of chitosan, a naturally occurring polycation commonly used as a 
non-viral gene delivery reagent, with hydrophilic and hydrophobic chains resulted in 
dramatic effects on the gene delivery properties of this modified polymer. Both 
modifications enhanced plasmid release and reduced non-specific adsorption, but only 
modification with the hydrophobic PMLA enhanced cell adsorption and cellular uptake 
[30]. 
In comparison to these studies, our study examines how directly modulating the 
hydrophilic / hydrophobic character of an end-modified cationic polymer (rather than 
adding hydrophobic moieties to an existing cationic polymer) might modulate 
transfection efficacy. Presumably, some of the advantages that would be granted to 
cationic polymers by modifying them with hydrophobic moieties might be conferred to a 
polymer which at its core was modified to increase its hydrophobicity. In particular, 
increasing hydrophobic character of the core polymer might increase the ability of that 
polymer to physically encapsulate the DNA cargo and may also promote adsorptive 
endocytosis, as in many of the hydrophobic-modified polymer cases [31]. 
To determine how changing the hydrophobicity of the diacrylate base and the 
amino alcohol side chain affects the performances of all polymers in the library, we first 
averaged the log-scale luminescence data for all end-modified polymers with the same 
base polymer together so that they represent one composite value for each particular base 
polymer (Fig. 4.9). Interestingly, increasing hydrophobicity of either the diacrylate base 
or the amino alcohol side chain resulted, in general, in increased transfection efficacy. 
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This trend is shown in the cases of end-capped polymers with B3, B3m, B5, and B6 as 
backbones and S3o and S3 as side-chains.  In the special case of B4-based polymers, only 
polymer B4-S4 is less effective than otherwise would be predicted.  In the case of S4-
based polymers, there is biphasic dependence on hydrophobicity with B4-S4 having 
minimal activity and B3-S4 and B6-S4 having comparable effectiveness.  In the case of 
S5-based polymers, efficacy is high and equivalent across all backbone types.    
Closer inspection reveals that there may be some interplay between backbone and 
side-chain hydrophobicity. Examining the results with respect to increasing amino 
alcohol side chain hydrophobicity (Fig. 4.9), it is clear that the only polymers which 
included the most hydrophilic side chain (S3o) to achieve significant transfection used 
the most hydrophobic B6-S3o backbone. For polymers with the S3 side chains, the most 
effective base polymers incorporated the two most hydrophobic diacrylates (B5, B6). 
Among the polymers with the most hydrophobic side chain (S5), the most effective end-
modified polymers were largely equivalent, although B4-S5 and B5-S5, with 
intermediate hydrophobicity, were slightly more effective with particular end-groups.  S4 
has intermediate hydrophobicity and S4-based polymers were shown to have biphasic 
dependence on backbone hydrophobicity, with the most hydrophilic (B3) or hydrophobic 
(B6) backbones being optimal compared to the intermediate hydrophobicity backbones 
(B3m, B4, B5). Overall, there was excellent transfection achieved with all five of these 
base diacrylates tested. These findings suggest that with increasing side chain 
hydrophobicity, the requirement for a hydrophobic base diacrylate decreases and also 
suggests that if we were to test even more hydrophobic side chains that we might notice 
that incorporating diacrylates with reduced hydrophobicity might be optimal.   
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For all base diacrylates, the optimal side chain in general was the S5 side chain. 
However, with increasing base diacrylate hydrophobicity, there is decreasing preference 
for the most hydrophobic side chain (Fig. 4.9). For the least hydrophobic (B3) backbone, 
there is nearly an order of magnitude increase in transfection efficacy between each 
increasingly hydrophobic side chain (from 2.94 for B3-S3o to 3.64 for B3-S3 to 4.72 for 
B3-S4 to 5.55 for B3-S5 in logscale units). For the most hydrophobic (B6) backbone, 
there is less than an order of magnitude difference in transfection efficacy between the 
extremes (from 4.49 for B3-S3o to 4.91 for B6-S3 to 4.80 for B6-S4 to 5.40 for B6-S5). 
This suggests that if we were to test even more hydrophobic base diacrylates, that it is 
likely that increasing the hydrophobicity of the side chain (by increasing carbon length) 
may not enhance the gene delivery properties of the resulting end-modified polymer. 
To evaluate the relative importance of the base diacrylate and the side chain 
amino alcohol on the transfection efficacy displayed by the polymer library statistically, 
we calculated a 2-way ANOVA with our data. In the 2-way ANOVA, the side chains 
accounted for the largest share of the variance seen (45%, p < 0.0001), and the diacrylate 
used accounted for a smaller, but still highly statistically significant portion of the 
variance (8.5%, p < 0.0001).  The interaction between the two groups accounted for an 
additional 9% of the variance (p < 0.0001). This demonstrates that side chain 
hydrophobicity produced even more dramatic results than increasing base diacrylate 
hydrophobicity (although both effects are significant). A potential explanation for this 
discrepancy is that increasing “B” (base diacrylate) hydrophobicity increases spacing 
between charged nitrogens in the backbone but increasing “S” (side chain) 
hydrophobicity does not. Thus, increasing the hydrophobicity of the side chains may 
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yield the advantages associated with increased hydrophobicity without interfering with 
charge spacing, but increasing the hydrophobicity of the base diacrylate both increases 
the hydrophobicity and increases the spacing between nitrogens. Also of note, increasing 
the hydrophobicity of either the backbone or the side chain while holding the same DNA 
to polymer wt/wt ratio constant effectively decreases the nitrogen to phosphate ratio at 
the same time, which may affect particle formation and DNA release.  
 Another way to examine bulk hydrophilicity / hydrophobicity of the polymers is 
to examine the solubility trends of polymers in the library. We took a subset of polymers 
which were end-modified with E7 and determined the solubility of the end-modified 
polymers in the buffer used to dissolve the polymers and form the nanoparticles (25 mM 
sodium acetate (NaAc) in water). The most hydrophilic polymers (B3-S3-E7 and B3m-
S3-E7) were soluble at concentrations exceeding 10 mg/ml, and all polymers tested 
except for B3m-S4-E7 were completely soluble at 5 mg/ml in 25 mM NaAc (Table 4.6).  
 
4.3.4 Effect of End-Modification 
End-modification of each polymer backbone significantly modulated its 
transfection efficacy and toxicity. Polymers formulated with the E9 end group exhibited 
significant toxicity, almost regardless of the base polymer they were reacted with. 
Polymers containing E10 and E12 tended to show low transfection efficiencies with a 
few notable exceptions (B5-S5 and B6-S5 base polymers end modified with E10 and E12 
showed transfection efficacies comparable to commercially available transfection 
reagents LipofectamineTM 2000 and FuGENE® HD).  
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To look at how changing side chains affected the performances of all polymers 
containing a particular end group, we collapsed log-scale luminescence data for all 
polymers containing the same backbone monomer together into one composite value (Fig. 
4.10). Among the side chains tested, polymers containing the most hydrophobic amino 
alcohol (S5) were in general the most effective for transfection of COS-7 cells (p < 0.01 
vs S4, p < 0.001 vs S3, S3o, 1-way ANOVA with Tukey’s multiple comparison test) and 
polymers containing the S4 and S3 side chains were significantly more effective than 
those containing the S3o side chain (p < 0.01 vs S4, p < 0.05 vs S3o). 
To look at structure-function relationships within the polymer library, using a 
non-parametric correlation (Spearman), we calculated correlation coefficients and two-
tailed p-value comparing each end-modifying amine (Table 4.7). The most structurally 
similar end-modifying amines were also the most highly correlated in this analysis. 
Performance of polymers containing E1 and E3 end groups (both diamines separated by 3 
carbons) was highly correlated (R = 0.951, p = 1.4x10-10); performance of polymers 
containing E6, E7 and E8 (one primary amine, one or two secondary/tertiary amines) 
were also highly correlated (E6 to E8: R = 0.950, p = 6.3x10-10; E6 to E7: R = 0.921, p = 
8.4x10-9; E7 to E8: R = 0.918, p = 1.23x10-8). Interestingly, the performance of polymers 
containing E3 was also highly correlated with the performance of polymers containing E6 
and E8 (E3 to E6: R = 0.930, p = 2.8x10-9; E3 to E8: R = 0.928, p = 3.6x10-9). 
With same base polymers such as B6-S3, it was interesting to find that end-group 
could significantly modify the overall efficacy from nearly no expression when end-
modified with E12, to increased expression that was over 3 log orders higher with B6-S5-
E5 and E6, even though neither end-modified polymer was very toxic (Figs. 4.6 and 4.7). 
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This effect is also seen across the whole library. If we average the log-scale luminescence 
seen with all polymers with the same end-modifying amine (Fig. 4.11), we find that all 
polymers modified with E9 were worse than all other end modified polymers (p < 0.001, 
1-way ANOVA with Tukey’s multiple comparison test), and that E5-end modified 
polymers were better than E12 end-modified polymers (p < 0.05, 1-way ANOVA with 
Tukey’s multiple comparison test). On average, E5 polymers were over 1-log order of 
magnitude more effective than E12-modified polymers.  
To investigate the effects of end-modification further, we synthesized leading 
end-modified polymers containing all of the diacrylates, the amino alcohol S5, and the 
end groups E1, E3, E4, E5, E6, E7, and E8, and evaluated their transfection efficacy by 
flow cytometry at three separate wt/wt ratios (Fig. 4.12, Table 4.8). For some polymers 
such as B3m-S5-E5, B3m-S5-E7, B4-S5-E1, B4-S5-E6, B4-S5-E7, B4-S5-E8, etc., 
optimal transfection occurred at 30 wt/wt, but in almost all of those cases the transfection 
efficacy did not fall off that significantly from 30 to 60 wt/wt; for some of these, 
transfection efficacy was relatively consistent in all three formulation conditions, but for 
others it decreased with increasing wt/wt, often decreasing most dramatically from 60 to 
90 wt/wt (3m57, 457, 557). There were also polymers that showed optimal transfection at 
60 wt/wt (better than at 30, 90 wt/wt) such as 355 and 454. From a base polymer 
perspective, B4-S5 was the most efficient (best at 30 wt/wt) and transfection did not drop 
off with increasing wt/wt ratio. On the other hand, B3-S5 polymers tended to get better at 
transfection with increasing wt/wt ratio; B5-S5 was optimal at 30 wt/wt and decreased 
from there; and B6-S5 didn’t transfect well at 30 wt/wt but tended to be optimal at 60 
wt/wt (and worse again at 90wt/wt). A comparison of the results obtained via the 
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luciferase assay with the results from flow cytometry indicates the same overall pattern, 
although there are some differences. Similar findings have been shown in the literature, 
both with similar polymeric systems and liposomal systems [24, 32]. Differences 
between in vitro gene delivery assay systems may be due to the fact that they report 
different things.  Luminescence measures a total protein yield per well, whereas flow 
cytometry highlights a binary separation of the individual cells within a cell population. 
In cases where a small percentage of cells express a high level of the exogenous gene or 
where a high percentage of cells express a low level of the exogenous gene, the assay 
results will diverge. Leading polymers were thoroughly evaluated by using both of these 
complementary assay methods.   
Generally, polymers were optimal or not significantly suboptimal at 60 wt/wt ratio. 
The top six polymers overall were B3-S5-E1, B3-S5-E5, B3m-S5-E7, B4-S5-E3, B4-S5-
E4, and B4-S5-E7; they transfected COS-7s at the following levels when formulated at 
60 wt/wt (RLU, %GFP+): 351 (1.64x106, 64.5%), 355 (2.02x106, 69.4%), 3m57 
(2.24x106, 67.2%), 453 (1.97x106, 67.63%), 454 (1.89x106, 76.6%) and 457 (5.63x105, 
72.5%). These polymers yielded superior efficacy (p < 0.001 for both luminescence and 
fluorescence via 1-way ANOVA of all polymers and using Dunnet’s post test) when 
compared to the positive controls, FuGENE® HD (7.21x105, 29.9%) and 
LipofectamineTM 2000 (8.07x105, 42.9%). 
As compared to other non-viral approaches found in literature, optimized PBAE 
formulations are superior to most alternatives. PEI complexes were reported to yield 29% 
transfection and optimized solid lipid nanoparticles were reported to result in 15% 
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transfection with reduced cytotoxicity as compared to PEI [33]. Electroporation has been 
reported to yield 71% transfection [34] .  
In comparing luminescence to GFP assays as measures of gene delivery efficacy, 
luminescence based assays offer rapid screening options when flow cytometry is either 
unavailable or cannot be done in a high-throughput fashion, and can quickly give 
information regarding the overall transfection level.  However, it cannot discriminate 
between a few very bright cells and many moderately transfected cells. 
 
4.4  Conclusions 
 In the study presented here, three hundred and twenty end-modified poly(beta-
amino)esters (PBAE) were synthesized and tested for gene delivery efficacy in COS-7 
cells. This library approach enabled us to not only synthesize and test a large variety of 
structures rapidly, but provided us with a reasonably robust dataset to analyze for the 
effect of small structural permutations to the polymer chain. Most PBAE formulations 
were optimal at 60 wt/wt (polymer:DNA ratio). Optimal PBAE formulations were 
superior (p<0.001) to commercially available non-viral alternatives FuGENE® HD and 
LipofectamineTM 2000, as they enabled ~3-fold increased luminescence (2.2x106 
RLU/well vs 8.1x105 RLU/well) and 2-fold increased transfection (76.7% vs 42.9%) as 
measured by flow cytometry with comparable or reduced toxicity. Increasing 
hydrophobicity of backbone and side chain tended to increase transfection efficacy, and 
polymers containing the most hydrophobic side chain (S5) and backbone (B6) tended to 
perform the best. However, increased hydrophobicity of the backbone reduced the 
requirement for a hydrophobic side chain, and increased hydrophobicity of the side chain 
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reduced the requirement for a hydrophobic backbone, suggesting that there might be 
some optimal total hydrophobicity for cationic polymer-based gene delivery. End-
modification of these polymers produced dramatic results, as differences of greater than 
3-log orders of transfection efficacy by luminescence was seen with the same base 
polymer but with different end-groups. These results taken together suggest that 
balancing hydrophobicity plays a crucial role in transfection efficacy of these polymers, 
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End Capping Amine
 
Figure 4.1. Effect of end-capping on number-averaged and weight-averaged 
molecular weight. Relative ratio of number-averaged and weight-averaged molecular 
weight resulting from end-capping 4 base polymers (B3m-S4, B4-S4, B5-S4, and B4-S5) 
with the end-capping amines shown at the bottom. 
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Figure 4.2. Correlation between amide formation and polymer molecular weight. 
There is a negative correlation (linear regression, R2 = 0.5637; p < 0.0001) between 
amide formation, as measured by the ratio (CONHCH2/ COOCH2) and the molecular 

























Figure 4.3. Correlation between the decrease in molecular weight of the resulting 
polymer and the transfection efficacy of the set of polymers with that end-capping amine. 





























































































































Figure 4.5. Transfection efficacy (average RLU/well, n=4) of representative polymers, 
formulated at a range of polymer:DNA wt/wt ratios. For most polymers, 60 wt/wt was 




Figure 4.6. Transfection efficacy of polymer library by luminescence. Average 
luminescence per well, 48 hours post transfection (n=4) with CMV-Luc DNA and 
polymer library at 60 wt/wt (polymer:DNA). In the control column, the green bar 






Figure 4.7. Cellular metabolic activity post transfection with the polymer library. 
Metabolic activity of COS-7 cells 24 hours post-transfection (n=4) with CMV-Luc DNA 
and polymer library at 60 wt/wt (polymer:DNA)assessed by the CellTiter 96® AQueous 
One MTS assay (n=4) and normalized to untreated control wells. In the control column, 

























Figure 4.8. Molecular weight vs. transfection efficacy. Base polymer molecular weight 
vs. average log-scale transfection efficacy for all end-modified polymers from the same 
base polymer. The solid line is the linear regression line (R2 = 0.003, p = 0.7833), and the 

























Figure 4.9. Average log-scale luminescence post transfection (mean +/- SE) of end-
modified polymers with the same base polymer, plotted with increasing base diacrylate 
hydrophobicity. As an example, the far left bar represents the average log-scale 
luminescence post transfection of all polymers containing the base polymer B3-S3o. 
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Figure 4.10. Average log-scale luminescence post transfection (mean +/- standard error) 
of polymers containing the side chain and end group listed. For example, the far left bar 
represents the average log-scale luminescence post transfection of all polymers 




Figure 4.12. Average transfection efficacy by flow cytometry (n=4) of end-modified 
polymers containing S5. In the control column, the green bar corresponds to FuGENE® 
HD, and the yellow bar corresponds to LipofectamineTM 2000. 
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Table 4.1. Amount of amide formation resulting from end-capping B3-S5 with the end-
capping amines on the left. This is quantified as the ratio of the integrals of the peaks 
corresponding to the CONHCH2 protons which are around 3.0-3.3 ppm, and the 









E1! 2.27! 0.53! 0.23348!
E3! 1.52! 0.34! 0.223684!
E4! 2.11! 0.36! 0.170616!
E5! 2! 0.1! 0.05!
E6! 2.41! 0.25! 0.103734!
E7! 2.46! 0.12! 0.04878!
E8! 2.47! 0.19! 0.076923!
E9! 1.87! 0! 0!
E12! 2.35! 0! 0!
(
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Table 4.2. Base polymer molecular weight by gel permeation chromatography 



























































































Table 4.3. Transfection efficacy (average RLU/well, n=4) of representative polymer 
formulations, formulated at a range of polymer:DNA wt/wt ratios. Increased blue 
intensity corresponds to increased luminescence. For most polymers, 60 wt/wt was found 
to be the optimal polymer:DNA ratio. 
! 30!wt! 60!wt! 80!wt! 100!wt! 125!wt! 150!wt!
B3XS4XE3! 6.05E+03! 9.04E+05! 6.46E+05! 4.25E+05! 1.19E+05! 2.55E+04!
B3XS4XE4! 1.53E+03! 1.10E+05! 5.27E+04! 4.07E+05! 8.18E+05! 9.59E+05!
B3XS4XE5! 9.46E+04! 1.43E+06! 1.41E+06! 1.19E+06! 8.65E+04! 1.11E+05!
B3XS4XE6! 8.15E+03! 1.23E+06! 9.55E+05! 6.81E+05! 3.55E+05! 7.89E+04!
B3XS4XE7! 2.84E+04! 1.04E+06! 8.83E+05! 6.44E+05! 3.85E+05! 1.55E+05!
B3XS4XE8! 2.54E+02! 6.75E+03! 6.73E+03! 2.44E+04! 6.90E+05! 7.06E+05!
B3XS4XE9! 1.92E+02! 3.84E+02! 3.83E+02! 4.72E+02! 2.08E+03! 2.95E+03!
B3XS5XE3! 6.73E+01! 6.81E+01! 6.12E+01! 5.87E+01! 4.98E+05! 3.92E+05!
B3XS5XE4! 6.70E+01! 6.82E+01! 6.00E+01! 5.93E+01! 2.15E+04! 2.58E+04!
B3XS5XE5! 6.73E+01! 6.67E+01! 5.97E+01! 5.87E+01! 5.61E+05! 2.22E+05!
B3XS5XE6! 2.57E+02! 5.79E+02! 3.72E+02! 3.25E+02! 1.32E+02! 3.12E+04!
B4XS4XE3! 5.47E+03! 1.87E+03! 2.22E+05! 7.98E+05! 1.20E+03! 7.69E+02!
B4XS4XE4! 4.75E+02! 8.09E+03! 3.61E+03! 4.29E+03! 2.07E+02! 1.89E+02!
B4XS4XE5! 8.43E+02! 7.26E+04! 4.40E+04! 9.46E+04! 1.16E+06! 2.75E+06!
B4XS4XE7! 2.83E+03! 3.16E+06! 3.37E+06! 3.08E+06! 3.16E+06! 2.44E+06!
B5XS5XE3! 1.79E+03! 5.57E+05! 2.28E+05! 1.52E+05! 1.53E+04! 1.54E+03!
B5XS5XE4! 6.73E+02! 4.09E+05! 8.59E+05! 5.62E+05! 7.93E+05! 3.33E+05!
B5XS5XE5! 3.92E+05! 2.73E+05! 1.57E+05! 1.16E+05! 3.66E+04! 5.92E+04!
B5XS5XE6! 1.31E+05! 3.94E+05! 5.32E+04! 9.79E+03! 1.61E+03! 2.98E+02!
B5XS5XE7! 5.86E+03! 5.06E+05! 1.52E+05! 9.44E+04! 5.71E+04! 2.52E+04!
B5XS5XE8! 8.00E+03! 6.40E+05! 2.03E+05! 8.57E+04! 2.82E+04! 1.73E+03!
!
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Table 4.4. Average luminescence per well, 48 hrs. post transfection (n=4) with CMV-
Luc DNA and polymer library at 60 wt/wt (polymer:DNA). At the left the base polymer 
is listed; at the top, the end-modifying amine is listed. For example, the cell which is the 
intersection of B6-S3 and E5 corresponds to B6-S3-E5 formulated at 60 wt/wt. In the 
control row, the control under E4 corresponds to FuGENE® HD, and the control listed 
under E7 corresponds to LipofectamineTM 2000. Increased blue intensity corresponds to 
increased luminescence. 
 E1 E3 E4 E5 E6 E7 E8 E9 E10 E12 
Controls   7.21E+05   8.07E+05     
B3-S3o 6.78E+02 1.62E+03 1.29E+03  1.60E+03 1.35E+03 1.41E+03 5.25E+01 1.34E+03 1.05E+03 
B3m-S3o 1.20E+03 1.13E+03 4.90E+02  8.69E+02 7.28E+02 7.42E+02 3.95E+01 1.53E+02 7.48E+02 
B4-S3o 8.74E+02 3.44E+02 2.91E+03 3.13E+03 4.91E+02 9.59E+02 4.79E+02 1.91E+02 4.26E+03 1.94E+03 
B5-S3o 5.14E+02 3.23E+02 4.23E+03 8.76E+03 4.74E+02 6.11E+02 8.30E+02 1.58E+02 1.34E+04 2.20E+03 
B6-S3o 3.02E+03 9.65E+04 5.43E+04 2.18E+05 1.62E+05 1.28E+05 1.51E+05 1.30E+03 1.06E+04 5.49E+03 
BL1-S3o 4.58E+01 4.45E+01 5.38E+01  7.05E+01 3.25E+01 3.28E+01 3.23E+01 3.93E+01 3.23E+02 
BL1-S3o 3.48E+01 3.63E+01 3.88E+01  4.10E+01 4.88E+01 6.88E+01 3.20E+01 3.23E+01 3.53E+01 
BH1-S3o 5.30E+02 5.93E+02 4.41E+02  3.84E+02 5.12E+02 4.24E+02 3.73E+01 5.38E+02 3.12E+02 
B3-S3 6.22E+03 6.61E+03 2.49E+04 4.69E+03 7.02E+03 5.90E+03 1.09E+04 2.36E+02 2.99E+03 1.51E+03 
B3m-S3 6.68E+03 4.42E+03 1.08E+04 1.33E+04 1.36E+04 1.36E+04 1.41E+04 7.77E+02 1.47E+03 4.63E+03 
B4-S3 1.76E+04 1.18E+04 1.17E+05 1.21E+04 1.58E+04 1.78E+04 2.46E+04 1.59E+03 8.77E+04 3.81E+03 
B5-S3 5.30E+05 2.97E+05 1.23E+05 1.67E+05 4.07E+04 4.49E+05 3.26E+05 4.57E+02 8.67E+03 3.09E+02 
B6-S3 1.24E+05 2.33E+05 1.36E+05 7.48E+05 7.66E+05 1.10E+05 1.17E+05 1.36E+03 4.18E+03 2.85E+02 
BL1-S3 2.66E+02 1.52E+02 1.25E+02 1.44E+02 1.01E+02 9.90E+01 6.15E+01 7.93E+01 8.28E+01 1.22E+02 
BL2-S3           
BH1-S3 3.02E+03 5.42E+03 6.55E+03 4.13E+03 9.71E+03 7.85E+03 5.81E+03 3.93E+03 7.73E+03 4.71E+03 
B3-S4 1.07E+05 1.05E+05 1.00E+05 1.82E+05 1.52E+05 8.96E+04 3.48E+04 5.56E+02 2.65E+04 1.17E+05 
B3m-S4 1.60E+03 4.06E+03 5.59E+05 1.29E+06 6.68E+03 8.15E+04 1.98E+03 9.25E+02 9.56E+03 2.81E+03 
B4-S4 4.75E+02 7.47E+02 1.17E+03 1.25E+04 1.45E+03 1.32E+04 8.22E+02 1.69E+03 9.18E+03 2.94E+03 
B5-S4 1.66E+03 5.32E+03 2.24E+05 4.95E+05 1.70E+05 5.73E+05 1.23E+05 1.89E+03 1.75E+04 3.24E+03 
B6-S4 6.87E+04 1.32E+05 1.97E+05 2.87E+05 2.66E+05 2.89E+05 1.61E+05 2.10E+03 1.80E+04 3.75E+03 
BL1-S4 1.23E+02 1.97E+02 2.55E+02 3.99E+02 4.02E+02 3.54E+02 3.62E+02 3.46E+02 4.26E+02 1.05E+03 
BL2-S4 1.83E+01 4.33E+01 3.63E+01 3.58E+01 3.78E+01 6.53E+01 1.42E+02 2.55E+02 6.18E+02 2.35E+03 
BH1-S4 7.58E+01 1.26E+02 1.55E+02 1.28E+02 1.79E+02 3.88E+02 6.70E+02 2.44E+02 7.00E+02 1.87E+03 
B3-S5 1.64E+06 1.61E+06 1.08E+06 1.67E+06 2.02E+06 1.43E+06 5.05E+05 6.67E+03 3.88E+04 2.00E+04 
B3m-S5 4.23E+05 6.14E+05 2.85E+05 1.60E+06 6.17E+05 2.24E+06 8.60E+05 6.63E+03 5.44E+04 6.22E+04 
B4-S5 2.15E+06 1.97E+06 1.89E+06 2.13E+06 3.48E+05 5.63E+05 1.87E+05 3.12E+03 3.34E+04 5.19E+03 
B5-S5 1.29E+06 1.03E+06 1.07E+06 7.51E+05 1.04E+06 9.00E+05 7.92E+05 8.50E+03 8.19E+05 6.55E+05 
B6-S5 3.34E+05 3.47E+05 4.59E+05 4.51E+05 4.35E+05 4.29E+05 3.48E+05 4.10E+03 3.86E+05 3.93E+05 
BL1-S5 3.63E+01 6.10E+01 4.90E+01 2.43E+01 2.80E+01 2.70E+01 4.08E+01 8.60E+01 1.91E+02 7.68E+02 
BL2-S5 3.63E+01 3.80E+01 3.30E+01 2.25E+01 2.78E+01 1.55E+01 2.20E+01 3.93E+01 6.13E+01 1.93E+02 
BH1-S5 5.03E+02 4.32E+02 7.95E+02 1.63E+03 7.99E+02 1.27E+03 5.20E+02 4.76E+02 1.70E+03 4.90E+03 
!
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Table 4.5. Metabolic activity of COS-7 cells 24 hr post-transfection (n=4) with CMV-
Luc DNA and polymer library at 60 wt/wt (polymer:DNA) assessed by the CellTiter 96® 
AQueous One MTS assay (n=4) and normalized to untreated control wells. At the left the 
base polymer is listed; at the top, the end-modifying amine is listed. For example, the cell 
which is the intersection of B6-S3 and E5 corresponds to B6-S3-E5 formulated at 60 
wt/wt.  In the control row, the control under E4 corresponds to FuGENE® HD, and the 
control listed under E7 corresponds to LipofectamineTM 2000. Increased orange intensity 
corresponds to increased toxicity of the nanoparticle formulations. 
! E1! E3! E4! E5! E6! E7! E8! E9! E10! E12!
Controls! ! ! 75.1! ! ! 80.4! ! ! ! !
B3XS3o! 83.7! 86.0! 82.5! 80.3! 80.8! 75.0! 84.3! 16.1! 98.6! 92.3!
B3mXS3o! 87.5! 97.3! 97.1! 92.3! 92.4! 91.1! 100.6! 34.5! 76.5! 91.9!
B4XS3o! 108.4! 115.9! 100.3! 106.1! 103.1! 99.1! 94.2! 5.7! 64.5! 83.5!
B5XS3o! 121.2! 98.6! 92.9! 105.9! 122.5! 101.8! 104.5! 11.6! 78.2! 112.9!
B6XS3o! 107.1! 88.4! 60.1! 70.0! 85.8! 79.3! 68.4! 12.7! 42.3! 79.4!
BL1XS3o! 98.8! 110.5! 108.6! 95.9! 101.0! 95.5! 99.0! 1.6! 74.9! 101.2!
BL1XS3o! 114.7! 59.2! 64.6! 7.3! 29.5! 8.2! 7.8! 0.5! 3.3! 14.7!
BH1XS3o! 58.1! 3.5! 3.1! 0.2! 0.7! X0.1! 0.1! 3.8! 0.2! 0.0!
B3XS3! 70.8! 70.6! 79.0! 96.9! 96.8! 103.1! 106.9! 6.5! 86.6! 114.0!
B3mXS3! 89.8! 102.4! 106.8! 103.1! 110.1! 112.0! 111.3! 2.1! 79.5! 115.5!
B4XS3! 68.5! 78.2! 100.0! 95.9! 99.9! 103.8! 110.0! 20.5! 43.2! 90.2!
B5XS3! 5.3! 4.0! 4.3! 4.0! 3.8! 3.1! 3.5! 3.1! 2.9! 2.9!
B6XS3! 71.5! 92.5! 93.8! 102.4! 95.5! 91.8! 113.4! 2.1! 4.2! 69.0!
BL1XS3! 6.6! 4.6! 5.1! 5.1! 6.1! 6.4! 6.6! 5.4! 5.7! 6.0!
BL2XS3! 9.1! 6.0! 5.7! 9.2! 11.3! 6.3! 12.5! 8.8! 11.7! 12.1!
BH1XS3! 100.3! 89.7! 99.2! 95.7! 89.9! 87.8! 91.0! 58.0! 83.5! 89.4!
B3XS4! 87.6! 97.7! 93.4! 91.7! 96.8! 94.7! 100.6! 19.0! 100.1! 109.1!
B3mXS4! 104.4! 84.3! 83.1! 85.3! 72.9! 93.0! 82.7! 85.5! 86.2! 80.7!
B4XS4! 124.5! 106.7! 92.3! 101.6! 84.3! 102.9! 92.7! 60.4! 83.6! 84.1!
B5XS4! 104.9! 86.3! 80.0! 87.3! 75.5! 78.1! 79.7! 95.4! 78.4! 84.7!
B6XS4! 97.3! 54.9! 69.6! 60.7! 59.5! 48.8! 44.7! 63.8! 32.1! 65.5!
BL1XS4! X0.9! X1.1! X1.0! X0.9! X1.3! X1.3! X0.9! 1.8! X0.9! X0.2!
BL2XS4! 2.2! 1.8! 2.3! 1.8! 1.7! 1.4! 1.0! 1.8! 1.7! 1.4!
BH1XS4! 84.9! 88.7! 84.9! 85.2! 75.2! 80.3! 76.1! 1.8! 65.0! 65.9!
B3XS5! 96.5! 82.3! 75.1! 63.0! 57.3! 50.7! 49.4! X1.1! 46.9! 64.7!
B3mXS5! 41.2! 56.8! 12.4! 52.5! 10.2! 49.3! 75.9! 1.3! 28.9! 98.9!
B4XS5! 68.3! 79.0! 88.2! 74.6! 110.6! 111.5! 98.2! 0.0! 9.3! 95.7!
B5XS5! 78.3! 87.5! 77.5! 77.1! 78.1! 71.8! 96.1! 3.6! 91.0! 116.0!
B6XS5! 62.4! 75.4! 70.7! 71.7! 76.6! 78.1! 61.9! X1.5! 40.3! 60.9!
BL1XS5! X1.1! X0.4! 0.4! 0.4! X0.8! X1.4! X1.3! 9.7! 1.5! X0.2!
BL2XS5! X0.6! X1.2! X1.0! X1.4! X0.9! X1.3! X1.4! X0.3! X0.5! X0.2!




Table 4.6. Solubility maximum in 25 mM NaAc for E7 end modified polymers and their 







































Table 4.7. Calculated non-parametric (Spearman) correlation coefficients and 2-tailed p-
values comparing each end-modified amine 
 E1 E3 E4 E5 E6 E7 E8 E9 E10 E12 
E1  0.968 0.792 0.649 0.859 0.811 0.878 0.663 0.586 0.772 
E3 0.968  0.821 0.728 0.922 0.874 0.931 0.749 0.635 0.772 
E4 0.792 0.821  0.905 0.814 0.853 0.811 0.797 0.720 0.699 
E5 0.649 0.728 0.905  0.783 0.831 0.711 0.759 0.492 0.575 
E6 0.859 0.922 0.814 0.783  0.902 0.914 0.838 0.633 0.821 
E7 0.811 0.874 0.853 0.831 0.902  0.941 0.850 0.678 0.801 
E8 0.878 0.931 0.811 0.711 0.914 0.941  0.795 0.704 0.843 
E9 0.663 0.749 0.797 0.759 0.838 0.850 0.795  0.802 0.809 
E10 0.586 0.635 0.720 0.492 0.633 0.678 0.704 0.802  0.868 
E12 0.772 0.772 0.699 0.575 0.821 0.801 0.843 0.809 0.868  
 
          
 E1 E3 E4 E5 E6 E7 E8 E9 E10 E12 
E1  2.6E-12 3.1E-05 3.6E-03 1.3E-06 1.5E-05 3.6E-07 1.4E-03 6.6E-03 2.8E-04 
E3 2.6E-12  9.1E-06 6.2E-04 7.8E-09 4.9E-07 2.7E-09 1.5E-04 2.7E-03 2.8E-04 
E4 3.1E-05 9.1E-06  2.5E-07 1.3E-05 1.8E-06 1.5E-05 2.6E-05 3.4E-04 1.8E-03 
E5 3.6E-03 6.2E-04 2.5E-07  1.2E-04 2.0E-05 9.4E-04 2.6E-04 3.8E-02 2.5E-02 
E6 1.3E-06 7.8E-09 1.3E-05 1.2E-04  5.4E-08 1.7E-08 4.1E-06 2.7E-03 5.3E-05 
E7 1.5E-05 4.9E-07 1.8E-06 2.0E-05 5.4E-08  6.3E-10 2.1E-06 1.0E-03 1.1E-04 
E8 3.6E-07 2.7E-09 1.5E-05 9.4E-04 1.7E-08 6.3E-10  2.8E-05 5.3E-04 2.1E-05 
E9 1.4E-03 1.5E-04 2.6E-05 2.6E-04 4.1E-06 2.1E-06 2.8E-05  2.2E-05 8.5E-05 
E10 6.6E-03 2.7E-03 3.4E-04 3.8E-02 2.7E-03 1.0E-03 5.3E-04 2.2E-05  6.4E-06 
E12 2.8E-04 2.8E-04 1.8E-03 2.5E-02 5.3E-05 1.1E-04 2.1E-05 8.5E-05 6.4E-06  
 
          
 
! 120!
Table 4.8. Transfection efficacy of newly synthesized polymers (n = 4), evaluated by 
flow cytometry. Increased green intensity corresponds to increased transfection efficacy. 
In panel (a), polymers were formulated at 30 wt/wt; in panel (b), polymers were 
formulated at 60 wt/wt; in panel (c), polymers were formulated at 90 wt/wt. 
(a)! E1! E3! E4! E5! E6! E7! E8!
B3XS5! 7.41! 40.97! 41.21! 59.00! 63.82! 56.21! 56.73!
B3mXS5! 44.01! 40.49! 41.35! 72.66! 64.92! 69.33! 60.80!
B4XS5! 74.76! 66.97! 58.60! 49.00! 70.65! 76.50! 71.60!
B5XS5! 29.29! 35.85! 9.64! 37.65! 31.65! 31.17! 34.40!
B6XS5! 33.82! 2.44! 11.92! 7.16! 2.96! 2.73! 1.80!
(b)! E1! E3! E4! E5! E6! E7! E8!
B3XS5! 64.46! 59.59! 38.01! 69.37! 66.82! 66.95! 63.13!
B3mXS5! 53.40! 64.05! 42.11! 63.11! 68.92! 67.24! 66.84!
B4XS5! 65.52! 67.63! 76.68! 35.15! 61.64! 72.54! 68.94!
B5XS5! 11.63! 31.56! 0.87! 25.34! 22.44! 36.89! 16.29!
B6XS5! 60.28! 59.31! 55.84! 44.07! 40.66! 38.29! 51.38!
(c)! E1! E3! E4! E5! E6! E7! E8!
B3XS5! 68.60! 71.38! 72.25! 40.46! 70.14! 74.51! 71.46!
B3mXS5! 37.38! 59.45! 35.52! 57.40! 60.31! 46.45! 56.99!
B4XS5! 68.92! 75.84! 45.29! 55.39! 67.84! 61.67! 59.86!
B5XS5! 10.46! 24.66! 1.87! 8.47! 29.53! 2.60! 5.51!


































































































5 Chapter 5: Uptake and transfection with polymeric 
nanoparticles are dependent on polymer end-group 
structure, but largely independent of nanoparticle 
physical and chemical properties4 !
5.1 Introduction 
Gene therapy is the treatment of disease through insertion or modification of 
DNA in cells. This treatment has tremendous implications for improving human health 
because almost all human diseases have a genetic component, including cancer. The 
fundamental challenge for successful gene therapy is finding both a safe and effective 
delivery system [1]. The traditional method for gene therapy has been viral gene delivery. 
Viruses have evolved to transduce cells with high efficacy but are limited by low cargo 
capacity, resistance to repeated infection, difficulty in production and quality control, and 
safety concerns [2].  
All of these challenges can be overcome with non-viral methods that utilize 
biomaterials, which can be designed to deliver genes similar to a synthetic virus. 
Biodegradable cationic polymers such as poly(ester amines) and poly(amido amines) are 
promising for non-viral gene delivery due to their ability to condense plasmid DNA into 
small and stable nanoparticles, their ability to promote cellular uptake, facilitate escape 
from the endosome, and allow for DNA release in the cytoplasm [3] Studying these 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This chapter contains excerpts from an article that was published as Sunshine JC, Peng DY, and Green JJ. 
“Uptake and Transfection with polymeric nanoparticles are dependant on polymer end-group structure, but 
largely independent of nanoparticle physical and chemical properties.” Molecular Pharmaceutics. 2012; 
9(11), 3375-3383. 
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properties is integral to understanding how to design biomaterials for optimal transfection 
efficacy. In order to deliver its plasmid cargo to the nucleus of the target cell, a particle 
must be able to cross the cell membrane, escape endocytosis, and release the plasmid 
intracellularly to allow for trafficking to the nucleus. Each of these steps is essential, and 
the contribution of small changes to the chemical structure of the polymers to these 
mechanistic steps will be examined in this manuscript.  
There are multiple necessary components for effective gene delivery using 
cationic polymers. First, the polymers must bind strongly to the DNA, encapsulating or 
condensing it to prevent its degradation. A cationic polymer, through positively charged 
amine groups, allows for electrostatic interactions with anionic DNA. Cationic polymers 
such as poly-L-lysine (PLL) have been demonstrated to form stable polymer/DNA 
complexes [4]. The next step is cellular uptake, where the polymer/DNA nanoparticles 
must penetrate the lipid bilayer plasma membrane. These polyplexes or nanoparticles are 
generally taken into cells through endocytosis. Positively charged particles are important 
for attraction to anionic proteoglycans on the cell surface. Both particle size and surface 
charge play key roles in this step. Other potential uptake methods include ligand-specific 
/ receptor-specific mediated endocytosis through various particle coatings [5, 6] or 
covalent attachment [7, 8]. 
Once in the endosome, the particles are then subjected to the endosomal-
lysosomal pathway, where the complexes need to avoid being enzymatically degraded by 
lysosomes or recycled out of the membrane. Bypassing lysosomal degradation has been a 
bottleneck in improving intracellular gene delivery. It has been shown that polymer/DNA 
particles can escape the endosome into the cytoplasm through the “proton sponge 
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effect”[9]. Inside of the endosome, the pH drops from 7.4 to around 5.1, where a 
polymers’ secondary and tertiary amine groups can buffer the acidification [10]. An 
influx of ions into the endosome can lead to osmotic swelling and eventual bursting to 
release the polyplexes into the cytoplasm [11]. The buffer capacity of titratable amine 
groups can effectively facilitate endosomal rupture, inducing efficient gene expression 
[10, 12]. An example of the importance of buffer capacity is that polyethylenimine (PEI) 
has an advantage over PLL in transfection due to its high buffering capacity. Studies have 
shown that polymers with secondary or tertiary amines are either able to provide more 
time to escape the endosome or mediate endosomal escape. Other strategies that have 
been utilized to promote endosomal escape include functionalizing polymers with 
endosomolytic peptides [13, 14], which utilize pH sensitive conformational changes that 
promote endosomal escape.  
Once inside the cytoplasm, it is beneficial for the polymer to degrade to enhance 
release of the DNA to prevent polymer-mediated cytotoxicity. For effective plasmid 
release, polymers can be designed to degrade hydrolytically through ester linkages [15] 
or reducibly through disulfide linkages [16]. Amine-containing polymers that can degrade 
hydrolytically have shown to have much higher transfection and lower cytoxicity than 
polymers such as PEI [17] and degradable versions of PEI have shown improved efficacy 
and lower cytotoxicity than non-degradable versions [18]. The DNA plasmid must then 
overcome nuclear import. This is more easily achievable in dividing cells when the 
nuclear envelope breaks down during mitosis. Another strategy for nuclear import is 
appending nuclear localization signals (NLS) to DNA which may help carry it into the 
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nucleus [19, 20]. Measuring gene expression ensures that all of these intracellular barriers 
have been crossed including transcription and translation of the exogenous DNA. 
Biodegradable cationic polymers such as end-modified poly(beta-amino ester)s 
have been demonstrated as promising biomaterials for non-viral gene delivery among 
various cell types [21-23]. End-modification with diamine monomers has shown that 
some of these polymers can rival adenovirus for gene delivery in vitro [17]. Additionally, 
PBAEs have been shown to have promise in the treatment of cancer in vitro and in vivo 
[24, 25] However, while previous studies have investigated certain physical and 
biological parameters [26-28], they have not fully looked at the chemical properties and 
mechanistic details that may fully explain the advantages that the lead structures possess 
[29] In particular, differences in polymer buffering capacity, polymer degradation, and 
the mechanistic differences between the same linear polymers with acrylate end-groups 
compared to differing amine-containing small molecules as end-groups needed to be 
more fully evaluated. This study aims to elucidate the polymer properties and biological 
process most responsible for the high gene delivery efficacy of end-modified PBAEs. 
 
5.2 Materials and Methods!
5.2.1 Cell Culture 
COS-7 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 
L-glutamine and sodium pyruvate (DMEM 11995, Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells 




Monomers were purchased from commercial vendors and used as received. 4-
amino-1-butanol (S4), 5-amino-1-pentanol (S5), 1,4-butanediol diacrylate (B4), 1,6-
hexanediol diacrylate (B6), 1-(3-aminopropyl)-4-methylpiperazine (E7) were purchased 
from Alfa-Aesar, Ward Hill, MA. 1,3-propanediol diacrylate (B3) and 1,5-pentanediol 
diacrylate (B5) were purchased from Monomer-Polymer and Dajac Laboratories 
(Trevose, PA). 2-methyl-1,5-diaminopentane (E4) was purchased from TCI America 
(Portland, OR). 2-(3-aminopropylamino)ethanol (E6) and branched 25 kDa poly(ethylene 
imine) (PEI) were purchased from Sigma Aldrich (St. Louis, MO). Enhanced green 
fluorescent protein plasmid driven by a CMV promoter (eGFP) was obtained from 
Aldevron (Fargo, ND). CellTiter 96 AQueous One MTS assay was purchased from 
Promega (Fitchburg, WI) and used according to manufacturer’s instructions.  
!
5.2.3 Polymer Synthesis 
Polymers were synthesized using a two-step procedure (Figure 5.1).  As an 
example, acrylate-terminated poly(1,4-butanediol diacrylate-co-4-amino-1-butanol), B4-
S4, was first synthesized in a solvent-free fashion at different acrylate: amine monomer 
molar ratios (1.2:1, 1.1:1, 1.05:1). Reactions took place in glass vials in the dark under 
magnetic stirring for 24 h at 90°C.  As a second step, amine-containing small molecules 
were individually conjugated to the ends of each polymer. Excess amine is used to fully 
end-modify the base polymer. 80 mg of polymer in 480 µL of DMSO was mixed with 
320 µL of a 0.5M solution of the end capping amine in DMSO in 1.5 mL eppendorf tubes 
in a multi-tube vortexer with constant agitation for 1 h at room temperature. As an 
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example, B4-S4 synthesized at a 1.1:1 ratio was end-modified by E7, and formed the B4-
S4-E7 1.1:1 end-modified polymer. Polymers were stored at 100 mg/ml in anhydrous 
DMSO at -4°C with desiccant until use. Polymer nomenclature refers to the number of 
carbons between functional groups as we have previously described [29, 30]. For 
example, polymer B4-S4 contains 4 carbons between acrylate groups in the polymer 
backbone, “B”, and 4 carbons between the amine and alcohol groups in the side chain, 
“S.” Polymer structure was characterized on a Bruker spectrometer by 1H NMR 
spectroscopy (400 MHz, d6-DMSO) and completion of end-modification was verified by 
elimination of the peaks corresponding to the acrylate termini of the polymer (at 5.9-6.4 
ppm) [30]. Spectra for B3-S5-Ac (acrylate-terminated base polymer) and B3-S5-E7 can 
be found in Figure 5.2. 
 
5.2.4 Particle Size and Charge 
Particle size was determined both by dynamic light scattering (DLS) using a 
Mavern Zetasizer Nano ZS (Malvern Instruments, Malvern, UK, detection angle 173°, 
633 nm laser) and by nanoparticle tracking analysis (NTA) using a Nanosight NS500 
(Amesbury, UK, 532 nm laser). Particle charge was determined using a Mavern Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). Polymer/DNA nanoparticles were made 
at a 60 w/w ratio in 25 mM sodium acetate buffer (pH = 5.0) at 30 ng/µL DNA and 
diluted into 150 mM PBS, pH 7.4. For the measurements on the Zetasizer, particles were 
diluted 5-fold into PBS, and particle size is reported as the intensity-weighted Z-averaged 
of the particle diameter in nm. Average electrophoretic mobilities were measured at 25°C 
and zeta potentials were analyzed using the Smoluchowsky model. For the NTA analysis, 
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particles were diluted 50 to 100 fold into PBS such that particle number would be 
between 108 and 109 particles/mL, and particle size is determined from a 60s movie from 
which the Brownian motion of the particles was assessed as previously described [28]. 
 
5.2.5 Gel Electrophoresis!
The gel electrophoresis experiments were conducted in 1% agarose gels made 
with 1 µg/ml ethidium bromide in the gel. Particles were formed at 30 ng/µL DNA and at 
a 60 w/w ratio (polymer:DNA; 1.8 µg polymer/µL) and allowed to complex for 10 
minutes before glycerol was added, with or without bromophenol blue (15 mg/mL), a 
negatively charged dye used to visualize the extent that the gel runs, and then 
immediately added to the gel. The gels were run for 40 min with 100 V applied. Gels 
were visualized with a Visi-BlueTM transilluminator (UVP, Upland, CA).  
!
5.2.6 Buffering Capacity!
The buffering capacities of the polymers were determined through acid-base 
titration. Ten micrograms of polymer in DMSO at 100 mg/mL was dissolved in 10 mL of 
0.1 M NaCl solution. The pH of polymer solutions was set to pH 3 using 1 M HCl and 
titrated to pH 11 using 0.1 M NaOH. The pH of solutions was measured after each 
addition using a Mettler Toledo S20 pH meter. Buffer capacity was calculated in two 
ways: by taking the ratio of total protons buffered between pH 7.4 and 5.1 to the total 
amines of the polymer and by taking the ratio of protons buffered between pH 7.4 and 5.1 
to total polymer mass. Titration of NaCl without the presence of polymer was used as 
background control. For end-modified PBAEs, the buffering contribution from excess 
! 131!
free end-capping amine monomer was subtracted out to characterize the buffering of the 
polymers. 
 
5.2.7 Degradation Studies 
Two and a half milliliters of a 100 mg/ml solution of polymer in DMSO was 
added to 247.5 mL of phosphate buffered saline (PBS) solution at 37°C, and magnetically 
stirred to mix. At each time point, 25 mL of this solution was removed and frozen, then 
lyophilized to remove the water. This sample was dissolved in 1 mL of a solution of 94% 
THF, 5% DMSO and 1% piperidine, and organic phase permeation chromatography 
(GPC) was performed using the same solvent as an eluent at a flow rate of 1 mL/minute. 
The detector (Waters 2414 refractive index detector) and columns (three Waters Styragel 
columns, HR1, HR3, and HR4, in series) were maintained at 40°C throughout the runs. 
Polymer molecular weights presented are relative to monodisperse polystyrene standards 
(Shodex, Japan). 
 
5.2.8 GFP transfections, with and without labeled plasmid!
Fifteen thousand COS-7 cells were plated in 100 µL per well in clear 96-well 
tissue culture plates (Starstedt) to allow for overnight adhesion. For transfection 
experiments, eGFP pDNA was diluted into 25 mM NaAc buffer (pH 5.0) to form a final 
concentration of 60 ng/µL. Polymers stored at 100 mg/ml in DMSO were aliquoted out 
into 96-well plates and diluted to 3.6 µg/µL in 25 mM NaAc, and equal volumes of 
diluted polymers and diluted DNA were mixed by pipetting up and down in another 96-
well plate. Ten minutes after mixing DNA and polymer solutions, 20 µL of nanoparticles 
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were added to 100 µL of media (DMEM containing 10% FBS, 1% 
penicillin/streptomycin v/v) on the cells for a final pDNA dose of 600 ng/well. PEI/DNA 
complexes were formed at a 3:1 polymer to DNA weight ratio and formed in 150 mM 
NaCl as previously described [23], and PEI/DNA complexes were added to the cells for a 
final pDNA dose of 600 ng/well. Four hours after transfection, the cells were washed 
with PBS and 100 µL of fresh media was added to the cells. Forty-eight hours after 
transfection, gene expression was measured using flow cytometry (Accuri C6 with 
HyperCyt high-throughput adaptor); gating was performed on FlowJo software and 
GFP+ cells were gated as a subpopulation of cells by two-dimensional gating of FL1 vs 
FL2 separate increased autofluorescence signal from increased signal (for examples, see 
Figure 5.3). 
For DNA uptake studies, eGFP pDNA was labeled with Cy3 using the Label IT® 
TrackerTM kit (Mirus Biopharma) following manufacturer’s instructions, and diluted into 
unlabeled pDNA resulting in a net ratio of 331 nucleotides / dye. Particles were 
formulated the same was as with the transfection experiment (but with labeled DNA), 
except that after washing the cells and changing the media 4 hours post transfection, the 
cells were washed again 2x, trypsin was added, and the cells were run on flow cytometry 
as above. Gating was performed on FlowJo 7.6.5 software and uptake was determined by 
two-dimensional gating (as a subpopulation of cells) of FL1 vs FL2 to separate increased 
autofluorescence signal from increased signal (for examples, see Figure 5.3).!
!
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5.2.9 Cell viability testing!
For cell viability testing, transfection was performed as normal, but twenty-four 
hours after transfection, cell viability was measured by the AQueousOne CellTiter MTS 
assay; after addition of the CellTiter reagent (20 µL/well), cells were incubated at 37°C 
for 1 hour and then absorbance at 490 nm was measured on a plate reader (Synergy 2). 
Background absorbance from media and reagent were subtracted off, and the absorbance 
was normalized to untreated cells.  
!
5.2.10 Statistical Analysis!
Assays were performed in quadruplicate, and presented data are mean ± SD. All 
statistics were performed using the GraphPad Prism 5 software package. To examine 
multiple comparisons, such as differences between nanoparticle size with Acrylate (Ac) 
and Amine (Am) terminated polymers, we performed 1-way ANOVA with Bonferroni 
post tests. 
!
5.3 Results and Discussion 
5.3.1 Synthesis and Characterization of Polymer Array 
 PBAEs have been extensively investigated in a high-throughput fashion for their 
ability to mediate non-viral gene delivery in vitro, but significant characterization of the 
polymer properties that lead to overcoming the barriers to intracellular gene delivery have 
not been fully explored [3, 27, 31, 32]. PBAEs have achieved transfection efficacies 
comparable to adenovirus for transfection of human endothelial cells [17], have been 
used systems for efficient siRNA mediated gene knockdown [33, 34], and have been used 
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to target cancer in vitro and in vivo [24, 25]. Hydrophobicity appears to play a significant 
role in the ability of PBAEs to mediate efficient gene delivery [30] and the number of 
plasmids per particle that PBAEs form can also play a role [28]. 
 To evaluate in greater detail why PBAEs are effective for non-viral gene delivery 
and to determine how subtle changes to structure affect efficacy, we synthesized an array 
of polymers with single carbon changes to the backbone, side chain, and small changes to 
the end-modifying amine (Figure 5.1). We synthesized 4 polymers with single carbon 
changes to the backbone (B3-S5-Ac, B4-S5-Ac, B5-S5-Ac, B6-S5-Ac) and end-modified 
each of those with E7 (B3-S5-E7, B4-S5-E7, B5-S5-E7, B6-S5-E7). We also synthesized 
two polymers with single carbon difference to the side chain (B4-S4 and B4-S5) and end-
modified those polymers with 3 end-capping amines (E4, E6, E7), and finally we 
synthesized B4-S4 at three different amine:acrylate ratios (1.2, 1.1, 1.05) to generate 
different molecular weight versions of the base polymer, and end-capped those with a 
single end-capping amine (E7). We then studied polymer properties that we hypothesized 
would be related to the ability to overcome the barriers to intracellular gene delivery. We 
evaluated at nanoparticle size, zeta potential, and ability to retard DNA from moving on a 
gel to look at stable particle formation. We studied the PBAEs’ buffering capacity to 
investigate how these polymers might be able to escape the endosome, and the polymer 
degradation rate to assess the ability of the polymer to promote release of DNA as well as 
avoid cytotoxicity. Finally, we evaluated particle uptake, viability, and transfection 
efficacy as biological outcomes, and as a way to assess where in the process particular 
polymer structure were failing or succeeding in overcoming barriers to gene delivery. 
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5.3.2 Particle size and charge 
Previous work with cationic polymers for DNA delivery has indicated that 
formation of small, positively charged nanoparticles is a prerequisite for efficient 
transfection [1, 35]. However, too high of a charge density can lead to unwanted toxicity, 
and there may be some intermediate, optimal charge density depending on the polymer of 
interest. These competing effects can been seen in HPMA-oligolysine copolymers [36] 
and cationic glycopolymers [37], polymers synthesized by Reversible Addition-
Fragmentation chain Transfer (RAFT) polymerization. 
In a series of cationic glycopolymers with either a positively charged pendant 
group or a sugar, Ahmed et al. showed that increased carbohydrate content significantly 
reduces toxicity but also reduces transfection efficacy [37]. Studies on a library of 
HPMA-oligolysine copolymers revealed that size of the charged moieties matters; 5- and 
10-lysine long oligocations were more effective than 15-lysine long oligocations. Shorter 
lysine chains were more salt stable (5 > 10 > 15). However, polymers with 10 lysine long 
oligocations were the best at transfection, followed by 5, then 15, indicating that there 
was some medium optimum between even distribution of charge and larger charged 
groups [36]. In addition, poly(glycoamidoamine) (PGAA) polymers, synthesized with 
repeating ethylenamines, were shown to be optimal transfection reagents when there were 
4 ethylenamines; having 5 or 6 ethylenamines does not increase transfection but does 
increase toxicity [38]. 
All polymers in this study spontaneously formed positively-charged (+21 to +29 
mV zeta potential) nanoparticles in the 130-150 nm diameter range (Figure 5.4).  
Previous studies have indicated that a zeta potential of greater than +10 mV was required 
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for PBAE nanoparticle transfection [27]. Acrylate-terminated polymers were found to be 
slightly larger than their end-modified versions by dynamic light scattering 
measurements; on average, E7-modified B3/4/5/6-S5 polymers were 170±20 nm in 
diameter, versus 221±8 nm for acrylate-terminated versions. There is a statistically 
significant difference between B4-S5-E7 and B4-S5-Ac (p < 0.05), but no statistically 
significant difference between the other pairs. There was no statistical difference between 
any of the polymers when looking at size by nanoparticle tracking analysis. In this study, 
we measured particle size in two ways: dynamic light scattering (DLS) and nanoparticle 
tracking analysis (NTA). NTA directly measures number-averaged size, thus the average 
particle size by number-weighting is the same for all acrylate and amine pairs. DLS 
measurements are intrinsically intensity-weighted, where large infrequent particles can 
cause a disproportionate contribution to the average size. Thus, particle formulations 
where DLS and NTA measurements are the same, such as B4-S5-E7, are monodisperse 
and formulations such as B4-S5-E6 are more polydisperse and have a minority 
component of slightly larger particles. It is only in case of B4-S5-E7 and B4-S5-Ac that 
the presence of a minority component of larger particles is statistically significant by end-
group, and in this case, the number-average size remains the same. 
Not surprisingly given the relatively narrow distribution of particle sizes and zeta 
potentials, particle size and zeta potential was not correlated with particle uptake or 
transfection efficacy to any significant degree (Figure 5.5a-c). However, particle size by 
dynamic light scattering appeared to be relatively negatively correlated with particle 
uptake (Figure 5.5d), indicating that smaller particles (as measured by DLS) tended to 
get taken up more efficiently than larger ones; this remains a weak trend. One potential 
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explanation is that as DLS size is intensity-weighted, a relatively small number of larger 
particles would skew the DLS average much more than NTA number average. Thus, if 
these larger particles are particularly inefficient at being taken up by the cells, and they 
segregate DNA away from the smaller particles, these formulations overall would be less 
efficient in being taken up by cells. Generally, these nanoparticles were found to all be 
very similar in surface charge and particle size, yet they had substantial differences in 
uptake and transfection as will be further described below.  
 
5.3.3 Gel electrophoresis 
In addition to a basic requirement to form small, positively charged nanoparticles, 
for efficient DNA delivery, the particles must bind to and protect DNA effectively. At 60 
w/w, all of the 14 polymers completely retarded the DNA except for B3-S5-Ac (Figure 
5.6a). When bromophenol blue was added to the lanes containing particles, the most 
hydrophobic polymers containing B5 and B6 diacrylates in their backbone were able to 
retard the DNA (B5-S5-Ac, B5-S5-E7, B6-S5-Ac, B6-S5-E7) as well as B4-S4-E6 and 
B4-S5-E7. The remaining polymers were unable to completely retard the DNA migration 
(Figure 5.6b). Interestingly, acrylate terminated polymers and their amine-terminated 
counterparts bound DNA in similar patterns, with the largest discrepancy occurring with 
respect to the difference between B3-S5-Ac and B3-S5-E7. In this, even with no 
competition, B3-S5-Ac was unable to retard the DNA electrophoresis, up to a 150 w/w 
ratio, while the end-modified polymer was able to retain the DNA even at a low 15 w/w 
ratio (Figure 5.7). Hydrophobicity of the polymer seemed to play a large role in polymer 
binding affinity, as the four most hydrophobic polymers (B5-S5-Ac, B5-S5-E7, B6-S5-
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Ac, B6-S5-E7) were all able to retain the DNA even after addition of the bromophenol 
blue. This may indicate a significant hydrophobic effect for the binding of PBAEs with 
DNA. Previous studies have demonstrated that hydrophobicity plays a strong role in 
enhancing gene delivery with PBAEs, generally increasing transfection efficacy but also 
increasing cytotoxicity [30]; these data may provide a mechanism for this effect. 
  
5.3.4 Polymer buffering capacity 
In order to escape the endosome, there needs to be a mechanism of endosomal 
escape. The ability of a polymer to buffer the endosome has been shown to be highly 
correlated with the amount of secondary and tertiary amine groups the polymers contain 
[10], as these amines tend to be protonatable across relevant pH ranges. To assess the 
ability of the polymers to buffer the endosome, titration curves were determined for 
polymers using acid-base titration (Figure 5.8). Using the titration curves, the buffering 
capacities of the polymers were calculated through the percentage of amine groups 
protonated between pH of 7.4 and 5.1. As references, sodium chloride (NaCl) showed a 
curve with no buffering indicated by its vertical slope, while polyethylenimine (PEI) 
displayed significant buffering indicated by a gradual slope between pH 5.1 and 7.4. 
Because PEI has an abundance of secondary and tertiary amine groups, it can buffer 
many protons in the endosome, where the pH drops from 7.4 to 5.1. The buffering 
capacities of gene delivery polymers affect their ability to escape the endosome via the 
proton sponge effect [9, 11]. 
Although the polymers differ only by small structural changes, their buffering 
capacities were found to have significant differences (Table 5.1). B4-S5-E7 1.05:1 was 
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found to have the lowest buffering capacity on a per-amine basis and on a per-mass basis, 
while B6-S5-E7 1.1:1 was found to have the highest buffering on both measures, 
buffering 4.6 mmol H+/g and having a per-amine buffering capacity of 95%.  
Additionally, when the buffering capacities of the PBAEs are compared to 
branched PEI on a per-mass basis, the comparison is initially not a favourable one. The 
PBAEs buffering capacity was concentrated in the relevant pH range (pH 5.1 – 7.4), with 
their per-amine buffering capacity varying from 34% to 95% as compared to 25 kDa 
polyethyleneimine (PEI), which only uses 25% of its amine content over that key range. 
However, due to the higher amine-density on PEI, on a per mass basis, all PBAEs 
buffered fewer protons than PEI (1.4-4.6 mmol H+/g for PBAEs vs 6.2 mmol H+/g for 
PEI). However, since the PBAEs are much less cytotoxic, and are typically formulated at 
60 w/w compared to 1-3 w/w for PEI, the total buffering capacity of PBAE based 
particles significantly exceeds that of PEI. As an example, the PBAE with the lowest 
buffering capacity per mass can buffer 1.7 mmol H+/g, but on a formulation basis, since 
the PBAE formulation contain on average 20 times more polymer than PEI formulation, 
60 w/w particles would be able to buffer 5.5-times as many protons as 3 w/w PEI.  
 The structure-function relationship for end-cap molecule and PBAE buffering 
extent per mass is clear (Table 5.1). Polymers end-capped with E7 generally have the 
highest buffer capacities, which is expected as the E7 group contributes two tertiary 
amines in its structure. Polymers end-capped with E6 also have relatively high buffer 
capacities as compared to E4, as each E6 group contributes an extra secondary amine 
group as opposed to an extra primary amine. Acrylate-terminated polymers showed only 
slightly lower buffering capacity compared to their end-modified counterparts (Table 5.1, 
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Figure 5.9).  The buffering for the acrylate-terminated polymers are not the lowest of the 
samples, indicating that the base polymers themselves, rather than their end-groups, drive 
buffering in the range of pH 5.1-7.4. Further, these results reveal that the modest 
differences in buffering capacity observed with these different polymer structures do not 
strongly correlate to the relatively large differences in particle uptake and transfection 
also observed with these structures (Fig. 5.5f,g). 
In the context of intracellular gene delivery, endosomal buffering is required to 
mediate endosomal escape and facilitate transfection of the cell. We hypothesized that 
low buffering capacity would result in the stranding of nanoparticles in the 
endosomal/lysosomal system, resulting in high uptake not allowing for high transfection. 
In general, however, this trend is not perfect due to other confounding factors, and 
demonstrates that high buffering capacity is likely necessary but not sufficient for 
effective transfection with PBAEs. As predicted, there is no correlation between 
buffering capacity (per mass) and particle uptake, but there is a weak positive correlation 
between buffering capacity per mass and transfection (Fig. 5.5f). This makes intuitive 
sense, as improvements in buffering capacity should improve endosomal escape, thus 
enhancing the transfection of cells that have already taken up particles. This correlation is 
not that strong because of the generally very strong correlation between uptake and 
transfection seen in this cell type. 
 
5.3.5 Polymer degradation 
Intracellular DNA delivery requires that the polymer forms stable complexes that 
can bind DNA, protect it from enzymatic degradation, and enter cells. However, 
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successful transfection also requires that the DNA be released for efficient transcription 
of mRNA [39]. Polymer degradation rate is an important chemical parameter as it 
determines the time scale that the polymers have to escape the endosome and enter the 
cytoplasm for effective transfection. It is also important to characterize the polymer 
degradation mechanisms to evaluate the basis of possible reduced cytotoxicity compared 
to other cationic polymers. Cationic polymers that cannot degrade effectively will likely 
not be as biocompatible with cells. An example of this is PEI, which typically mediates 
high uptake and has a very high total buffer capacity (Table 5.1), but has a lower 
transfection efficacy and higher toxicity than other polymers [40]. Polymer degradation 
can be helpful in terms of enhancing the release of DNA from the polymer and reducing 
cytotoxicity; but if degradation is too quick, it could decrease particle stability, DNA 
protection, and cellular uptake.  
Generally, the PBAEs degrade very rapidly in aqueous conditions, with half-lives 
in PBS at 37°C ranging from 90 minutes to just over 6 hours (Figure 5.10, Table 5.1). 
We hypothesized that due to the trade off between wanting to increase particle stability 
extracellularly, but also promote DNA release intracellularly, we may find a biphasic 
response between polymer half-life and transfection efficacy. We found that a modest 
biphasic trend is demonstrated when we compare transfection to half-life (Figure 5.5e). 
In addition, the two polymers with the shortest half-lives (B5-S5-E7 at 1.2 h and B4-S4-
S7 1.2:1 at 1.6 h) showed the largest discrepancy between uptake and transfection, which 
may suggest that modestly long (> 2 h) half lives are required to protect the DNA all the 
way to the nucleus. Overall, these degradation rates are surprisingly rapid. Faster than 
anticipated degradation of polymers is observed in other related systems such as 
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poly(glycoamidoamine) (PGAA) polymers, which contain hydroxyl groups alpha to the 
amide bonds and secondary amines in the backbone of the polymer, and show rapid 
hydrolysis at pH 7.4 (half-lives of around 20 hr), even though amide bonds should 
hydrolyze much more slowly than ester bonds [41]. Interestingly, there is faster 
degradation in pH 7.4 than in pH 5; this is attributed to the effect of the proximal –OH 
group [41]. In particular, the secondary amines in the PGAAs are located a similar 
distance away from the amide bonds as the tertiary amines in the PBAEs are to the ester 
bonds, supporting the theory that they could likely be responsible for the rapid 
degradation of the PBAEs seen here. This very rapid degradation rate could be another 
reason for the general effectiveness and low cytotoxicity seen with this class of polymers, 
but it does pose potential challenges for eventual in vivo translation of this technology.  
 
5.3.6 Particle Uptake, Transfection Efficacy, and Cytotoxicity 
 In order to compare polymer properties to biological outcomes, we investigated 
the cellular uptake, transfection efficacy, and cytotoxicity of our nanoparticle 
formulations (Figure 5.11). Polymers B4-S5-E6, B4-S4-E7 1.1:1, B3-S5-E7, and B4-S5-
E7 were all found to have superior uptake and transfection to PEI, and B6-S5-E7 was 
found to have superior uptake but comparable transfection to PEI (Figure 5.11a,b; p < 
0.05 for all comparisons). Most of the tested polymers were non-cytotoxic at the 
formulation ratio and dose tested with the exceptions being B4-S5-E4, B4-S4-E7 1.1, B4-
S4-E7, B4-S4-E7, and PEI, which showed increased cytotoxicity relative to untreated 
controls (Figure 5.11c; p < 0.05 for all comparisons). 
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Increasing the number of carbons along the polymer backbone from 3 through 6 
and leaving the side chain length at 5 carbons tended to increase cytotoxicity without 
increasing transfection efficacy. This result mirrors previous findings in COS-7 cells and 
RPE cells, where there is a limit at which increasing hydrophobicity of the polymer 
backbone does not improve transfection efficacy and only increases toxicity [22, 30]. 
Increasing the side-chain length from 4 carbons to 5 carbons resulted in mixed effects; 
end-modification of B4-S4 with E6 leaded to superior cell uptake and transfection 
compared to end-modification of B4-S5 with E6, but end-modification of B4-S5 with E4 
had superior cell uptake and transfection compared to end-modification of B4-S4 with E4. 
Increasing initial polymer molecular weight also had mixed effects. We 
synthesized B4-S4-E7 at 3 different molar ratios of acrylate to amine, resulting in 3 
different molecular weights for the same base polymer. B4-S4-E7 at 1.1:1 had the highest 
transfection and uptake, but it also was the most toxic. These results are evocative of the 
recent work by Eltoukhy, et al, where they showed that intermediate length PBAEs 
mediated optimal transfection [42]. 
Acrylate-terminated PBAEs were found to have significantly lower uptake and 
transfection than their amine-terminated counterparts (p < 0.001 for all comparisons). 
Previous studies had indicated that acrylate-terminated polymers showed significantly 
reduced transfection efficacies [26, 27, 43], but were not able to determine the specific 
cause. Our investigation shows that this difference in transfection efficacy is due to 
differential uptake of the acrylate-terminated polymer nanoparticles as compared to the 
amine end-capped polymers. This is particularly striking given that there were no 
significant differences in particle formation as measured by gel electrophoresis or in 
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nanoparticle properties with respect to particle sizes and zeta potentials. Furthermore, the 
acrylate-terminated polymers were non-cytotoxic.  Therefore, end-capping linear PBAEs 
with small molecules containing amines is necessary for sufficient cell uptake and 
transfection in a manner largely independent from nanoparticle biophysical properties. 
Further studies on specific mechanisms of gene delivery uptake will help improve our 
understanding of how differential polymer structure affects transfection efficacy and we 
are currently undertaking these studies. 
 
5.4 Conclusions 
Development of non-viral nanoparticles for gene delivery requires a greater 
understanding of the properties that enable gene delivery nanoparticles to overcome the 
numerous barriers to intracellular DNA delivery. Here we evaluated the effects of small 
structural perturbations within an array of linear poly(beta-amino ester)s (PBAEs) on 
polymer properties which are related to the barriers to intracellular gene delivery. 
Previous work has not investigated PBAE buffering capacity or examined the 
degradation rate of PBAEs formed from Michael addition of a primary amine containing 
side chain and a diacrylate. Interestingly, the PBAE polymers generally showed very 
rapid degradation in physiological conditions (t½ = 90 min – 6 hours). On a per mass 
basis, PBAEs buffered 1.4-4.6 mmol H+/g. When compared to 25 kDa 
polyethyleneimine (PEI), PBAEs buffer significantly fewer protons/mass. However, 
since the PBAEs are much less cytotoxic and degrade so rapidly, they can be formulated 
at significantly higher weight ratios without substantial toxicity, and thus total buffering 
capacity of PBAE based particles significantly exceeds that of PEI. This may explain the 
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requirement for higher w/w ratios to achieve optimal efficacy using PBAEs compared to 
other polymer systems, and the rapid degradation rate may explain the low toxicity 
observed with large amounts of polymer.  
 Acrylate-terminated base polymers were much less efficacious than 
corresponding small molecule amine-containing end-capped versions, both in terms of 
uptake and transfection, even though there are minimal differences between acrylate and 
amine-terminated polymers in terms of DNA retardation in gel electrophoresis, 
nanoparticle size, nanoparticle zeta potential, polymer buffering capacity and cytotoxicity. 
This is a very interesting finding, and further investigation into the source of the 
considerable difference in efficacy seen here would be important. These studies further 
elucidate the role of polymer structure for gene delivery and highlight that small 
molecule end-group modification of a linear polymer can be critical for cellular uptake in 





Figure 5.2a: NMR of B3-S5-Ac  
1.15-1.25 (2H, quint, NCH2CH2CH2CH2CH2OH),  
1.25-1.35 (2H, quint, NCH2CH2CH2CH2CH2OH), 
1.35-1.45 (2H, quint, NCH2CH2CH2CH2CH2OH),  
1.85-1.95 (2H, quint, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)),  
2.3-2.4 (6H, t, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO) and t, 
NCH2CH2CH2CH2CH2OH),  
2.6-2.7 (4H, t, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)),  
3.3-3.4 (2H, obsc, NCH2CH2CH2CH2CH2OH),  
3.45 (t, CH2CH2NCH2CH2(COO)CH2CH2CH2OH) 
4.0-4.1 (4H, t, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)),  
5.9-6 (d, COOCH=CH2),  
6.1-6.2 (dd, COOCH=CH2),  




Figure 5.2b: NMR of B3-S5-E7 
 1.15-1.25 (2H, quint, NCH2CH2CH2CH2CH2OH),  
1.25-1.35 (2H, quint, NCH2CH2CH2CH2CH2OH), 
1.35-1.45 (2H, quint, NCH2CH2CH2CH2CH2OH),  
1.50 (2H, quint, -NHCH2CH2CH2N<(CH2CH2)2>NCH3) 
1.85-1.95 (2H, quint, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)),  
2.13 (3H, s, -NHCH2CH2CH2N<(CH2CH2)2>NCH3) 
2.3-2.4 (6H, t, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO) and t, 
NCH2CH2CH2CH2CH2OH and -NHCH2CH2CH2N<(CH2CH2)2>NCH3 and -
NHCH2CH2CH2N<(CH2CH2)2>NCH3),  
2.47 (2H, t, -NHCH2CH2CH2N<(CH2CH2)2>NCH3) 
2.6-2.7 (4H, t, CH2CH2NCH2CH2(COO)CH2CH2CH2(COO)),  
3.06 (br m, -CONHCH2-) 
3.3-3.4 (2H, t, NCH2CH2CH2CH2CH2OH),  
3.45 (t, CH2CH2NCH2CH2(COO)CH2CH2CH2OH) 




Figure 5.3. Example flow cytometry plots for (A) uptake of Cy3-labeled eGFP plasmid 
(5 hours post transfection) and (B) transfection of eGFP reporter plasmid (48 hours post 
transfection) 2D-gating analysis.  
!
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Figure 5.4. (A) Zeta potential of selected polymers. (B) Nanoparticle diameters measured 




Figure 5.5. Comparison plots of various parameters vs. uptake and transfection. 
Transfection and uptake vs. (A) particle diameter, as measured by dynamic light 
scattering (DLS); (B) particle diameter, as measured by nanoparticle tracking analysis 
(NTA); (C) zeta potential; (D) polymer molecular weight; (E) polymer half-life; (F) 




Figure 5.6. Gel electrophoresis of PBAE/DNA nanoparticles formed at 60 w:w 
(polymer:DNA ratio) (A) without bromophenol blue and (B) with bromophenol blue. For 
brevity, polymer names were shortened to remove the B-S-E designation, such that 444 is 




Figure 5.7. Gel electrophoresis of acrylate terminated and E7-end modified PBAE/DNA 
nanoparticles formed at the polymer:DNA ratio listed above the lane without 
bromophenol blue; 15 indicates that 15-fold more mass of polymer was used relative to 
the DNA mass. Each gel is from a single polymer. (A) B3-S5-E7 (B) B3-S5-Ac (C) B4-





Figure 5.8. Acid-base titration curves for selected polymers and normalized for 150 mM 
aqueous NaCl. Measurements were taken using a Mettler Toledo S20 pH meter. pH was 





Figure 5.9. Acid-base titration curves for acrylate-terminated polymers and their E7-end 
modified counterparts normalized for 150 mM aqueous NaCl. Measurements were taken 
using a Mettler Toledo S20 pH meter. pH was adjusted to pH 3 with HCl, then titrated 
with NaOH. Horizontal lines correspond to pH 5.1 and 7.4 which were used for analysis. 
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Figure 5.10. Degradation of polymers over time by GPC. MW is normalized (set = 1) to 




Figure 5.11. DNA nanoparticle uptake (A), cellular transfection (B), and cellular 
viability (C) after application of nanoparticles to cells. Data are presented as mean ± 
SEM. * Statistically significant improvement (p < 0.05) vs. 25 kDa PEI control for 
uptake and transfection plots; statistically significantly increased cytotoxicity (p < 0.05) 
vs. untreated control. 
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Table 5.1. Buffer capacities, molecular weights, and degradation half-lives of polymers. 
Buffer capacities of selected polymers were calculated using the titration curves found in 
Figure 5.4, and the half-lives were calculated from the GPC curves in Figure 5.10. 
 






MW (kDa) Half Life (h) 
B3-S5-E7 80 4.4 8.8 4.4 
B3-S5-Ac 64 2.8   
B4-S5-E7 80 4.2 5.8 5.1 
B4-S5-Ac 72 3.0   
B5-S5-E7 65 3.3 20.1 1.2 
B5-S5-Ac 69 2.7   
B6-S5-E7 95 4.6 11.7 3.6 
B6-S5-Ac 73 2.7   
B4-S4-E4 49 2.3 18.0 6.1 
B4-S5-E4 49 2.2 11.7 5.3 
B4-S4-E6 52 2.5 10.7 5.5 
B4-S5-E6 52 2.5 6.9 6.5 
B4-S4-E7 
1.2 
61 2.8 21.1 1.6 
B4-S4-E7 
1.1 
58 2.6 22.6 4.6 
B4-S4-E7 
1.05 
38 1.7 33.1 3.9 
PBAEs 34-95 1.4-4.6 5.8-33.1 1.6-6.5 


























































































































6 Chapter 6: Gene delivery nanoparticles specific for 
human microvasculature and macrovasculature5 
6.1 Introduction 
Endothelial cells play important roles in various ocular diseases, such as age-
related macular degeneration, diabetic retinopathy, and retinoblastoma [1]. The 
dysregulation and subsequent angiogenic proliferation of these ocular microvascular 
endothelial cells represents the key step in most retinal causes of blindness. Regulation of 
this angiogenesis by anti-angiogenic drugs such as ranibizumab is now the first-line 
therapy and there is continued interest in more effective anti-angiogenic therapies [2]. 
Gene delivery is one such alternative method for delivery of antiangiogenic factors to 
endothelial cells, such as endostatin, angiostatin, and vascular endothelial growth factor-
binding protein [3, 4]. In addition, gene therapy can be used to correct specific genetic 
deficiencies within the endothelial cell population.  In this strategy, therapeutic genes that 
can either add or block a function are delivered to a targeted cell population. Additionally, 
such gene delivery methods can also be very useful in the study of cellular biology and 
disease.  
Non-viral transfection of human retinal endothelial cells (HRECs) remains a 
challenge as does transfection of many other cell types. For example, one recent report 
using lipid coated magnetic nanoparticles achieved only ~5% transfection efficacy [5]. 
Leading commercial reagents, such as Lipofectamine 2000, can improve the transfection 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This chapter contains excerpts from an article that was published as Shmueli RB*, Sunshine JC*, Xu Z, 
Duh EJ, Green JJ. “Gene delivery nanoparticles specific for human microvasculature and 
macrovasculature.” Nanomedicine: Nanotechnology, Biology, and Medicine. 2012; 8(7):1200-1207. 
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of HRECs. One study found that this approach could lead to 42%-67% knockdown of a 
target receptor’s surface expression following plasmid transfection [6]. Macrovascular 
(human umbilical vein endothelial cells, HUVECs) are also generally difficult to transfect 
as a lead polymer (polyethylenimine) plus magnetofection yielded transfection efficacy 
of only 39% positive cells [7]. New nanomedicines are needed to further increase the 
effectiveness of non-viral gene delivery.  
Certain poly(β-amino esters) (PBAEs) have recently shown good transfection 
efficacy to a variety of cell types, including hard to transfect cell types like human 
mammary epithelium in 2D and 3D [8], human brain cancer cells [9], and HUVECs [10]. 
Particular polymers formulations have shown selectivity in terms of transfecting brain 
cancer cells as compared to normal astrocytes [9]. In addition, polymer end-group 
modification has been suggested as a tool to tune transfection efficacy [10-12]. The 
objectives of this study were to investigate the endothelial and retinal cell-type 
specificities of PBAE-based nanoparticles and also to identify novel nanoparticles that 
can achieve high transfection of human endothelial cells with minimal toxicity. A new 
PBAE combinatorial polymer library was synthesized and evaluated to discover 
nanoparticles that can transfect either macrovascular (HUVECs) or microvascular 
(HRECs) human endothelial cells or both.  
 
6.2 Materials and Methods 
6.2.1 Materials 
All chemicals and solutions were used as received unless otherwise indicated. Monomers 
and vendors used for synthesis are the following:  from Acros Organics [1-(3-
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aminopropyl)pyrrolidine (E8)], Alfa Aesar [3-amino-1-propanol (S3), 4-amino-1-butanol 
(S4), 5-amino-1-pentanol (S5), 1,4-butanediol diacrylate (B4), 1,6-hexanediol diacrylate 
(B6), 1-(3-aminopropyl)-4-methylpiperazine (E7)], Fluka [2-(3-
aminopropylamino)ethanol (E6)], Monomer-Polymer and Dajac Laboratories [1,3-
propanediol diacrylate (B3), 1,5-pentanediol diacrylate (B5)], Sigma-Aldrich [1,3-
diaminopropane (E1), 2,2-Dimethyl-1,3-propanediamine (E2), cystamine dihydrochloride 
(E10), 2-(1H-imidazol-4-yl)ethanamine (E12)], and TCI America [1,3-diaminopentane 
(E3), 2-methyl-1,5-diaminopentane (E4), (PEO)4-bis-amine (E5)]. Anhydrous DMSO 
and 3 M sodium acetate buffer were purchased from Sigma Aldrich. Sodium acetate 
buffer was diluted to 25 mM and filtered through 0.2 µm filter. pCMV-eGFP DNA was 
purchased from Aldevron. PBS, 0.25% trypsin-EDTA, Fu-Gene HD, and Lipofectamine 
2000 were purchased from Invitrogen. CellTiter 96® AQueous One MTS assay was 
purchased from Promega. 96-well TCP and non-TCP round-bottom plates were 
purchased from Sarstedt. Human Umbilical Vein Endothelial Cells (HUVECs) and 
EGM-2 Bullet Kit and Reagent Pack were purchased from Lonza. Human retinal 
endothelial cells (HRECs) were obtained from Cell Systems and cultured in EGM2-MV 
(from Lonza), as previously described [13, 14]. The immortalized human RPE cell line, 
ARPE-19, was obtained from the Dr. James Handa [15]. 
 
6.2.2 Synthesis of Poly(beta-amino ester) (PBAE) 
The structures of these polymers were chosen so that there are ester linkages to ensure 
degradability of the polymers and amine groups to ensure the ability to bind DNA and 
form nanoparticles. The base polymers were synthesized by mixing diacrylates, labeled 
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as ‘B#’ in the text, and amino alcohols, ‘S#’, at a molar ratio of 1.2:1 in glass scintillating 
vials with teflon stir bars, forming ‘B#-S#’ base polymers (Figure 6.1a). The reaction 
was run at 90oC for 24 hours. The base polymer was then dissolved at 167mg/mL in 
DMSO. In the last step of the reaction, 480 µL containing 80 mg of the base polymer and 
320 µL of 0.5 M end-capping amine, ‘E#’, were mixed in a 1.5 mL eppendorf tubes in a 
shaker for 1 hour (Figure 6.1b). Completed polymers were aliquoted into smaller 
volumes and stored at 4oC. The completed polymers are designated as ‘B#-S#-E#’; for 
example, B3-S5-E1 is an end-modified PBAE formed from the B3-S5 base polymer 
which is then end-modified with the end-capping amine E1 (Figure 6.1c). Polymer 
molecular weights were typically ~10 kDa as we previously have reported and among 
these polymers we have found that molecular weight is not correlated to transfection 
efficacy [16]. We have recently published the polymer characterization of these synthetic 
biomaterials including 1H-NMR and Gel Permeation Chromatography of each polymer 
[16]. 
 
6.2.3 Nanoparticle Sizing 
DNA was diluted in 25 mM sodium acetate buffer to 0.01 mg/mL. Polymer was diluted 
in sodium acetate buffer to either 30 or 60 times that concentration (30 and 60 weight to 
weight, w/w, ratios), added to the DNA solution and incubated at room temperature for 
10 minutes. Nanoparticles were then diluted 20 fold into PBS and loaded into NS500 
nanosight tracking analysis (NTA) system. Nanosight videos were captured for 60 
seconds and then analyzed used the NTA software, version 2.2. 
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6.2.4 Transmission Electron Microscopy (TEM) imaging 
Nanoparticles were prepared the same way as for sizing by NTA. 10 uL of sample was 
dropped onto carbon coated copper grids and left to dry in chemical hood for 2 hours. 
Unstained TEM imaging was then performed using the Philips CM120 system. 
Nanoparticle sizing was performed using ImageJ software. 
 
6.2.5 Green Fluorescent Protein (GFP) transfection 
HUVECs and HRECs were seeded at 2,500-5,000 cells/well onto 96-well plates and 
allowed to adhere overnight, in 100 µL of the appropriate media per well (EGM-2 for 
HUVECs and EGM-2 MV for HRECs). Immediately before transfection, media in plates 
were replaced with 10% supplemented FBS HUVEC media, 100 µL per well. For RPE 
transfections, ARPE-19 cells were seeded at 15,000 cells/well and allowed to grow to 
confluence over 3 days, and then transfected in DMEM with 10% supplemented FBS. 
Polymers and pCMV-eGFP DNA were diluted in 25mM sodium acetate buffer. The final 
DNA concentration of the mixture was 0.03 mg/mL, with PBAEs at either at 0.9 or 1.8 
mg/mL (30 w/w and 60 w/w ratios, respectively). Solution was mixed, incubated for 10 
minutes at room temperature and then 20 µL were added per well. FuGene HD and 
Lipofectamine 2000 were screened to find best formulation by following the 
manufacturer’s guidelines. FuGene HD-DNA ratio of 4-1 was used, with 10 µL added 
per well, while Lipofectamine 2000-DNA ratio of 1.5-1 was used, with 10 µL added per 
well. Plates then incubated for 4 hours, after which nanoparticle loaded media was 
removed and fresh EGM-2 and EGM-2 MV media were added, 100 µL/well. Each 
experimental condition was evaluated in quadruplicate. Duplicate plates were made for 
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each experimental group to use one each for cell viability and transfection efficiency 
measurements. 
 
6.2.6 Cell metabolism/viability 
Twenty-four hours after transfection, designated plates were used for the CellTiter 96® 
AQueous One MTS assay. 10 µL of the aliquoted assay solution was added per well. Plates 
were incubated for 1-4 hours, after which absorbance at 490 nm was measured using the 
BioTek Synergy 2 Plate Reader. Absorbance measurements were corrected from 
background media signal and normalized by untreated groups. Each experimental 
condition was evaluated in quadruplicate. 
 
6.2.7 Flow cytometry  
Forty-eight hours after transfection, flow cytometry was performed using the Accuri C6 
flow cytometer with IntelliCyt high-throughput attachment. Cells were washed with 1x 
PBS and trypsinized with 30 µL/well of 0.25% trypsin-EDTA. 170 µL FACS buffer (2% 
FBS, 1x PBS) was added to cells and 200 µL/well transferred to 96-well round-bottom 
plates. The plates were centrifuged at 1000 rpm for 5 minutes, after which 170 µL/well of 
the supernatant was removed. The pellets were re-suspended in the remaining 30µL of 
buffer. Plates were then placed onto the IntelliCyt high-throughput attachment and 




6.3 Results and Discussion 
6.3.1 Polymer and Nanoparticle Synthesis 
A polymer library was synthesized for gene delivery, such that a large diversity of 
structures could be investigated, each with small differential structural changes from each 
other. The structures of these polymers were chosen so that there are ester linkages to 
ensure degradability of the polymers and amine groups to ensure the ability to bind DNA 
and form nanoparticles. These polymers were synthesized from a pool of 4 acrylate 
monomers, 3 side chain monomers, and 12 end-chain capping molecules as described in 
the methods. The synthetic polymers are referred to by a ‘B’ number, a ‘S’ number, and 
an ‘E’ number, each referring to their constituent monomers. The number following the 
‘B’ or the ‘S’ corresponds to the number of carbons between functional groups in the 
diacrylate or amino-alcohol monomers; thus ‘B4-S5’ is a polymer formed from a base 
diacrylate with 4 carbons between each acrylate group, and an amino-alcohol with 5 
carbons between the amine and the alcohol functional groups. 
Nanoparticles are formed through electrostatic self-assembly, due to attractive 
interactions between cationic polymers and anionic DNA. We use relatively high 
polymer to DNA weight ratios (w/w) such that the polymers encapsulate 100% of the 
DNA as we have recently described [17]. Representative polymers of interest were 
chosen for sizing measurements. Even though polymer structure varied, nanoparticle size 
was found to be similar with these different types of polymers (Figure 6.2A). 
Hydrodynamic diameter of the nanoparticles was approximately 150 nm, with a range of 
110-190 nm in the particle distributions that was dependent on polymer to DNA weight-
to-weight (w/w) formulation ratio. The average diameter of a nanoparticle formed from 
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B3-S5-E1 at 60 w/w as measured by TEM was 147 nm (Figure 6.2B), which closely 
matches the results found from NTA. There was no correlation between the sizes of 
nanoparticles that transfected the cells well (B3-S5-E# and B4-S4-E# series) as compared 
to those that transfected the cells less well (B3-S4-E# series). Therefore, we hypothesize 
that chemical structure, not nanoparticle physical properties, is the driver of the 
differences seen in transfection efficacy. 
 
6.3.2 Nanoparticle-mediated Gene Delivery  
Leading polymeric nanoparticles were found to be very effective for gene 
delivery to human microvascular and macrovascular endothelial cells. Significantly, 
transfection efficiencies of up to 85% for HRECs and 65% for HUVECs were observed 
as opposed to 49% (HREC) and 32% (HUVEC) with a leading commercially available 
reagent, Lipofectamine 2000 (Figure 6.3A and 6.3B). Lipofectamine 2000 was also 
more toxic than the PBAE nanoparticles (Figures 6.3C and 6.3D). The polymeric 
nanoparticles were found to display a wide range of transfection efficacies with both 
HRECs and HUVECs, which was dependent on polymer structure. Both the choice of 
base polymer and end-capping groups had a large effect on the transfection efficacy. The 
B4, B5, and B6 diacrylates differ by one carbon, yet there are significant differences in 
toxicity and transfection efficacy. A similar effect was observed when changing the side-
chain amines. For example, B3-S4-based polymeric nanoparticles had very low 
transfection (< 10%), but a single carbon added to each of the side-chain monomers (B3-
S5-based polymeric nanoparticles) resulted in highly effective gene delivery for both 
HRECs (up to 76%) and HUVECs (up to 64%). The end-group of the polymer made a 
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big difference to endothelial cell gene delivery as well, where the best formulations 
usually contained E5, E6, and E7. 
In order to better isolate the effects from changing each component of the 
polymer, the data were averaged together across two of the three polymer elements that 
compose each synthetic polymer. In general, B4 and B5 based polymers had the highest 
gene delivery efficacy (Figure 6.4A) and reveal an optimal base diacrylate length. On the 
other hand, we observe an increasing monotonic trend with increasing length for the 
various side-chain amines used in this experiment, with S5 based polymers performing 
best (Figure 6.4B). Unlike with the structure of the base polymers, a clear trend in the 
structure of the end-group with transfection efficacy is not observed (Figure 6.4C). 
However, there are some end-capping amines, such as E6, which dramatically improve 
delivery, and others, such as E12, that are much less effective. These results motivate 
further studies on how polymer structure affects endothelial cell gene delivery.   
 
6.3.3 Endothelial Cell-specific Gene Delivery  
Comparing the transfection efficiencies between the different cell types and 
tissues revealed interesting trends (Figure 5.4). In this study, the HREC and HUVEC 
transfection profiles were positively correlated (linear regression, R2= 0.81), with greater 
transfection efficiencies for HRECs overall. Similar viability profiles were also observed 
between HUVECs and HRECs. On the other hand, using the same set of nanoparticles, 
there is very little correlation between the transfection efficacies for gene delivery to 
HRECs as compared to retinal pigment epithelium (RPEs, linear regression, R2 = 0.21), 
or HUVECs as compared to RPEs (linear regression, R2 = 0.23). Polymers that 
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performed better on the endothelial cell types as compared the regression line include B4-
S4 and B3-S5, as well as some B4-S5-based polymers (upper left hand corner of Figures 
6.5b and 6.5c). As a group, these polymers were synthesized by diacrylate monomers 
that were less hydrophobic and contained 3 or 4 carbons between diacrylate monomer 
groups. On the other hand, there are some polymers that work better on the epithelial 
cells, such as B6-S5 (lower right hand corner of Figures 6.5b and 6.5c). This polymer is 
more hydrophobic than the polymers that tend to be better at transfecting endothelial cells 
and this polymer contains 6 carbons between its diacrylate monomer groups. The 
polymers that work well on both endothelial and epithelial cell types include B5-S5 
based-polymers (upper right hand corner of Figures 6.5B and 6.5C), which have an 
intermediate level of hydrophobicity and 5 carbons between its diacrylate monomer 
groups. Strikingly, these structural changes are quite subtle and they do not influence 
nanoparticle size (Figure 6.2). 
 
6.4 Conclusions 
Synthesis and testing of a PBAE library resulted in the identification of polymeric 
nanoparticles that can transfect human endothelial cells, HRECs and HUVECs, with high 
efficiency as compared to current commercially available standards. The best polymers 
(both good transfection and viability), B3-S5-E# and B4-S4-E# series, are new PBAE 
structures that were able transfect at least as well as the commercially available reagents 
and in some cases with less toxicity. Additionally, Small molecular changes to polymer 
backbone, side chain or end-group structure dramatically changed transfection efficiency. 
The best polymers were ones that contained B4 and B5, and S4 and S5, with a few 
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different E# groups. The most hydrophilic polymers, such as B3-S4, were not good at 
transfecting the cells, while their toxicity was also minimal. On the other hand, the most 
hydrophobic polymers, such as the B6-S5 series, were usually relatively toxic to the 
endothelial cells, subsequently also reducing the transfection efficiency. This trend is 
mirrored when looking at the effects of the different diacrylate monomers used (Figure 
6.4A), where B4 and S5 performed best. While among certain structures, high 
hydrophobicity correlated to increased cytotoxicity and reduced transfection, overall, 
when all the data is evaluated together, there is not a strong correlation between 
transfection efficiency and viability (R2 =0.06, data not shown).   
Interestingly, the gene delivery efficacy across the entire polymer library was 
highly correlated between transfection of HREC and HUVEC cells – nanoparticle 
formulations that performed well for HRECs also performed well for HUVECs (R2 = 
0.81). This is dramatically different when compared to the performance of the same 
nanoparticles with retinal pigment epithelium, indicating that formulations could 
potentially be found which selectively transfect one ophthalmic cell type and not the 
other, as can be observed in Figures 6.5B and 6.5C. To our knowledge, this phenomenon, 
that specific ocular cell types can be targeted directly by fine-tuning of the polymer 
structure that composes nanoparticles, is striking and surprising. This finding also 
suggests that biomaterial-mediated targeting from this class of materials may be able to 
be combined with other methods of gene delivery targeting such as ligand or coating-
mediated cell uptake [18-20] and transcriptional targeting [21, 22] to further improve 
specificity and efficacy to only one specific type of cell. 
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In particular, we show that the polymers in the middle of the hydrophobicity scale 
for this PBAE library worked very well for the endothelial cells, but much less so for the 
epithelial cells. On the other hand, those that were more hydrophobic, such as the B6-S5, 
worked well for the epithelial cells. Taken together, these correlations indicate that there 
may be natural cell type specificity for polymeric nanoparticles of this class.  
Safe and effective gene delivery vehicles can have a large impact on biological 
studies and for the treatment of diseases. For example, researchers have developed a 
system for gene delivery of sFLT using adeno-associated virus (AAV) to bind VEGF in 
monkeys as a potential treatment for age-related macular degeneration [23]. However, 
viral gene therapy has limitations that may preclude many clinical applications due to 
carrying capacity constraints and safety concerns [24]. In contrast, our study reveals 
premiere non-viral nanoparticles that are enabling technologies for transfection of 
endothelial cells in vitro and are promising for use in vivo as delivery vehicles for genetic 
nanomedicines. We also show that polymer structure itself, may enable cell-specific non-





Figure 6.2. (A) Hydrodynamic diameter by nanoparticle tracking analysis. (B) 
Transmission Electron Microscopy of nanoparticles formed from B3-S5-E1 (60 w/w); 




Figure 6.3. Transfection efficiency (% GFP+ cells) for transfection of HREC and 
HUVEC cells with the polymer library. (A) HUVEC and (B) HREC transfection 
percentage. (C) HREC and (D) HUVEC metabolic activity relative to untreated control. 




Figure 6.4. Panel of monomer effects on transfection %. Collapsing (averaging) two of 
three types of monomers attempt to isolate effects of each monomer change. (A) 
Diacrylate base, (B) Side-chain amine base, (C) End-group amine. 
! 178!
 
Figure 6.5. Correlation between transfection of HUVEC, HREC, and RPE cells with the 
polymer library. (A) There is a strong correlation between transfection of HUVEC and 
HRECs and (B) a much weaker correlation when compared to transfection of RPEs, or 








































































7 Chapter 7: Transfection Of Retinal Pigment 
Epithelial Cells With A Combinatorial Library Of 
Poly(β-amino ester)s6  
7.1 Introduction 
Many of the most debilitating ocular diseases are caused by gene deletion 
mutations.  The ability of an ocular disease to be treated with a single gene replacement 
therapy was shown to be successful in principle in a canine model of Leber’s Congenital 
Amaurosis in which RPE 65 was replaced using a recombinant adeno associated viral 
(AAV) delivery system that resulted in visual restoration in these animals [1]. 
Furthermore, early phase clinical trials studying this therapy in people suggest that gene 
therapy is a feasible potential strategy for retinal dystrophies [2]. A variety of genetic 
diseases of the retina, including retinitis pigmentosa, Best’s disease, and Stargardt’s 
disease might be excellent targets for gene replacement therapy. 
Despite the initial success of gene replacement, gene delivery methods need to be 
optimized.  There are significant limitations to viral delivery systems such as the AAV 
vector.   The AAV vector is limited in what ocular diseases it could potentially treat 
because it is capable of optimally carrying 4.7-4.9 kilobases (kb) with a maximum 
carrying capacity of 5.2 kb [3-5] while many ocular diseases are caused by mutations to  
genes that are larger than 5 kb. Notable examples include Best’s disease, caused by a 
mutation in Bestrophin-1 (14.6 kb) [6], or Stargardt’s disease, caused by a mutation in the 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This chapter contains excerpts from an article that was published as Sunshine JC*, Sunshine SB*, Handa 
JT, Green JJ. “Poly(β-amino ester)-Nanoparticle Mediated Transfection Of Retinal Pigment Epithelial Cells 
in vitro and in vivo.” PLoS ONE. 2012; 7(5), e37543 
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ABCA4 gene (6.8kb) [7]. To address this problem, we recently reported that our non-
viral delivery system using poly(beta-amino) esters (PBAEs) can accommodate large 
inserts to deliver up to 100 plasmids and ~500 kbp of nucleic acid per nanoparticle [8]. 
Non-viral systems for gene delivery offer a host of potential advantages over 
viruses, including reduced toxicity [9], reduced immunogenicity [10], and ease of 
production. However, to date, most non-viral systems are significantly less efficient at 
transfecting hard to transfect cell types compared to viral methods, so the major challenge 
remains finding an effective non-viral delivery system [11, 12]. Multiple alternative non-
viral gene delivery approaches have been reported in the literature for in vitro 
transfection of retinal pigment epithelial (RPE) cells, with limited success. One report on 
transfection of the established RPE cell line, ARPE-19 cells, with solid lipid 
nanoparticles details difficulty in uptake of the particles that resulted in a transfection 
efficacy of only 2.5% [13]. Another study looked at optimizing several different 
commercially available reagents (Tfx-50, Lipofectin, Lipofectamine, Cellfectin, and 
DMRIE-C) for the transfection of primary RPE cells [14]. This study utilized serum free-
conditions and non-confluent RPE cultures, which are associated with higher transfection 
efficacy [15], yet the best reagent formulated optimally, Tfx-50 at 3:1 DNA:liposome 
ratio, only achieved 12-15% transfection efficiency [14]. Another study looking at the 
transfection of primary RPE cells showed transfection efficiencies of less than 1% for 
Lipofectin, between 1 and 3% for DOTAP/DOGS, and up to 5% by using degraded 
dendrimers [15]. This limited success in transfection of ARPE-19 cells or primary RPE 
cells in vitro indicates a need for improved transfection reagents for use in the lab. 
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Poly(beta-amino) esters (PBAEs) [16] have shown great potential as gene 
delivery reagents and are easily synthesized, rapidly screened, and can be transfected into 
a wide variety of cell types with high efficacy in vitro [17-21]. PBAE nanoparticles have 
several advantages which help to overcome the barriers to intracellular plasmid DNA 
(pDNA) delivery [12]. PBAEs, when added to pH 5 buffer, are positively charged and 
can spontaneously form positively-charged nanoparticles (generally less than 200 nm) 
when added to negatively charged pDNA [8]. They get taken up via endocytosis, and 
enable endosomal escape by buffering the endosome [22]. They are degraded by 
hydrolysis of the ester bonds in the polymer backbone, enabling reduced cytotoxicity 
when compared to non-degradable controls [16]. Previous studies have indicated that not 
only was the base polymer important to its gene delivery properties, but that modification 
of the polymer ends can further improve transfection efficiency [17-19, 22]. We have 
recently found that PBAEs are highly effective (65%-85%) for the transfection of human 
macrovascular cells (human umbilical vein endothelial cells) and human microvascular 
cells (human retinal endothelial cells) and that although the efficacies of these 
nanoparticles are highly correlated between human vascular cell types, their efficacies are 
uncorrelated to human retinal pigment epithelial cells, which are also a more difficult cell 
type to transfect [23]. 
In this study, we synthesized and evaluated an expanded combinatorial library of 
PBAEs for evaluation of transfection efficacy and toxicity in ARPE-19 cells to identify 
lead polymer structures and transfection formulations for this difficult-to-transfect cell 
type.  We discovered a lead polymer, polymer (1-(3-aminopropyl)-4-methylpiperazine-
end-modified poly(1,5 pentanediol diacrylate-co-5-amino-1-pentanol) (B5-S5-E7) and 
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characterized it for the first time in terms of polymer molecular weight, polymer half-life, 
nanoparticle size, nanoparticle zeta potential, and vitro efficacy compared to leading 
commercially available reagents. To validate the in vitro screen and to evaluate the 
efficacy of a PBAE-based nanoparticle for gene delivery to the eye for the first time, 
nanoparticles were administered to mouse RPE in vivo by subretinal injection. 
Lyophilized DNA nanoparticles, utilizing a technology designed to enhance the stability 
and shelf-life of the biodegradable nanoparticles, were used for the in vivo injections. 
These novel nanoparticles offer opportunity both for studying diseases in the laboratory 
and as a potential treatment modality. 
 
7.2 Materials and Methods 
7.2.1 Materials 
All reagents and solvents were obtained from commercial suppliers and used as 
received. Monomers were purchased from Acros Organics, Alfa Aesar, Fluka, Monomer-
Polymer and Dajac Laboratories, Sigma-Aldrich, and TCI America. CMV-eGFP was 
amplified by Aldevron (Fargo, ND). X-tremeGENE HP DNA, Lipofectamine 2000, and 
Opti-MEM I were purchased from Invitrogen and used according to the manufacturer’s 
instructions. 25 kDa PEI was purchase from Sigma Aldrich and diluted to a stock 
solution at 1 mg/ml in deionized water. 96 AQueous One MTS assay was purchased from 
Promega and used according to the manufacturer’s instructions. Dulbecco’s Modified 
Eagle Medium (DMEM) F12 was purchased from Invitrogen and supplemented with 
10% fetal bovine serum (FBS; Invitrogen). 
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7.2.2 Polymer Synthesis 
The library of PBAEs was synthesized by adding primary amines to diacrylate 
compounds (1.2:1 molar ratio of diacrylate:amine) at 90oC for 24h (Figure 7.1a). The 
base polymerization reaction was performed without the use of any solvent in 20 mL 
glass scintillation vials, in an oven in the dark under magnetic stirring. By providing 
excess diacrylate in the initial polymerization reaction, diacrylate-terminated polymer 
was synthesized. We have recently described the synthesis and characterization of these 
materials [19]. The naming convention used here is designed to describe the chemical 
structure of each polymer. The diacrylates form the base (“B”) chain of the polymer, and 
the primary amines form the side (“S”) chains of the forming polymer. To further identify 
the structure of the base or side chain, a number corresponding to the number of carbons 
in the hydrocarbon portion of the “B” or “S” is appended; thus, B5 is a base diacrylate 
with 5 carbons in it’s hydrocarbon portion between acrylate groups, and B5-S5 is a base 
polymer with 5 carbons in the hydrocarbon portion of its side chain between the amine 
and alcohol groups as well as 5 carbons in its hydrocarbon portion of its base chain 
between acrylate groups. In a second step, the acrylate ends of the polymer intermediates 
are modified by a second amine, resulting in the final end-modified polymers (Figure 
7.1b). The base polymers were end-capped by end-capping (“E”) amines (at 10-fold 
molar excess of amine to diacrylate termini) at room temperature in DMSO at 100 mg/ml 
for 1 hr (Figure 7.1b). Specifically, 80 mg of base polymer was dissolved in 400 µl of 
DMSO, and combined with 320 µl of a 0.5M solution in DMSO of the end-capping 
amine, and placed on a multitube vortexer (VWR) and vortexed for 1 hr at 1000 RPM. 
The library of monomers used here is shown (Figure 7.1c). For the end capping amines, 
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the number is simply sequential; B5-S5-E7 is an end-modified polymer with 5 carbons in 
the base, 5 carbons on the side chain, and which was end-modified with the E7 end-
capping amine.  For this study we synthesized a combinatorial library of PBAEs using 5 
diacrylates, 3 amino-alcohol side chains, and 11 end-modifying amines to form 165 end-
modified polymers with only small, single carbon changes to the backbone and side 
chains, and small modifications at the ends of the polymers. Base polymerization of all 
base polymers and end-capping of one base-polymer with all end-capping amines was 
verified by NMR; for spectra, see [19]. 
 
7.2.3 In vitro Polymer Library Transfection Screening 
ARPE-19 cells were maintained as previously described [24], plated at 100,000 
cells/cm2 in 96-well plates, and allowed to grow for 72 hr until visually confluent  prior 
to transfection with nanoparticles containing eGFP pDNA. To form the particles, 
polymer stock solutions at 100 mg/ml in DMSO and pDNA stock solutions at 1 mg/ml in 
water were separately dissolved in 25 mM sodium acetate (NaAc) buffer at pH 5.0, then 
combined and mixed by pipeting. Ten minutes later, 20 µl of particle solution containing 
600 ng pDNA and 36 µg polymer was added to 100 µl of medium on the cells and 
allowed to incubate for 4 hr, when the medium was then replaced with fresh medium. For 
the commercially available lipid based controls Lipofectamine 2000 and X-tremeGENE 
HP DNA, reagents were formulated as specified by the company (at 100 ng pDNA/ well), 
and also tested at the same DNA dose as used in our screening (600 ng/well) to ensure 
that optimal, comparable controls were chosen. For PEI transfection, a PEI stock solution 
at 1 mg/ml was diluted in Opti-MEM I, and mixed with pDNA in Opti-MEM. The 
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solution was then vortexed and allowed to stand for 20 minutes before being added to 
cells.  24 hr post-transfection, cell viability was analyzed by the CellTiter 96® AQueous 
One MTS assay using a plate reader (BioTek® Synergy 2), and is reported as a reduction 
in cell viability relative to untreated wells (100% - absorbance of well/untreated, 
normalized to no cells in the well). 48 hr post-transfection, transfection efficacy was 
analyzed by flow cytometry (Accuri C6 with Hypercyte high-throughput plate adaptor). 
 
7.2.4 Preparation of lyophilized nanoparticles 
Freeze dried pDNA nanoparticles were prepared by dissolving 36 µl of 100 
mg/ml polymer in DMSO in 324 µl of 25 mM sodium acetate buffer (pH 5.0), and then 
adding 60 µl of 1 mg/ml pDNA (total 60µg) with 60 µl of 25 mM sodium acetate buffer 
(pH 5.0). The mixture was vortexed, and allowed to self-assemble for 10 minutes. The 
nanoparticles were split into two batches and 120 µl of 90 mg/ml sucrose was added to 
each. The sample was then flash-frozen in liquid nitrogen, and placed on a lyophilizer for 
freeze-drying. The dried particles (containing 30 µl pDNA) were then resuspended to 30 
µl total volume in deionized water (thus resulting in a particle DNA concentration of 1 
mg/ml) just prior to subretinal injection. 
 
7.2.5 Particle Sizing and Zeta Potential measurements 
Particle sizing was performed using a NanoSight NS500 (NanoSight Ltd. 
Wiltshire, UK). Each sample was diluted 1:50 from the transfection concentrations (n=3); 
for the lyophilized samples, each sample was diluted to the same DNA concentration as 
the freshly prepared samples. For zeta potential measurements, 800 microliters of particle 
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solution containing 5 micrograms of pDNA was diluted into PBS to a total volume of 800 
µl and added to a disposable zeta cuvette, and measured in using a Malvern Zetasizer 
NanoZS. 
 
7.2.6 Polymer Degradation 
250 ml of a 100 mg/ml solution of B5-S5-E7 in DMSO was added to 250 mL of 
phosphate buffered saline (PBS) solution at 37oC. At each time point, 25 mL of this 
solution was removed and frozen, then lyophilized to remove the water. This sample was 
dissolved in a solution of 94% THF, 5% DMSO and 1% piperidine, and organic phase 
permeation chromatography (GPC) was performed using the same solvent as an eluent at 
a flow rate of 1 mL/minute. The detector (Waters 2414 refractive index detector) and 
columns (three Waters Styragel columns, HR1, HR3, and HR4, in series) were 
maintained at 40°C throughout the runs. Polymer molecular weights presented are 
relative to monodisperse polystyrene standards (Shodex, Japan). 
 
7.2.7 Subretinal Injections 
Subretinal injections were performed in both eyes of 3 month old C57Bl6 mice 
using a Pico-Injector (PL1-100, Harvard apparatus, Holliston, MA). Mice were 
anesthetized by intramuscular (IM) injection of Ketamine (80mg/kg)/Xylazine (16mg/kg). 
Pupils were dilated using 2.5% Phenylephrine Hydrochloride Ophthalmic solution (AK-
DILATE, Akorn, Lake Forest, IL) followed by administration of 0.5% Tetracaine 
Hydrochloride Ophthalmic solution (Phoenix Pharmaceutical Inc., St. Joseph, MO) eye 
drops just before the injection. The conjunctiva adjacent to the cornea was grasped with 
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forceps to allow optimal exposure of the injection site. A hole was made at the pars plana 
with the tip of a 30-gauge sterile (PrecisionGlide) needle. A 20~30µm (I.D.) micropipette 
glass needle tip mounted on a Pico-Injector holder was inserted in the hole, through the 
vitreous, and into the potential subretinal space. One ml of PBAE nanoparticles with 
eGFP pDNA and/or naked eGFP pDNA (at 1 mg/ml DNA, as described above in 
“Preparation of lyophilized nanoparticles”) was then delivered.  The retinal area injected 
was visualized as a retinal bleb or a slight retinal detachment. Subretinal injections were 
made under direct observation aided by a Zeiss dissecting microscope at 6x magnification. 
Immediately following injection of the nanoparticles, a small amount of Bacitracin Zinc 
and Polymyxin B Sulfate Ophthalmic ointment (Akorn, Buffalo Grove, IL) was applied 
to the eye. Mice were sacrificed 72 hr later with ether and cervical dislocation.  Eyes 
were enucleated, and the cornea and lens were removed. The retina and RPE/choroid 
were dissected and prepared for RNA extraction. The fellow eye was prepared for flat 
mount using confocal microscopy. Fluorescence intensity was analyzed with ImagePro 
software. The eyes with surgical complications were excluded from the study. 
 
7.2.8 Statistical Analysis 
GraphPad Prism 5 software was used for all statistical analysis. For comparison of 
best polymer formulation (B5-S5-E7 at 60 w/w) with commercially available controls 
with respect to transfection and reduction in cell metabolic activity, we performed a 1-
way ANOVA with a Dunnet post-test using B5-S5-E7 at 60 w/w as the control column. 
For comparison of base polymer structural effects with respect to transfection and 
reduction in cell metabolic activity, we performed a 2-way ANOVA with a Bonferroni 
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post-test to compare all columns to each other.  A student’s T-test was used for 




7.3.1 Transfection efficacy and cytotoxicity in ARPE-19 cells 
The transfection efficacy of the nanoparticle formulations (30 and 60 w/w 
polymer:DNA ratio, 600 ng/well DNA dose in a 96 well plate)  ranged from 0-44% 
GFP+ cells (Figure 7.2), with only small, single carbon changes to the backbone of the 
polymer structure or small changes to the ends of the polymers. To look at the effects of 
single carbon changes along the base polymer with respect to transfection efficacy, we 
averaged across the various end-modified versions of the same base polymer (Figure 7.3) 
and performed a 2-way ANOVA to examine the trends statistically (Table 7.1). 
Generally, transfection efficacy tended to increase with increasing hydrophobicity of the 
diacrylate or side chain in the base polymer. Interestingly, for the least hydrophobic 
backbones (B3b, B4) the biggest changes (and the only statistically significant ones) with 
respect to transfection efficacy occurred when increasing the side chain hydrocarbon 
length from 3 to 4 carbons, whereas with the more hydrophobic backbones (B5, B6), the 
only statistically significant increases in transfection efficacy occurred when increasing 
the side chain hydrocarbon length from 4 to 5 carbons. Only intermediately hydrophobic 
base diacrylates B4 and B5 showed strong statistically significant improvements when 
increasing the side chain length from 3 to 5 carbons.  
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The vast majority of the nanoparticle formulations showed only small reductions 
in cell metabolic activity compared to untreated controls (Figure 7.4), with the exception 
of some of the B6-S4, B6-S5 and E9-end modified polymers. To look at the effects of 
single carbon changes along the base polymer with respect to cell cytotoxicity, we 
averaged across the various end-modified versions of the same base polymer (Figure 7.5) 
and performed a 2-way ANOVA to examine the trends statistically (Table 7.1). 
Cytotoxicity, like transfection efficacy, also tended to increase with increasing 
hydrophobicity of the diacrylate or side chain in the base polymer (Figure 7.5). There 
was increased cytotoxicity with the most hydrophobic side chain, S5 (p<0.001 for 60 w/w 
with B3, B4, B5 and B6) as compared to the least hydrophobic side chain S3. 
Interestingly, The least hydrophobic backbones (B3, B3b) only showed increased 
cytotoxicity when the side chain length increased from 4 to 5 carbons and not from 3 to 4 
carbons at 60 w/w, whereas the more hydrophobic backbones (B4, B5, and B6) showed 
increased cytotoxicity when the side chain length increased from 3 to 4 carbons (p < 0.01 
for all 3), but no significant increase in cytotoxicity with side chain length increasing 
from 4 to 5 carbons. Cytotoxicity also increased with increasing hydrophobicity of the 
base diacrylate, although there seems to be no increase in toxicity when the backbone 
contains 4 carbons (B4) between diacrylate groups as compared to only 3 (B3).  
The formulation with the highest transfection efficacy was B5-S5-E7 at 60 w/w 
polymer:DNA (44±5%), and it was also relatively non-toxic (23% cell cytotoxicity) 
following transfection. This is significantly higher transfection than has been previously 
reported in the literature [13-15], and was significantly higher than optimized 
formulations of FuGeneHD (Roche) or Lipofectamine 2000 (Invitrogen), two of the 
! 192!
leading commercially available, cationic lipid based transfection reagents, or 25 kDa 
branched polyethyleneimine  (Figure 7.6). Lipofectamine 2000 was optimal at a 4 to 1 
ratio of lipid:DNA and enabled 26±7% transfection and 16±3% toxicity. X-tremeGENE 
HP DNA was optimal at a 600 ng DNA dose with a 5 to 1 ratio of lipid:DNA, yielding 
22±6% transfection and 32±9% toxicity. Branched 25 kDa polyethyleneimine (PEI) 
performed optimally at a 3:1 ratio at 600 ng DNA/well, only achieving 8±1% transfection 
efficacy with 25±6% toxicity. A 1-way ANOVA with a Dunnet post-test with B5-S5-E7 
as the control column showed that B5-S5-E7 at 60 w/w was significantly more 
efficacious than any of the positive controls (p < 0.001) but maintained comparable cell 
viability (p > 0.05 for all controls at 600 ng/well except for Lipofectamine 200 at a ratio 
of 2:1). 
In general, increased transfection brought with it concomitant increased 
cytotoxicity (Figure 7.7), but many formulations were either ineffective but moderately 
toxic or effective but fairly non-toxic. In general, among the base polymers which 
enabled high transfection, polymers containing B3-S5 were on the “bad” side of the best 
fit line (higher cytotoxicity relative to their transfection) and B4-S5 containing polymers 
were on the “good” side of the best fit line (lower cytotoxicity relative to their 
transfection). This can also vary by end group – B5-S5-E7 achieved the highest 
transfection efficacy (44±5%) with relatively low cytotoxicity (23±6%), but B5-S5-E4, 




7.3.2 Nanoparticle Physical Characterization 
Our lead polymer from the in vitro study, B5-S5-E7, when prepared in a large 
batch and purified, is moderately polydisperse, with a polydispersity index of 3.2, a 
number averaged molecular weight of 25,000 Da, and a weight-averaged molecular 
weight of 80,000 Da.  It is hydrolytically degradable, with a free polymer half-life of 4.6 
hr in physiological salt solution at 37oC (Figure 7.8). When complexed with pDNA, it 
forms nanoscale particles (hydrodynamic diameter of 180 nm), which are positively 
charged (zeta potential of +26 mV). The particles, when lyophilized, retain these 
characteristics, showing very comparable zeta potential and particle size after undergoing 
the freeze-drying process and being resuspended (Figure 7.9). 
 
7.3.3 Subretinal Injection of Lyophilized GFP-Nanoparticles 
A successful subretinal injection caused a bleb or retinal detachment of 
approximately 1/8 to 1/4 of the retina.  Subretinal injection (n=5) of 1 µl of 1 mg/ml 
lyophilized pDNA nanoparticles (60 w/w B5-S5-E7:DNA) resulted in significant 
transfection in the area of injection (Figure 10b), and quantitatively increased by over 
1000-fold the expression of GFP mRNA by RT-PCR in both the retina (p < 0.001) and 
the RPE/choroid (p = 0.003; Figure 10c) 72 hr post injection as compared to control 
subretinal injections of pDNA alone (n=3).  
 
7.4 Discussion 
Standard non-viral transfection protocols for in vitro transfection of RPE cells 
achieve only limited to moderate success in terms of transfection efficiency. In addition, 
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unlike typically optimal in vitro transfection conditions, where the transfection is done 
without serum and with cells in a sub-confluent state to maximize transfection, in vitro 
conditions were chosen here to more closely match the in vivo state. As RPE cells in the 
mature eye are not rapidly dividing and particles will come into contact with proteins 
before reaching cell surfaces, we used confluent cells in the presence of serum for our in 
vitro studies.  
 Figures 2-6 show interesting trends to guide the design of polymeric 
nanoparticles for transfection of retinal pigment epithelial cells.  As seen previously in 
studies looking at transfection of COS-7 monkey kidney cancer cells [19], we can see 
interplay between the hydrophobicity of the base diacrylates and the side chain amino-
alcohols (for statistical analysis, see Table 7.1). For example, relatively hydrophilic base 
polymers containing the shortest side chain, S3, were generally ineffective, and required 
the most hydrophobic base diacrylates, B5 and B6, to see any transfection efficacy. They 
were also non-toxic. On the other hand, polymers containing the most hydrophobic side 
chain, S5, were nearly all reasonably effective in transfection. Optimal transfection for 
many end-groups was achieved with the intermediately-hydrophobic base-diacrylates B4 
and B5 and most hydrophobic side chain S5. End-modified polymers with the most 
hydrophobic base group (B6) did not tend to be as effective and also were associated with 
more cytotoxicity, and B3-S5 end-modified polymers were not as efficacious but were 
non-toxic. Interestingly, increasing the hydrophobicity of the side chain from 3 to 4 
carbons in length tended to increase the transfection efficacy of polymers containing the 
least hydrophobic base diacrylates without increasing the cytotoxicity, whereas 
increasing the side chain length from 4 carbons to 5 carbons for the most hydrophobic 
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base diacrylate only increased the cytotoxicity of the formulation without increasing 
transfection efficacy. Taking this together suggests that polymer hydrophobicity plays a 
key role in the transfection efficacy of these complexes, but that there is a limit at which 
polymer hydrophobicity no longer increases transfection efficacy as fast as it increases 
cytotoxicity, such that there is an optimal hydrophobicity for PBAE based non-viral gene 
delivery vectors. 
End-modification of the polymers had a clear and strong effect, with polymers 
end-modified with E1 and E3-E8 tending to be more successful, and polymers modified 
with E9, E10, and E12 end-modifications tending to be less effective. Increasing polymer 
to pDNA weight ratio from 30 w/w to 60 w/w tended to both increase transfection 
efficacy and cytotoxicity; however, even at 60 w/w the cytotoxicity was moderate for 
most transfection conditions. Molecular weight was previously found to not vary the 
transfection efficacy of these materials [19], so that these differences in efficacy are 
likely due directly to the small changes in chemical structure that we observe. These 
small changes in structure may play a role in changing the DNA/polymer binding 
properties, changing the particle size, and changing the degradation rate of the 
nanoparticles, all of which could play a significant role in the observed gene delivery 
properties of the polymer library.  
We next sought to test the most successful type of nanoparticle in vivo.  However, 
in vivo injections into the eye require low volumes and highly concentrated pDNA 
nanoparticles.  The maximum volume that can be injected into the mouse eye is 1 µL. 
Simply scaling down our transfection protocol to the 1 µl volume required for the 
subretinal injections would have allowed us to deliver only 30 ng of DNA to the eye. Due 
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to the hydrophobicity of the polymers, formulation of particles at greater than 30-fold 
higher concentration (which would be required for our desired 1 µg dose to the eye) in 
standard aqueous conditions is not possible due to polymer solubility constraints. 
However, our lab has recently developed a protocol to formulate PBAE-based 
nanoparticles by adding sucrose as a cryoprotectant and then freeze-drying the particles. 
This process has been shown to allow long-term storage of the particles, with complete 
retention of transfection efficiency in glioblastoma cells after 3 months [20]. Although in 
vitro transfection efficacy has been validated using this procedure, in vivo efficacy of 
these lyophilized PBAE nanoparticles is unknown. Since the dry polymer/DNA 
nanoparticles can be resuspended following lyophilization in minimal water volumes, we 
hypothesized that we could increase nanoparticle concentration using this procedure. This 
is likely because resuspension of the nanoparticles requires formation of a colloidal 
suspension of polymer/DNA nanoparticles and does not require solvation of free polymer 
at the same concentrations. The cryoprotectant is also required for this step, as particles 
formed without cryoprotectant were unable to be resuspended. We were able to formulate 
60 w/w particles with 30 µg of pDNA, add sucrose, freeze dry the particles, and then 
resuspend the particles to 30 µl total volume in water, thus allowing the injection of 1 µg 
of DNA in 1 µl. This technique has several advantages beyond simply increasing the 
concentration of the particles, such as easy storage and low risk of degradation. 
Significant transfection of the RPE and retina was achieved with subretinal 
injection of 1 µl of 1 mg/ml DNA nanoparticles, in the area of injection (Figure 9b).  
Quantitatively, there was over 1000-fold increase in expression of GFP mRNA by RT-
PCR in both the retina and the RPE/choroid (Figure 9c). The relative expression of GFP 
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mRNA varied between the different mice (86-3800 fold increase in the retina, and 50-
5000 fold increase in the RPE/choroid), compared to naked eGFP DNA injection. 
Nonetheless even the lowest transfection is significantly higher than other delivery 
systems.   A recent article by Muna Naash’s laboratory studied CK30PEG10k complexed 
with eGFP to transfect RPE and found a 2.5 fold increase in eGFP expression in the RPE 
compared to a naked pDNA control [25]. Interestingly, they found similar uptake of GFP 
with CK30PEG10k as with naked GFP due to the RPE cell’s ability to phagocytoze 
naked GFP, and attributed their 2.5-fold improvement in transfection to improvements in 
downstream nuclear import [25]. Here, we are able to show a >1000-fold increase in GFP 
expression in the retina and RPE with our nanoparticles, which are specifically designed 
for improved intracellular delivery. PBAE nanoparticles are believed to improve 
intracellular delivery by binding and protecting pDNA, and facilitating both endosomal 
escape and the release of the DNA to the cytoplasm [22].  
 Here we show that poly(beta-amino) ester-based nanoparticles have great promise 
for delivery of plasmids to RPE cells. These nanoparticles are small in size (180 nm), 
have a positive zeta potential (+26 mV), and easily degrade in water. Many polymer 
formulations showed transfection efficacy that was significantly superior to 
Lipofectamine 2000 and FuGeneHD, two of the lead commercially available alternatives 
for non-viral gene delivery, with comparable cellular viability. The lead polymer, 1-(3-
aminopropyl)-4-methylpiperazine-end-modified poly(1,5 pentanediol diacrylate-co-5-
amino-1-pentanol) (B5-S5-E7), at 60 w/w polymer:DNA ratio was able in vitro to 
transfect 44% of ARPE-19 cells that were visually confluent with minimal cytotoxicity.  
Therefore, this novel nanoparticle has many potential benefits to further investigate 
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ocular diseases. The successful transfection of the RPE in vivo with lyophilized 
nanoparticles using this polymer formulation suggests that this technology could be 
useful in the future in vivo both in the lab and possibly in the clinic, to help ameliorate 





Figure 7.3: Comparison of base polymer structure with transfection efficacy. Each bar 
represents the average transfection efficacy associated with the end-modified polymers 
that contained the base polymer shown (n=11; error bar = SEM). Base diacrylate and side 
chain amino-alcohols are shown from least hydrophobic to most hydrophobic from left to 
right. (a) Transfection efficacy of 30 w/w formulations averaged over 11 end-modified 
amines containing the base polymer shown. (b) Transfection efficacy of 60 w/w 
formulations averaged over 11 end-modified amines containing the base polymer shown. 
For statistical analysis, see Table 1. 
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Figure 7.4: Reduction in metabolic activity following PBAE nanoparticle administration. 
Formulations plotted at 0% reduction of metabolic activity here had equivalent or slightly 
higher metabolic activity than untreated controls. (a)  Reduction in metabolic activity 
post transfection with polymer library formulated at 30 w/w ratio (n=4). (b)  Reduction in 
metabolic activity post transfection with polymer library formulated at 60 w/w ratio (n=4).  
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Figure 7.5: Comparison of base polymer structure with reduction in metabolic activity. 
Each bar represents the average toxicity associated with the end-modified polymers that 
contained the base polymer shown (n=11; error bar = SEM). Base diacrylate and side 
chain amino-alcohols are shown from least hydrophobic to most hydrophobic from left to 
right. (A) Reduction in metabolic activity of 30 w/w formulations averaged over 10 end-
modified amines containing the base polymer shown. (B) Reduction in metabolic activity 
of 60 w/w formulations averaged over 10 end-modified amines containing the base 





Figure 7.6: Comparison to commercially available transfection reagents. (XG HP = 
XtremeGENE HP; Lipo = Lipofectamine 2000; PEI = 25 kDa branched 
polyethyeleneimine). The numbers next to the reagent name corresponds to the ratio of 
lipid (v/v) or polymer (w/w) to DNA used. (A) Transfection efficacy of control 
formulations and B5-S5-E7 at 60 w/w (n=4); * indicates p < 0.001 vs. B5-S5-E7 at 60 
w/w. (b) Reduction of metabolic activity of control formulations and B5-S5-E7 at 60 w/w 
(n=4); # indicates p < 0.05 vs. B5-S5-E7 at 60 w/w. 
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Figure 7.7: Comparison of transfection efficacy to reduction in metabolic activity of the 
polymers in the polymer library. There is an overall trend of increasing cytotoxicity with 
increasing transfection efficiency (the best-fit line represents a 0.77% decrease in cell 
metabolic activity with every 1% increase in transfection efficiency of the formulation) 
but the trend only explains a portion of the results (R² = 0.37). A number of polymer 
formulations exhibited high transfection efficiencies and low concomitant cytotoxicities. 
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Figure 7.8: Number-averaged molecular weight versus time of B5-S5-E7 in PBS at 37C 
with agitation. The half-life of the polymer in solution was 4.6 hr (R2 = 0.984), and the 




Figure 7.9: Comparison of freshly prepared to lyophilized particles by particle size and 
charge. (a) Hydrodynamic diameter of freshly prepared DNA/B5-S5-E7 particles versus 
lyophilized particles (n=3; bars are standard error). (b) Zeta potential of freshly prepared 
DNA/B5-S5-E7 particles versus lyophilized particles (n=3; bars are standard error). 





Table 7.1: Results of 2-way ANOVA examining the effect of increased hydrophobicity 
of the side chain with respect to the base diacrylate it is paired with. NS is non-
significant; P < 0.05 is *; P < 0.01 is **; P < 0.001 is ***.   
Reduction in Metabolic Activity Transfection Efficacy 
30 w/w S3->S4 S4->S5 S3->S5 30 w/w S3->S4 S4->S5 S3->S5 
B3 NS NS NS B3 NS NS NS 
B3b NS NS NS B3b ** NS NS 
B4 NS * ** B4 NS NS ** 
B5 *** NS *** B5 NS ** *** 
B6 NS ** ** B6 NS ** NS 
60 w/w S3->S4 S4->S5 S3->S5 60 w/w S3->S4 S4->S5 S3->S5 
B3 NS *** *** B3 NS NS NS 
B3b NS * NS B3b *** NS NS 
B4 ** NS *** B4 * NS *** 
B5 ** NS *** B5 NS ** * 













































































8 Chapter 8: Particle shape determines efficient T cell 
activation and enhances tumor immunotherapy by 
artificial Antigen Presenting Cells7 
8.1 Introduction 
Geometry and spatial organization are critical components in many biological 
systems. The cytoskeleton, its organization, and the physical cues that it can transmit, 
result in dramatic effects on cell fate [1]. This is seen within the immune system in a 
variety of ways including during the interaction of a T cell with an antigen presenting cell 
(APC), which is a critical determinant of T cell fate and effector function. With activation, 
APC such as dendritic cells have major changes in their cell morphology resulting in 
significant increases in their overall cell surface area facilitating interaction with naïve T 
cells to direct T cell fate. Once an initial contact has been made by a T cell and an APC 
or some other target cell, T cell activation is further modulated by the formation of the 
immune synapse, a large surface area of close membrane apposition between the DC and 
T cell membrane, with concomitant cytoskeletal rearrangement and clustering of surface 
proteins [2-6]. Materials science approaches have helped to elucidate how the spatial 
organization and clustering of ligands that make up this synapse are important [7]. Thus, 
taking into account the geometry and spatial organization at cell-cell interfaces is 
important in studying biological responses. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This chapter contains excerpts from an article that was published as Sunshine JC*, Perica K*, Schneck JP, 
Green JJ. “Particle shape dependence of CD8+ T cell activation by artificial Antigen Presenting Cells.” 
Biomaterials. 2013. http://dx.doi.org/10.1016/j.biomaterials.2013.09.050 
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Reductionist systems have facilitated the study of effective immune responses.  
One such system is the acellular artificial antigen presenting cell (aAPC).  aAPCs have 
been made by coupling proteins required for T cell activation to particles.  Minimally, T 
cell activation requires two sets of receptor-receptor interactions. One interaction, Signal 
1, is the binding of major histocompatibility complexes (MHC) or a surrogate, such as 
anti-CD3, to bind the T cell receptor (TCR). A second interaction, Signal 2, is the binding 
of co-stimulatory receptors on the APC, such as B7.1, to ligands on the T cell, such as 
CD28.  aAPC have been generated by coupling proteins that deliver Signal 1 and 2 to the 
surface of particles (Fig. 8.1A) made from a range of materials, including magnetic 
microparticles [8, 9], polystyrene particles [10] and PLGA microparticles [11-13]. Such 
systems have been broadly applied to tumor immunotherapy, vaccination, and 
immunosuppression, and are amenable to in vivo or ex vivo T cell stimulation and offer 
possible novel translational approaches to immunotherapy [9, 14-18]. 
While useful, the Signal 1 and 2 paradigms alone do not capture aspects of spatial 
organization or the geometry of interactions. Previous work developing aAPCs have not 
attempted to re-capitulate these aspects of APC behavior. As a result, all aAPCs tested 
thus far have used spherical particles for their aAPC platforms, which unlike DCs 
minimize surface area for a given volume (Fig. 8.1B).  
Particle shape has only recently become a design parameter of interest in the field 
of material design for drug delivery. Shape can play a role in tuning the rate and 
mechanism of cellular uptake [19], can dramatically reduce internalization by phagocytic 
cells such as macrophages [20, 21], can change the biodistribution of the drug delivery 
vehicle [22, 23], and has been posited as potentially modulating the ability of a particle to 
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bind a cell in part by increasing the surface area for interaction [22, 24]. In fact, a recent 
study by Barua et al showed that antibody coated polystyrene nanorods had higher 
specific and reduced non-specific uptake than spherical counterparts, demonstrating a 
significant relationship between particle shape and cell binding/unbinding [25]. 
We adapted a method for controlling the shape of microparticles made from 
biocompatible polymer poly (lactic-co-glycolic) acid (PLGA)[26] to generate ellipsoid 
aAPCs with varying long axis lengths and aspect ratios (ARs)(Fig. 8.1C,D). These 
ellipsoidal aAPC were successful at stimulating T cells, modulating both significantly 
enhanced T cell expansion in vitro and tumor rejection in vivo. Confocal imaging of cell-
aAPC interactions indicates that this effect may be due to improved interaction along the 
long axis of the aAPC. These findings suggest that particle geometry is a critical design 
criterion in the generation of aAPC, and may offer insight into the essential role of 
geometry involved in the interaction between T cells and biological APCs. 
 
8.2 Results 
8.2.1 Ellipsoidal aAPC synthesis and characterization 
Ellipsoidal, biodegradable aAPCs were synthesized by first fabricating PLGA 
microparticles which were then stretched into ellipsoids using a film stretching method 
[26] This method offers the advantage of allowing a direct comparison of particle shape 
and surface area, while retaining equivalent volumes.  
The single emulsion PLGA (50:50 LA/GA, MW 38,000-54,000) microparticle 
synthesis resulted in spherical microparticles (Fig. 8.1D, spheres) with a number-
weighted average diameter of 4.3 µm and a volume-weighted diameter of 6.7 µm (Fig. 
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8.1E). We were able to control the aspect ratio (AR) of ellipsoidal microparticles with a 
high degree of accuracy by imposing different degrees of stretch (STR) onto the film (Fig. 
8.1D). This technique exhibits a high correlation between predicted AR and empirically 
measured AR (by SEM) for a fixed volume ellipsoid that has been elongated in one 
direction (AR = STR1.5) (Fig. 8.1F). This indicates that particle stretching is a feasible, 
controllable process that allows for flexibility in specifying the shape of the resulting 
particles. Ellipsoidal and spherical microparticles were then made into aAPCs by 
EDC/sulfo-NHS mediated covalent coupling of a dimeric MHC-Ig fusion protein[27] and 
an antibody against CD28 to free carboxyl groups on the particle surface.  
Key parameters to evaluate these aAPCs include characterizing the total protein 
on the surface, the protein density, the dimer/anti-CD28 antibody ratio and the surface 
distribution on the spherical and ellipsoidal aAPCs. To characterize the conjugation 
efficiency with different amounts of protein added, we synthesized spherical and 
ellipsoidal (STR 2/AR 2.8) aAPC with fluorescently labeled MHC-Ig dimer and 
unlabeled anti-CD28 antibody, and characterized the particles by fluorimetry (Fig. 8.1G). 
By increasing the amount of MHC-Ig used during synthesis, we achieved protein 
coupling of up to 0.75 mg MHC-Ig/mg PLGA (Fig. 8.1G). Coupling efficiency was 15-
20% over the entire range of protein analyzed, and there were no statistically significant 
differences between spherical and ellipsoidal aAPC in terms of their total protein content 
or protein density (p > 0.35 for all comparisons) (Fig. 8.1G). PLGA microparticles 
showed only minor auto-fluorescence and did not interfere with dye emission (Fig. 8.S1).  
To evaluate whether spherical or ellipsoidal aAPCs might show differences in 
dimer/anti-CD28 antibody ratio or surface distribution of the two proteins, we 
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synthesized spherical or ellipsoidal aAPCs with fluorescently labeled MHC-Ig dimer and 
unlabeled anti-CD28 antibody, and characterized the particles by fluorimetry and by 
confocal microscopy (Fig. 8.S2). Spherical and ellipsoidal aAPC did not show significant 
differences in MHC-dimer amount or density, anti-CD28 amount or density, or MHC-
dimer/anti-CD28 ratio (Fig. 8.S2). Approximately 85-90% of the protein on the surface 
required the EDC/NHS pre-activation step (Fig. 8.S2). The fluorescence signals from the 
two proteins were co-localized in both cases (quantified here by the Pearsons correlation), 
and the distribution pattern was equivalent between the two groups (Fig. 8.S2). Taken 
together with the modest (16%) increase in total surface area for 2-fold stretched particles 
(AR 2.8) as compared to spherical particles (Table 8.1), the protein surface 
characterization data indicate that there are not substantial differences between spherical 
and ellipsoidal particles with respect to protein density, total protein amount, protein 
organization, or surface release.  
 While bulk polymer degradation from PLGA microparticles have been well 
investigated in the drug delivery field [28-30], the effect of degradation on release of 
surface-coupled proteins is less well studied. For aAPCs, presentation of immobilized 
proteins are critical for T cell activation and thus it is important to study release of these 
proteins [10]. To characterize surface degradation, aAPCs bearing fluorescently labeled 
MHC-Ig were incubated for varying amounts of time at 37°C.  Supernatants were 
recovered through centrifugation of the aAPCs and released protein quantified by protein 
fluorescence.  For both spherical aAPCs and ellipsoidal aAPCs, 60-70% of the protein 
that was conjugated to the surface was released over 7 days, with 30-40% of the protein 
released in the first 3 days. At 7 days, 30-40% of the protein remained on the surface of 
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the aAPCs, as quantified by total fluorimetry from the particles (Fig. 8.1H). There was no 
significant difference in this release profile between ellipsoidal and spherical aAPCs.  
We characterized the stability of the ellipsoidal aAPC shape by analyzing their 
relaxation rate to the more stable spherical shape.  Previous studies have indicated that 
relaxation rates are dependent on surface characteristics, molecular weight, polymer 
composition, and temperature [26]. We observed very little shape relaxation for high 
aspect ratio ellipsoidal aAPC over 1 week at 37°C in PBS, indicating that the shape 
transition is slow for ellipsoidal aAPCs with the chosen lactide to glycolide ratio (Fig. 
8.S3). This agrees with published relaxation timescales for high aspect ratio PLGA with 
hydrophilic surfaces, such as those used here [26].  
 
8.2.2 High aspect ratio aAPCs efficiently induce T cell proliferation 
In order to assess the impact of particle elongation, we measured the ability of 
aAPC to induce antigen specific T cell expansion of pMEL TCR transgenic T cells. 
Spherical and 2-fold stretched (AR = 2.8) ellipsoidal aAPCs were synthesized at 3 
different cognate MHC-peptide densities by adding 4, 1, and 0.5 µg of Db-Ig GP100/mg 
PLGA with corresponding amounts of anti-CD28 antibody, resulting in spherical and 
ellipsoidal aAPC with 0.75, 0.14, and 0.08 µg of MHC-dimer/mg PLGA (Fig. 8.1G). 
Spherical aAPCs bearing non-cognate Db-Ig ASN at the highest protein density were 
used as a negative control. The aAPCs were added to pMEL TCR transgenic T cells at 3 
aAPC to cell ratios (1, 0.1 and 0.01 mg aAPC/105 cells). Proliferation was assessed at day 
4 by CFSE dilution (see methods for details) and on day 7 by cell counts. Day 4 CFSE 
dilution for a representative Db-Ig density (0.75 ug Db-Ig/mg PLGA) is shown at each 
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aAPC:cell ratio (Fig. 8.2A), while day 7 fold proliferation data are shown for all three 
parameters of aAPC shape, aAPC:cell ratio, and Db-Ig density (Fig. 8.2B). 
At a subsaturating dose of aAPC, 0.01 mg/105 cells, ellipsoidal but not spherical 
aAPCs induced T cell proliferation as measured by CFSE dilution (Fig. 8.2A 0.01mg). 
This was reflected in Day 7 cells counts, with only ellipsoidal aAPC bearing 0.75 or 0.14 
µg Db-Ig/mg PLGA inducing T cell expansion, of 22-fold and 11-fold expansion, 
respectively (Fig. 8.2B 0.01mg; p<0.001 and p<0.01 for 0.75 and 0.14 µg Db-Ig/mg, 
respectively). At an intermediate aAPC:cell ratio (0.1 mg/105 cells), ellipsoidal aAPC 
also induced higher levels of CFSE dilution (Fig. 8.2A 0.1mg) than spherical aAPC. Cell 
counts indicated ellipsoidal aAPC conferred an approximately 3-fold increase in total T 
cell expansion by day 7 compared to spherical aAPCs (Fig. 8.2B 0.1mg; p<0.001 and 
p<0.01 for 0.75 and 0.14 µg Db-Ig/mg, respectively). At saturating high aAPC:cell ratios 
(1 mg/105 cells) and the highest Db-Ig density, differences between ellipsoidal and 
spherical aAPCs were substantially smaller but still statistically significant (p<0.05) (Fig. 
8.2A/2B, 1mg). However, when Db-Ig density on aAPC was titered to 0.1 mg Db-Ig/mg 
PLGA, ellipsoidal aAPC regained their advantage, stimulating significantly more T cell 
expansion than spherical aAPC (p<0.001). aAPC bearing non-cognate MHC-peptide did 
not induce CFSE dilution or T cell proliferation (Fig. 8.2A left).  
Two parameters that are important in T cell activation are total amount of antigen-
MHC complex and antigen density [31-33]. We wanted to study the impact of shape 
independent of total antigen-MHC complex or antigen density. To separate the effect of 
shape from the effect of total antigen-MHC dose or antigen density, we replotted the 
expansion data from Fig. 8.2B versus total antigen-MHC dose (Fig. 8.2C) and antigen 
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density (Fig. 8.2D). Increasing total dose results in increased CTL expansion, but at all 
total doses, ellipsoidal aAPC (in red) outperform their spherical counterparts (in black) 
(Fig. 8.2C). For example, at a total dose of MHC near 0.1 µg/105 cells, all 3 ellipsoidal 
formulations showed higher fold-expansion than the 3 spherical formulations. There is 
also a positive correlation between increased antigen density and T cell proliferation at a 
given particle dose (Fig. 8.2D), but across the probed density ranges, ellipsoidal particles 
(in red) show higher fold-expansion than comparable spherical particles (in black).  For 
example, in Fig. 8.2D 0.1mgs, ellipsoidal particles with an MHC density of 400±140 and 
240±70 MHC-Ig dimer/µm2 displayed higher fold expansion (19.7±0.7 and 6.3±0.8 fold 
respectively) than spherical particles with an intermediate MHC density of 350±60 
MHC-Ig dimer/µm2 (2.3±1 fold expansion). Thus, across a range of total antigen doses 
and protein densities, when controlling for dose and density, ellipsoidal aAPC were more 
efficient at inducing T cell expansion than spherical aAPC. 
To further study the importance of AR on T cell stimulation, PLGA 
microparticles were synthesized, stretched varying amounts, and made into aAPCs. There 
was a striking correlation between increased AR and increased T cell proliferation (Fig. 
8.3). Interestingly, the greatest gain in T cell numbers was seen by increasing the aspect 
ratio of the ellipsoidal aAPC by increasing the applied stretch from 1.5-fold to 2-fold, 
which resulted in approximately 2 fold expansion up to approximately 20 fold T cell 
expansion at a 0.01 mg aAPC/105 cells dose (Fig. 8.3C). Analysis of the number of 
divisions from the CFSE dilution data (Fig. 8.3A) revealed that increasing AR further 
resulted in a larger percentage of cells have gone through significantly greater number of 
divisions (Fig. 8.3B). The fraction of non-responders (generations 0-1) progressively 
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decreases with increasing AR, eventually resulting in only 11% non-responders for the 
3.5-fold stretched (AR 6.6) aAPCs.  The number of cells undergoing 4-5 or 6-7 divisions 
also increases with every additional .5-fold increase in applied film stretch. This effect 
was also saturable with very high doses of aAPCs (Fig. 8.S4). Therefore, increasing 
aspect ratio of the aAPCs resulted in increased T cell expansion consistently up to 3.5 
fold stretched aAPCs (AR 6.6), with the greatest improvement in overall T cell expansion 
seen when going from 1.5-fold to 2-fold applied stretch, which corresponds to a change 
in AR from 1.8 to 2.8.  
Thus, increasing aspect ratio of ellipsoidal aAPC results in improved T cell 
activation, and this enhanced proliferation that is mediated by ellipsoidal aAPC is 
primarily dependent on aAPC geometry rather than potential subtle differences in the 
density or amount of conjugated surface protein. 
T cell quality, as reflected by the amount and diversity of cytokines and cytotoxic 
markers produced when T cells are re-challenged by antigen, is a critical parameter for 
assessing responses [34]. To determine the functional status of the expanded T cell 
population, we re-challenged aAPC-activated T cells with peptide-pulsed splenocytes and 
measured the production of a key cytokine, IFNγ, as well as measured the degranulation 
marker, CD107a in an intracellular cytokine staining (ICS) assay. Function tracked with 
proliferation; there was no significant difference in the quality of T cells generated from 
spherical or ellipsoidal aAPCs as determined by IFNγ or CD107a expression (Fig. 8.S5).  
There was no significant difference when comparing T cell quality after equal doses of 
aAPCs (which resulted in higher proliferation with the ellipsoidal aAPC) or when 
comparing equal proliferation (from lower doses of ellipsoidal aAPC). 
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8.2.3 High aspect ratio ellipsoidal aAPCs enhance T cell conjugate formation 
Antigen recognition on APC is known to trigger coordinated cytoskeletal 
rearrangements in both T cells and APCs, leading to close apposition of their cellular 
membranes. The resulting interactions mediate T cell activation and, when visualized by 
imaging or flow cytometry, are termed cell-cell conjugates [35].  
To evaluate the formation of T cell-aAPC conjugates, naïve T cells were 
incubated at 37°C with spherical or ellipsoidal aAPCs. Cell-aAPC interactions were 
visualized after a one-hour incubation by confocal imaging. In the presence of ellipsoidal 
aAPCs bearing cognate MHC/peptide, T cell membranes could be observed in close 
apposition to the aAPC’s long but not short axis, creating a T cell “cap”, characteristic of 
conjugate formation (Fig. 8.4A).  
Conjugate formation was observed for T cells incubated in the presence of either 
ellipsoidal (Fig. 8.4B) or spherical (Fig. 8.4C) aAPC. Importantly, conjugate formation 
was a process driven by recognition of cognate antigen, as neither spherical nor 
ellipsoidal aAPCs bearing non-cognate MHC/peptide induced cap formation (Fig. 8.4D, 
E). When quantitated, conjugate formation was approximately 2.5-fold more frequent 
with ellipsoidal aAPC, with 4.6 ± 0.9% of the T cells forming conjugates with the 
ellipsoidal aAPC compared to 1.8 ± 0.4% with spherical aAPC (p = 0.01, Fig. 8.4F). In 
addition to being 2.5-fold more frequent, we observed a significant increase (p = 0.01, 
Fig. 8.4G) in the contact length between the T cells and the ellipsoidal aAPC (3.6 ± 0.6 
µm/interface) as compared to spherical aAPC (1.9 ± 0.2 µm/interface). 
Time-lapsed imaging revealed a striking reorientation and rearrangement of the T 
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cell surface against the aAPC long axis.  Initially, the T cell appears to contact the aAPC 
along the short axis but with time migrates along the long axis rearranging its membrane 
against the long axis of the ellipsoidal aAPCs (Fig. 8.4H). Membrane reorientation and 
alignment against the long axis of ellipsoidal aAPC strongly suggests a preference for the 
flat surface presented by the long axis of ellipsoidal aAPC.  We thus observe that 
ellipsoidal aAPCs generate increased biomimetic interactions with T cells compared to 
spherical aAPCs, and suggests that the improved T cell expansion seen in vitro is due to 
increased frequency and size of T cell-aAPC contact along the long axis of the ellipsoidal 
aAPCs. 
 
8.2.4 High aspect ratio, ellipsoidal aAPCs enhance tumor killing in vivo 
To test the activity of high aspect ratio aAPCs in vivo, we utilized a subcutaneous 
B16 melanoma tumor model. We injected a dose of aAPC subcutaneously 3 days before 
and a second dose 3 days after tumor injection into the hindlimb (see Fig. 8.5A).  
Treatment with either ellipsoidal (p = 0.0009 vs. non-cognate) or spherical (p = 0.02 vs. 
non-cognate) cognate aAPCs led to significant reductions in tumor size as compared to 
controls that received control non-cognate aAPCs or T cells alone (Fig. 8.5B). By day 19, 
cognate ellipsoidal aAPC treated tumors had only reached a size of 42.5 ± 14.9 mm2, 
compared to 90.5 ± 33.8 mm2 for cognate spherical, 164.5 ± 28.6 mm2 for non-cognate 
ellipsoidal, and 154.4 ± 35.4 mm2 for T cell alone treated mice. Area under the curve 
(AUC) of tumor growth over the course of the entire experiment showed a similar pattern, 
with tumors growing a total of 44.3 ± 15.6 mm2, compared to 105.3 ± 34.7 mm2 for 
cognate spherical, 251.0 ± 46.6 mm2 for non-cognate ellipsoidal, and 238.0 ± 46.6 mm2 
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for T cell alone treated mice. Cognate ellipsoidal aAPCs thus reduced tumor size more 
than spherical aAPCs, but this effect did not achieve statistical significance (p = 0.13).  
Survival studies revealed statistically significant differences in survival between 
mice injected with ellipsoidal cognate aAPC over spherical cognate aAPC (Fig. 
8.5C)(p=0.05), as well as ellipsoidal non-cognate control aAPCs (p=0.004). 25% of the 
animals in the cognate ellipsoidal aAPC group completely cleared tumor by day 19 and 
survived the course of the experiment, which did not occur in any other treatment or 
control groups. Furthermore, ellipsoidal aAPC treatment led to a significant delay in 
tumor growth, with no mice reaching substantial tumor burden until 22 days after tumor 
injection, compared to 19 days for the other three groups. 
 Critically, this demonstrates that increased aspect ratio acellular aAPCs, which 
only differ in their shape (and importantly not in their volume or significantly in their 
protein content or antigen density) as compared to spherical controls, not only engender 
enhanced antigen specific activation in vitro but in vivo as well, and this enhanced 
activation has functional consequences which lead to reduced tumor burden and 
enhanced survival.  
 
8.3 Conclusion 
The key consideration in cancer immunotherapy remains the efficient stimulation 
of antigen (Ag)-specific cytotoxic T cells (CTLs). In vivo, a key interaction for 
generation of activated, effector Ag-specific CTLs is the interaction between antigen 
presenting cells, such as dendritic cells or macrophages, with T cells. In the development 
of acellular systems for CTL stimulation, previous literature has focused predominantly 
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on the proteins involved in the interaction between APCs and T cells [8, 9, 13, 36-38], 
and recent studies extended this to release of cytokines [12, 39]. 
However, the biological interaction between T cells and their targets is distinctly 
not an interaction that is most appropriately represented by two spheres interacting. We 
evaluated the effect of 1-dimensional stretching of aAPCs on the ability of these acellular, 
biodegradable aAPCs to induce T cell proliferation in vitro and tumor killing in vivo. In 
this study, antigen dose, antigen density, protein ratio, protein colocalization, and particle 
volume are held essentially equivalent between spherical and ellipsoidal aAPCs, and yet, 
at sub-saturating aAPC doses, high aspect ratio ellipsoidal aAPCs show significantly 
enhanced activity beyond spherical aAPCs. Increasing the aspect ratio of ellipsoidal 
aAPCs shows enhanced activity up to AR 6.6. This enhanced activity was also reflected 
in vivo, where ellipsoidal cognate aAPCs caused increased survival in mice compared to 
ellipsoidal non-cognate aAPCs (p=0.004) as well as cognate spherical aAPCs (p=0.05). 
One key parameter that is altered in with particle stretching is increases in surface area 
(Table 8.1B). However, while total surface area increases modestly with stretching, with 
a maximum increase in net surface area of the aAPCs of 50% for AR 6.6 aAPCs, 
stretching the aAPCs dramatically increases surface flatness along the long axis of the 
aAPCs, with the radius of curvature increasing 23-fold over the same range (Table 8.1E). 
Confocal imaging suggests that the observed improvement in T cell activation is due to 
improved interaction along this flatter, long axis of the biomimetic, ellipsoidal aAPCs.  
These findings indicate that shape matters and that aAPC geometry is a critical 
design criterion to consider in the synthesis of biomimetic acellular aAPC systems. While 
particle-based T cell stimulation systems have yielded crucial insights regarding early 
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activation events [36, 40], aAPC that more closely mimic endogenous cell-cell 
interactions may provide a more complete understanding of the underlying process, such 
as the role of close membrane apposition and a large surface area of contact in the APC/T 
cell interation. aAPCs thus may not only be an enabling tool for antigen-specific 
immunotherapy, but also for studying basic aspects of T cell biology. 
  
8.4 Materials and Methods 
8.4.1 Microparticle fabrication 
The poly(lactide-glycolide) (PLGA) microparticles were made by dissolving 200 
mg of acid-terminated PLGA (50:50 LA/GA, MW 38,000-54,000, Sigma-Aldrich) in 5 
ml of dicholoromethane (ACS grade, Sigma-Aldrich). The dissolved PLGA was then 
added dropwise to 50 ml of an ice-cold 1% poly(vinyl alcohol) (PVA) solution, which 
was homogenized at 5,000 rpm. After dropwise addition, the solution was allowed to 
homogenize for an additional minute, and then added to a 100 ml solution of 0.5% PVA 
which was stirring at 500 rpm in the cold room (at 4°C). After stirring for 4 hours to 
allow for solvent evaporation, the particles were centrifuged (4000 rpm for 5 min) and 
washed 3x, resuspended in 5 mL of deionized water and lyophilized.  
For confocal imaging, tetramethyl rhodamine (TAMRA) loaded microparticles 
were synthesized via single emulsion as follows: The TAMRA was dissolved in 
dichloromethane at 1 mg/ml. 200 mg of acid-terminated PLGA was dissolved in 4.9 ml 
of DCM and 100 µl of TAMRA solution was added to the PLGA DCM phase. Particle 
synthesis otherwise followed the same protocol as the single emulsion particles above. 
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8.4.2 Preparation of MHC-Ig Dimers  
Briefly, Db-Ig molecules were stripped under mildly acidic conditions (pH 6.5) 
and refolded in the presence of 40 fold molar excess peptide and 2-fold molar excess of 
human β2-microglobulin. Peptides GP100 (KVPRNQDWL; the “cognate” peptide) and 
ASN (ASNENMETH; a “non-cognate” peptide) were purchased from Genscript 
(Piscataway, NJ). Protein concentration was determined after labeling by size exclusion 
High Performance Liquid Chromatography. 
 
8.4.3 Film formation and particle stretching 
Lyophilized microparticles were added to a solution containing 10% PVA and 2% 
glycerol by weight at 5 mg/ml (particles/ml solution). The solution was poured on a flat 
surface and allowed to dry overnight. After drying, strips of the resulting film were cut 
out and placed on an aluminum-stretching device consisting of two aluminum blocks that 
can be separated by sliding on aluminum rods. The film and custom-made stretcher were 
placed in a 90°C oven for 10 minutes and then the film was slowly stretched inside of the 
oven to the desired stretch ratio by separating the two blocks. After allowing the film to 
cool down to room temperature, the film was removed and dissolved in 10 ml of 
deionized water, then the particles were centrifuged (4000 rpm for 5 min) and washed 3x, 
and finally resuspended in deionized water, frozen, and lyophilized. Spherical particles in 
all experiments were also prepared similarly; they were heated along side of the 
ellipsoidal particles but simply not stretched. 
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8.4.4 aAPC synthesis 
Soluble MHC-Ig dimers were prepared and loaded with peptide as described.[41] 
Spherical and ellipsoidal microparticles were resuspended in coupling buffer (0.1M MES 
pH 6.0), and activated with EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, 
Sigma-Aldrich) and sulfo-NHS (N-hydroxysulfosuccinimide). As an example, 5 mg of 
microparticles were resuspended in 1 ml of coupling buffer and activated with 10 mg of 
EDC and 13 mg of sulfo-NHS for 15 min at 1000 rpm on a multitube vortexer (VWR). 
Activated microparticles were then centrifuged, the supernatant was removed, and the 
activated particles were resuspended in 1 ml PBS (pH 7.4) and transferred to a 5 mL 
glass scintillation vial for coupling. As an example, 8 µg of MHC-dimer and 10 µg of 
anti-CD28 antibody (always in this ratio) were added to 2 µg of activated PLGA 
microparticles, and then the reaction was allowed to proceed in the cold room (4°C) for 4 
hours. After 4 hours, the aAPCs (here, 2 mg of aAPCs) were centrifuged and washed 2x 
with PBS, then centrifuged, re-suspended in 200 µl of 0.2 mm-filtered sterilized 100 
mg/ml endotoxin-free sucrose solution, frozen, and lyophilized overnight. 
 
8.4.5 Characterization of aAPCs  
8.4.5.1 Measuring)size)and)aspect)ratio)by)SEM)
Lyophilized particle samples were spread on conductive carbon tape mounted on 
aluminum SEM mounts (Eletron Microscopy Sciences, Hatfield, PA). Samples were 
sputter coated with a chromium sputter coater and imaged on a Leo/Zeiss Field emission 
SEM in the Johns Hopkins Core Microscopy facility. Particle size and aspect was 
quantified using ImageJ software. For spherical particles, a single diameter was measured 
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for each particle. For ellipsoidal particles, two diameters were measured (long-axis and 
short-axis) and the aspect ratio was calculated by dividing the two. 
 
8.4.5.2 Surface)protein)quantification)and)release)
Surface protein quantification was performed by conjugation of unlabeled anti-
CD28 mAb and fluorescently labeled MHC-IgG dimer to the surface of pre-activated 2-
fold stretched (AR 2.8) ellipsoidal or spherical PLGA microparticles for 4 hours at 4C. 
These aAPC were centrifuged washed 3x, and then their fluorescence was characterized 
on a Synergy 2 plate reader (Biotek, Winooski, VT). Release from surface was 
characterized by incubating 10 mg of aAPC (spherical, ellipsoidal) with labeled dimer in 
500 µl PBS at 37°C for 1 week. At 3 days and 7 days, the particles were centrifuged and 
the supernatant was removed and stored for subsequent analysis. At 7 days, the 




Six days after primary stimulation with aAPC, T cell functional activity was 
assessed by re-challenge with peptide-pusled C57Bl/6j splenocytes. Splenocytes were 
pulsed with the indicated concentration of peptide for 2 hours at 37°C then washed.   
200,000 aAPC-activated T cells were incubated in complete RPMI with 200,000 
splenocytes for 4 hours in a round bottom 96 well plate in the presence of 0.2 µl 
GolgiPlug, 0.2 ul GolgiStop, and anti-CD107a-fitC (BD Biosciences, Mountain View, 
CA). Cells were washed and fixed using a BD Cytofix/Cytoperm kit (BD Biosciences) 
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according to the manufacturer’s instructions, then stained with anti-IFNγ PE (BioLegend). 
Cytokine staining was assessed by flow cytometry and frequency of cytokine functional 
cells was assessed by comparison with an unstimulated control in FlowJo (TreeStar). 
 
8.4.6 In vitro CTL induction and CFSE dilution  
T cells used were obtained from homogenized mouse spleens after depletion of 
RBC by hypotonic lysis. Cytotoxic lymphocytes were isolated using a CD8-negative 
isolation kit and magnetic enrichment column from Miltenyi Biotec (Cologne, Germany) 
and labeled with carboxyfluorescein succinimidyl ester (CFSE) for 15 minutes at 37°C, 
then washed extensively. Cells and aAPCs at the indicated amounts and dosages were 
mixed and cultured for 4-7 days in complete RPMI media supplemented with T cell 
factor, a cytokine cocktail harvested from human plasma [42]. Cell proliferation was 
quantified by manual cell counting, and final T cell count was divided by the initial T cell 
count for fold-change data. 
 
8.4.7 aAPC-T cell conjugate formation evaluation 
For confocal imaging, PLGA microparticles with encapsulated 5(6)-carboxy-
tetramethylrhodamine dye (TAMRA, Nova Biochem, San Diego, CA) were synthesized 
(see supplemental methods). These labeled particles were then cast into a film, and the 
film stretching and subsequent sythesis of aAPC from spherical and ellipsoidal TAMRA-
loaded particles were done as before. 1x106 CFSE-labeled T cells were incubated with 1 
mg spherical or ellipsoidal aAPC for 60 minutes at 37oC in a No. 1.5 glass bottom dish 
(MatTek, Ashland, MA). Images were acquired on a Zeiss LSM 510 META (Zeiss, 
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Oberkochen, Germany) laser scanning confocal at 40x magnification at the Johns 
Hopkins School of Medicine Microscopy Facility. aAPC/T cell areas of contact were 
quantitated by image analysis on ImageJ. 
 
8.4.8 In vivo activity of aAPCs  
We performed a subcutaneous B16 melanoma tumor prevention mouse model 
(Fig 6a). The animals were preinjected intravenously (i.v.) with naïve pmel T cells (day -
1, 2x106 cells/animal), subcutaneously (s.c.) in the flank with aAPCs (day 0, 2 mg 
aAPCs/animal), then injected with 2x105 tumor cells in the hindlimb (day 3). Responses 
were boosted with subsequent s.c. injection of a second aAPC batch (day 6, 2 mg 
aAPCs/animal), and tumor growth over the course of the experiment was followed by 
measurement with external calipers. Once the tumor size reached 200 cm2, the mice were 
sacrificed. Treatment groups consisted of ellipsoidal and spherical cognate aAPC (n=8), 




All statistics were performed in GraphPad Prism. For analysis of surface protein 
quantification, we performed pairwise t-tests. For analysis of specific T cell proliferation 
in response to specified aAPC dose, protein density, and shape of aAPC, we performed 
two-tailed t-tests with a Bonferroni correction for multiple comparisons. For analysis of 
quantification of cognate formation and area of contact between aAPCs and T cells, we 
performed pairwise t-tests. For analysis of tumor size, we performed a 1-way ANOVA 
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with Tukey post test. For in vivo survival analysis, we used the Log-rank (Mantel-Cox) 





Figure 8.1: (A) Schematic of an aAPC. (B-D) Schematic of the interaction between a T 
cell, modeled as a sphere, interacting with (B) a sphere; (C) an ellipsoid (AR 2.83; stretch 
ratio 2). (D) Characterization by SEM (2000x magnification) of spherical and ellipsoidal 
aAPCs. Scale bar corresponds to 10 µm. (E) Size distribution of aAPCs. (G) Comparison 
of degree of stretch imposed on the film (STR) with the aspect ratio (AR) of the 
generated ellipsoidal aAPCs. Predicted AR = STR3/2 (F) Coupling efficiency for protein 
during synthesis of aAPC from spherical and ellipsoidal microparticles (n=2). (G) Protein 






Figure 8.5: In vivo tumor-prevention model. (A) Experimental protocol and timeline. (B) 
Tumor size measurements for mice injected with cancer and T cells alone or also injected 
with non-cognate ellipsoidal (NonCognate), cognate spherical (Spherical), and cognate 
ellipsoidal aAPC (Ellipsoidal). AUC = area under the curve. * p = 0.02 vs. non-cognate; 
** p = 0.0009 vs. non-cognate. For comparison of ellipsoidal cognate and spherical 
cognate by AUC, p = 0.13. (C) Survival curve – mice were sacrificed and declared 
“dead” when tumor size reached 200 mm2. Subcutaneous injection of ellipsoidal aAPC 
resulted in increased survival vs. spherical non-cognate particles (p=0.05), ellipsoidal 




Figure 8.S2: Surface MHC-dimer (fluorescently labeled with alexa 488) and anti-CD28 
(fluorescently labeled with APC) quantification by fluorescence. (A) Spherical and 
ellipsoidal aAPC synthesized with EDC/NHS chemistry did not have significant 
differences in MHC-dimer amount (p = 0.92) or density (p = 0.42), anti-CD28 amount (p 
= 0.70) or density (p = 0.39), or MHC-dimer/anti-CD28 ratio (p = 0.72). Approximately 
85-90% of the protein on the surface required the EDC/NHS pre-activation step. (B) 
Representative confocal images of ellipsoidal and spherical aAPC showing anti-CD28 
(red), MHC-dimer (green), and overlay of the two channels. (C) Pearson’s correlation 




Figure 8.S3: aAPCs do not change their shape in physiological conditions over one week. 
SEM of freshly prepared aAPCs (a) and aAPCs incubated in PBS at 37°C for (b) 1 day, 
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Figure 8.S4: Fold expansion of PMEL T cells post incubation with (A) 0.01 mg / 
100,000 cells, (B) 0.1 mg / 100,000 cells, and (C) 1 mg / 100,000 cells of differentially 
stretched ellipsoidal aAPC as indicated. Negative controls with non-cognate peptide-in-




Figure 8.S5: Intracellular cytokine staining after stimulation of aAPC-activated T cells. 
CD8+ isolated splenocytes were activated with 0.1 mg spherical aAPC (filled circle), 0.1 
mg of ellipsoidal aAPC (filled square), or 0.01 mg of ellipsoidal aAPC (unfilled square). 
Seven days later, T cells were restimulated with splenocytes from C57BLACK6 mice 
pulsed with the indicated dose of cognate GP100 peptide. Unpulsed splenocytes (No 
Peptide) or no splenocytes (No Stim) were used as controls. Cytokine production is 
reported as percentage of T cells making indicated cytokine. 
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Table 8.1: Key physical parameters altered by stretching of particles: (a) Aspect ratio 
(AR). (b) Surface area (SA) of ellipsoidal particles, relative to spheres. (c) Protein density 
on surface of aAPC with equivalent total protein content relative to spheres. (d-f) Radius 
of curvature, R, for the tip of the ellipsoid (Ra), and for the flat face of the prolate 
spheroid in either direction (Rb, Rc). For equations used, and description of derivations, 
see Supplemental calculation. 
Stretch AR Rel. SA Rel. Density Ra Rb Rc 
Sphere 1 1 1 1 1 1 
1.5 1.84 1.06 0.94 0.44 2.8 0.82 
2 2.83 1.16 0.86 0.25 5.7 0.71 
2.5 3.95 1.27 0.78 0.16 9.9 0.63 
3 5.20 1.38 0.72 0.11 16 0.58 
3.5 6.55 1.48 0.67 0.08 23 0.53 
 
 
Figure 8.S6: A prolate ellipsoid (a > b = c) with axes labeled and key points numbered. 
 
Supplemental calculation: See Fig. S6 for the identities of a, b, c, 1, and 2. 
Determining the lengths of a, b, c: For a spheroid that has been elongated in 1 dimension, 
since total volume is conserved from a sphere, the length of the short axes is related to the 
length of the long axis by 
€ 




Surface area of a prolate spheroid: Since the geometrical shape corresponds to a prolate 




SA = 2πb2 + 2π ab
e
sin−1e  where 
€ 




This surface area was then normalized by the surface area of a sphere with radius 1. 
 
Equivalent protein density: Equivalent protein density with total protein content held 
constant is the inverse of the normalized surface area (density = 1/SA). 
 
Radius of curvature: The radius of curvature is the radius of a circle with the same 
curvature as the observed curve at that point. Thus, for flatter curves, the radius of 
curvature increases, as that flatness requires a larger circle to describe it. 
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An ellipse can be described parametrically by 
€ 
x(t) = acos(t)
y(t) = bcos(t) . 
For any parameterized equation of the form 
€ 
x = x(t)
y = y(t) ,  
the radius of curvature can be calculated[44] from: 
€ 
R =
(( " x )2 + ( " y )2)3 / 2




" y = dy /dt
 and
€ 
" "x = d2x /dt 2
" "y = d2y /dt 2
. 
 
So for an ellipse: 
€ 
R = (a
2 sin2(t) + b2 cos2(t))3 / 2
absin2(t) + abcos2(t)
=




To calculate the radius of curvature at the tip, since t = 0 corresponds to point 1 (Fig. S5), 
Ra can be calculated using a and b as the two axes of the ellipse. To calculate the radius 
of curvature at the tip, since t = π/2 corresponds to point 2 (Fig. S5), Rb can be calculated 









































































































































9 Chapter 9: Future Directions 
!
9.1 Next generation artificial Antigen Presenting Cells 
for Tumor Immunotherapy8 
For the development of next-generation nanoengineered aAPCs special attention 
should be paid to particle size and particle shape, and at the protein level, surface density, 
spatial organization and dynamics are key parameters of interest (Table 9.1). 
There are potentially many advantages to a nanosized immunostimulatory platform 
for use in vivo. Smaller particles (20-200 nm in diameter) can transit directly to the 
lymphatics after subcutaneous injection without the aid of phagocytosis [1], where they 
could reach the T cell population in the ideal setting for T cell expansion. Nanosized 
constructs are also potentially i.v. injectable, as micro-sized particles would potentially be 
trapped in the capillary bed of the lungs, blocking capillary flow. Additionally, control 
over surface topology on the nanoscale (shape), surface density, and surface organization, 
would more precisely mimic the biological setting. The fabrication of such technology 
would also allow for greater understanding about the role of geometry, protein surface 
organization, and dynamic rearrangement play with natural biological APCs. 
 
9.1.1 Nanoscale surface patterning 
 Most aAPC systems utilize uniform presentation of ligands on the surface, due to 
ease of fabrication and simplicity of design. However, the interaction of a biological APC 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
8  This chapter contains excerpts from an article that was published as Sunshine JC, Green JJ. 
“Nanoengineering approaches to the design of artificial antigen-presenting cells.” Nanomedicine 2013, 8(7), 
1173-1189. 
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with a T cell results in the formation of an organized, anisotropic arrangement of surface 
proteins termed the immunological synapse (IS) [2, 3]. When mature, the IS consists of 
two main distinct concentric rings of organized proteins. The central supramolecular 
activation cluster (cSMAC) consists primarily of TCRs in contact with peptide-MHC 
molecules on the APC surface and other costimulatory molecules (such as the B7:CD28 
interaction). This is surrounded by a peripheral supramolecular activation cluster 
(pSMAC), formed by integrin:adhesion molecule interactions (principally LFA-1 on the 
T cell surface binding ICAM-1 on the APC surface). Taking advantage of these dynamic 
rearrangements and anisotropic protein arrangements could be of great advantage in 
future aAPC systems. 
 One potential way of mimicking the biomolecular organization of the immune 
synapse on aAPC systems would be to utilize recent advances in the synthesis and design 
of patchy particles [4]. By formation of particles with at least two distinct surface 
subdomains, one could synthesize a particle that had the components of the cSMAC 
(pMHC and various costimulatory molecules) in one subdomain, with the components of 
the pSMAC (principally ICAM-1) in the other subdomain. As these designs get more 
advanced, more precise biomimicry could be achieved with such systems. 
  Janus particles, named after the Roman god Janus who had two faces, are 
particles that have two distinct faces. The various synthetic approaches to Janus particles 
are helpfully reviewed by Walther and Muller [5], and these approaches to double sided 
particles could prove useful for the development of aAPCs. 
Lithography has proved to be an incredibly useful tool in a number of fields, for 
computers, to microfulidics, to biology. In the 2D setting, researchers have developed 
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immunological synapse arrays, which are stimulatory patches surrounded by integrin 
fields in a flat lithographically patterned substrate [6], and used them to study how the 
disruption of these 2D immunological synapses might affect the response of T cells to 
these substrates. Complex particle lithography, on the micro- and particularly nano-scale, 
has proven to be challenging. However, some work has been done in this area to develop 
particles that might be suitable for nanoscale aAPC design. Snyder et al. used 
polyelectrolytes to cover the exposed surface of amine-functionalized PS spheres adhered 
to negatively charged cover slips as a mask [7]. Using microcontact printing techniques 
and PDMS molds, Cayre et al were able to synthesize dipolar particles [8]. In addition, 
they extended their method to allow printing of one colloidal layer onto another, which 
enables the formation of “raspberry” particles if the particles are of very dissimilar sizes 
[9].  
Another approach to the formation of patchy particles with multiple patches 
involves the use of glancing angle deposition (GLAD) [10]. The GLAD technique 
involves the deposition of gold or silver vapor onto a close-packed colloidal monolayer at 
low pressure. The technique is referred to as “glancing angle” because the sample is 
angled with respect to the vapor deposition. Changing the angle allows alterations in the 
geometry of and location of the vapor deposition. To produce multiple patches of 
different functionalities, the vapor deposition is done in two steps. To position the second 
group differently, the angle of deposition is changed. This can allow for two separate 
patches on the same side of the particle that also interconnect. Patches can be produced 
on opposite poles of the particles by using a PDMS stamp to flip the particles and then 
allow vapor deposition to proceed on the opposite side [11]. These techniques have also 
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been applied to colloidal crystals. By using upper single or double layers in colloidal 
crystals as masks during the vapor deposition, Zhang et al. were able to develop patterns 
on the 3rd layer of nanoparticles with nanoscale feature resolution [12].  
Recently, Kamalasanan et al. reported a novel technique to produce multiple 
circular patches on the surface of microspheres. The technique involves applying liquid 
polydimethylsiloxane (PDMS) to a 3D colloidal crystal or various 2D arrays of spherical 
polystyrene microparticles. During this process, selective solidification of the PDMS 
happens at particle interfaces, allowing for those sites to be selectively blocked by the 
PDMS masks (Fig. 9.1) [13]. This process allows ligand to be conjugated at the 
unblocked sites, followed by exposure of the PDMS patches, and addition of a second 
ligand or set of ligands to the newly exposed sites. The number of PDMS patches is 
determined by the coordination number of the particle in the colloidal crystal / 2D array 
[13].  
 Microfluidics has also been used to address the problem of synthesizing particles 
with multiple functionalities. Particles are synthesized by flowing multiple polymers or 
monomers into a single stream [14]. Janus and ternary particles can be synthesized by 
mixing of 2 or 3 monomers with photoinitiator in a microfluidic device. A surfactant-
containing stream is flowed in outside of the monomer containing streams, and these 
streams are then forced through a narrow opening that causes the fluid to break up into 
droplets. The droplets are then polymerized by UV irraditation [15]. This approach does 
not, however, generate particles with nanoscale features, as the particle sizes generated 
were around 100 microns. Biphasic Janus particles were generated with nanoscale 
features by the use of simultaneous electrohydrodynamic jetting [16]. In this case, instead 
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of the particles being generated by being forced through a narrow opening, an electric 
field is applied and the nano-janus particles are collected on the collecting plate which 
houses the counter-electrode (Fig. 9.2) [16]. This method can be performed using two of 
the same polymers while loading in different drugs in each half, and/or can allow 
selective chemical modification of one portion of the particle, making this setup 
amenable to the generation of biphasic nano-scale aAPCs. This technique does not allow 
the precise patterning afforded by some of the printing strategies, but future advances in 
the technique may make this a viable option. In addition, one could envision using this 
dual approach to provide cytokine release from one portion of the nanoparticle and stable 
ligand presentation from another portion of the nanoparticle, successfully avoiding some 
of the compromises often required for controlled release and surface presentation of 
ligands. Critically, this type of approach allows generation of a “top” and “bottom” or 
“front” and “back” which can each contain appropriate surface molecules and in this 
manner better mimic biological cells. 
  
9.1.2 Dynamic surface rearrangement – Liposomes and Protocells 
More recent advances in the use of liposomes as aAPCs help to demonstrate 
additional parameters of likely importance for nanoengineered approaches to aAPC 
design. In particular, the signal 1-signal 2-signal 3 model which emphasizes the identity 
of the molecular signals involved in the directed signaling by an APC to a T cell may be 
supplemented by developing approaches to mimic other critical aspects of the biological 
system.  
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Liposomes afford two advantages to solid particle systems that mimic the 
biological system more directly. First of all, liposomal membrane fluidity enables the 
aAPC to dynamically rearrange the proteins on its surface, in a similar fashion as the 
dramatic protein rearrangements that occur during APC / T cell interaction and generate 
the immune synapse. In addition to the ability of liposomes to allow for biomimetic 
nanoscale reorganization of the proteins expressed on the surface, further advances in the 
ability to control initial organization of the expressed proteins might also be enabling. 
With respect to immune synapse formation, an innovative study using 2D SLBs showed 
that the imposition of patterned lines disrupted the geometry of the immune synapse [17]. 
These data indicate that initial TCR engagement is followed by formation of TCR 
microdomains, which are then followed by directed transport of microclusters to form the 
final cSMAC. Lipid rafts, which are small, 10-200 nm domains that are highly enriched 
in sterols (such as cholesterol) or sphingolipids [18], have shown to be critical organizing 
features of biological membranes![19, 20], and molecular simulations have indicated the 
importance of these nano-domains to improve protein-protein interaction [21]. In fact, 
biological APCs have been shown to pre-cluster antigen even in the absence of T cells 
[22], and concentration of MHC molecules into lipid rafts has been shown to improve 
antigen presentation in biological APCs [23]. Perhaps partitioning cSMAC components 
into small lipid rafts for initial TCR signaling and allowing flow in the membrane to 
rearrange into larger clusters might be a particularly effective method to mimic the 
biology and achieve optimal stimulation from aAPCs. 
Giannoni et al. showed that preclustering of peptide-MHC and costimulatory 
signals in a nanoscale liposomal system resulted in higher T cell stimulation than with 
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soluble tetramers or liposomal aAPC without preclustering [24]. The beta subunit of 
cholera toxin interacts strongly with cholesterol, a major component of lipid rafts. 
Preclustering was accomplished by linking the surface proteins to cholera toxin by biotin-
neutravidin interactions (with biotin on the antibodies, and neutravidin on the beta 
subunit of cholera toxin). Importantly, the distribution alone (with no alteration in the 
quantity of any ligand critically modulated the strength of the stimulation by the aAPC. A 
subsequent study where the same group added anti-LFA-1 (the major adhesion molecule 
involved) to anti-CD3 (for general T cell activation) and anti-CD28 (for costimulation) 
all preclustered in microdomains as before resulted in increased expansion of polyclonal 
T cells and MART-1-specific CD8+ T cells than commercially available systems [25]. 
Interestingly, this second approach of preclustering LFA-1 with cSMAC components 
does not allow for subsequent segregation of the LFA-1 into the surrounding pSMAC. 
Perhaps future experiments might investigate whether pre-clustering of signal 1 and 
signal 2 separate from adhesion molecules such as LFA-1 might more directly mimic the 
biological situation and further enhance activation. 
A major difficulty that has hindered the use of liposomes as aAPC surrogates is 
their relative instability when compared to solid particles. One potential novel new 
solution, which has been used for drug delivery but has yet to be applied to the design of 
aAPC, is the concept of particle-supported lipid bilayers (pSLBs).  
Particle systems which incorporate lipid monolayers or lipid bilayers on their 
surfaces have been developed which offer improved stability and drug delivery particles 
to standard liposomal formulations [26]. To synthesize aAPC, the focus is on supported 
lipid bilayers (SLB) as opposed to the systems that utilize only lipid monolayers at the 
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particles surface, because SLBs enable the replication of the fliuidity of biological 
membranes in artificial systems. In particular, for the design of future aAPCs, mimicking 
the biological situation that allows for large-scale protein rearrangement subsequent to 
TCR triggering is likely of significant benefit. 
Supported lipid bilayers have been used extensively as a model system for the 
study of the molecular dynamics of immune synapses, as they provide a flexible platform 
that is compatable with modern imaging techniques and have most of the characteristics 
of a real APC membrane [27]. This technique, extensively studied in 2D, has been 
recently applied to the synthesis of nanoparticles with supported lipid bilayers on a 
hydrogel [28], silica particle [29, 30], or polymeric (PLGA) particle core [31]. These 
particle-supported lipid bilayers can be anchored (by covalently attaching the inner layer 
to the surface) or can be unanchored, with a lipid bilayer sitting on the surface of the 
silica or polymeric particle core. 
Ashley et al. developed a “protocell” which consists of a nanoporous silica core 
and a supported lipid bilayer which can be modified with targeting ligand, fusogenic 
peptides, and polyethylene glycol (PEG) that enables increased stability and drug 
delivery capacity (Fig. 9.3) [32]. Interestingly, the nanoporous silica particles showed 
increased membrane fluidity when compared with protocells formed from non-porous 
solid silica nanoparticles or unsupported liposomes. These protocells can be loaded with 
a variety of cargoes, such as small molecule druges, siRNA, toxins, or quantum dots, and 
show vastly improved (106-fold) anticancer activity when compared to comparable 
liposomes. Critically, this indicates the potential to use this system to release 
immunomodulatory cytokines from the construct, potentially allowing the synthesis of a 
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system which can provide signal 1, signal 2, and signal 3 while replicating the fluidity of 
biological membranes in a stable fashion. 
Porotto et al. have used larger (3 µm) protocells designed to inactivate enveloped 
viruses by presenting viral entry receptors on the surface of the protocells. This enables 
the protocells to act as cellular decoys, inactivating viruses that would otherwise infect 
healthy cells by triggering premature fusion of the viruses. Interestingly, at low 
temperatures (4 °C), the protocells were unable to activate virus, whereas at 37 °C, 
considerable inactivation was demonstrated. This indicates that membrane fluidity is 
required for protocell inactivation of the virus. Importantly, the protocells did not 
accumulate virus, but rather were renewable, as binding led directly to premature fusion 
and permanent inactivation of the viruses [33]. 
In addition to fully chemically synthesized supported lipid bilayers, natural 
erythrocyte membranes have been used to coat biodegradable polymeric microparticles 
[31], and leukocyte-membranes have been fused to silica cores [34]. These approaches 
present an alternative to the reductionist systems typically used in acellular aAPC 
systems, and offer the potential to generate particles which are coated with real DC 
membranes and perhaps subsequently modified to generate an off-the-shelf, acellular 
aAPC which has much of the benefits of an acellular system while retaining all the 
critical components of a real DC membrane.  
9.1.3 Conclusion & Future Perspective 
Acellular aAPC have particularly shown great initial promise for ex vivo 
activation of CTL and have been investigated for in vivo applications as well. The 
development of aAPCs has focused mainly on the choice of proteins to use for surface 
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presentation to T cells when conjugated to various spherical, micro-scale particles. Key 
recent advances have allowed for the development of acellular aAPCs that incorporate 
more biological cues than antigen recognition (signal 1) and costimulation (signal 2). 
aAPCs have been developed that incorporate secretable cues (cytokines, “signal 3”) and 
surface geometric cues that operate from the nanoscale to the microscale, such as 
interfacial geometry, surface protein organization and segregation, and dynamic protein 
rearrangement. Early work has demonstrated a critical role for particle size, showing that 
the surface area available for contact is crucial in these systems. Additionally, 
preclustering of protein signals into nanodomains (lipid rafts) has been shown to be of 
substantial benefit for aAPC-based stimulation.  
New synthetic particle technology has been developed to synthesize patchy 
particles with varying geometry and nanoscale features. These technologies may allow 
for the development of nanoscale anisotropic aAPCs with that mimic the physical 
segregation evident in the immune synapse.  
Liposome based aAPCs, and lipid rafts, enable the generation of nanoclustered 
surface functionality, and the fluidity of the membranes allows for more biomimetic 
dynamic rearrangement of surface proteins upon contact with target cells. However, 
liposomes suffered from relative instability as compared to solid particles. Recent 
advances in the development of supported lipid bilayers might enable the generation of 
SLB based aAPCs that offer the advantages of liposomal systems with superior stability 
and improved drug release.  
Biodegradable particles offer strong biocompatablility and are useful for release 
of secretable cues or other immunomodulatory factors. Recent advances in the 
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development of methods for the generation of non-spherical biodegradable particles may 
enable next-generation aAPC with interfacial geometry that more closely mimics the 
biological situation. In addition, non-spherical aAPC offer the potential of developing 
nanoparticles with interfacial geometry similar to successful microparticulate systems, 
with improved in vivo performance due to easy access to draining lymph nodes and 
suitability for intravenous injection. 
Of particular interest may be an approach that combines all of these techniques to 
generate non-spherical supported lipid bilayers with sustained surface presentation on the 






Figure 9.2: (a) The experimental setup used for generation of nanoscale biphasic Janus 
particles. The bipolar jetting fluid is exposed to applied electrical potential and the 
particles are collected on the counter electrode. (b) Digital image of the biphasic taylor 
cone with jet. Reproduced with permission from Macmillan Publishers Ltd: Nature 




Figure 9.3: A schematic showing a particle supported lipid bilayer, with the range of 
cargoes and surface ligands that can be encapsulate or presented on the surface of the 
particle. Reproduced with permission from Macmillan Publishers Ltd: Nature Materials 






Key Parameter Activated Biological 
APC / DC 
Current aAPC Future aAPC 













Signal 2 - 
Costimulation 
B7.1, B7.2, etc. 
 
Anti-CD28 mAb Anti-CD28 
mAb and others 




Various (eg. IL-2) or 
chemokine (eg. CCL3, 
CCL4, etc.) [35] 
IL-2 release[36] Cytokine or 
chemokine 
release 




Shape Long, thin, sheet like 
projections/veils in many 
directions from the cell 
body; highly 
dynamic[38] 
Spherical  Non-spherical 
Density Dynamic local density 2000 MHC/µm2 > 





Organization Before T cell contact: 
Microclustering 
After contact with T cell: 
Dynamic reorganization; 
Immune synapse 
formation[2, 3, 17, 22, 
23, 40]  
Liposomes/lipid 
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